BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Carey LA, Dees EC, Sawyer L, Gatti L, Moore DT, Collichio F, Ollila DW, Sartor CI, Graham ML, Perou CM. The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes. Clin Cancer Res. 2007;13:2329-2334. [PMID: 17438091 DOI: 10.1158/1078-0432.ccr-06-1109] [Cited by in Crossref: 1329] [Cited by in F6Publishing: 687] [Article Influence: 94.9] [Reference Citation Analysis]
Number Citing Articles
1 Polyak K. Breast cancer: origins and evolution. J Clin Invest 2007;117:3155-63. [PMID: 17975657 DOI: 10.1172/JCI33295] [Cited by in Crossref: 306] [Cited by in F6Publishing: 187] [Article Influence: 23.5] [Reference Citation Analysis]
2 Lee YR, Park MS, Joo HK, Kim KM, Kim J, Jeon BH, Choi S. Therapeutic positioning of secretory acetylated APE1/Ref-1 requirement for suppression of tumor growth in triple-negative breast cancer in vivo. Sci Rep 2018;8:8701. [PMID: 29880821 DOI: 10.1038/s41598-018-27025-9] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
3 Cabello P, Pineda B, Tormo E, Lluch A, Eroles P. The Antitumor Effect of Metformin Is Mediated by miR-26a in Breast Cancer. Int J Mol Sci. 2016;17:pii E1298. [PMID: 27517917 DOI: 10.3390/ijms17081298] [Cited by in Crossref: 21] [Cited by in F6Publishing: 24] [Article Influence: 4.2] [Reference Citation Analysis]
4 Lønning PE. Molecular basis for therapy resistance. Mol Oncol 2010;4:284-300. [PMID: 20466604 DOI: 10.1016/j.molonc.2010.04.005] [Cited by in Crossref: 33] [Cited by in F6Publishing: 27] [Article Influence: 3.0] [Reference Citation Analysis]
5 Yoshida T, Ozawa Y, Kimura T, Sato Y, Kuznetsov G, Xu S, Uesugi M, Agoulnik S, Taylor N, Funahashi Y, Matsui J. Eribulin mesilate suppresses experimental metastasis of breast cancer cells by reversing phenotype from epithelial-mesenchymal transition (EMT) to mesenchymal-epithelial transition (MET) states. Br J Cancer 2014;110:1497-505. [PMID: 24569463 DOI: 10.1038/bjc.2014.80] [Cited by in Crossref: 178] [Cited by in F6Publishing: 167] [Article Influence: 25.4] [Reference Citation Analysis]
6 Ramirez NE, Zhang Z, Madamanchi A, Boyd KL, O'Rear LD, Nashabi A, Li Z, Dupont WD, Zijlstra A, Zutter MM. The α₂β₁ integrin is a metastasis suppressor in mouse models and human cancer. J Clin Invest 2011;121:226-37. [PMID: 21135504 DOI: 10.1172/JCI42328] [Cited by in Crossref: 147] [Cited by in F6Publishing: 80] [Article Influence: 13.4] [Reference Citation Analysis]
7 Chuang E, Paul C, Flam A, McCarville K, Forst M, Shin S, Vahdat L, Swistel A, Simmons R, Osborne M. Breast cancer subtypes in Asian-Americans differ according to Asian ethnic group. J Immigr Minor Health 2012;14:754-8. [PMID: 22286607 DOI: 10.1007/s10903-012-9577-7] [Cited by in Crossref: 20] [Cited by in F6Publishing: 11] [Article Influence: 2.5] [Reference Citation Analysis]
8 Lee KH, Keam B, Im SA, Kim TY, Han SW, Oh DY, Kim JH, Lee SH, Han W, Kim DW, Kim TY, Park IA, Noh DY, Heo DS, Bang YJ. Body mass index is not associated with treatment outcomes of breast cancer patients receiving neoadjuvant chemotherapy: korean data. J Breast Cancer 2012;15:427-33. [PMID: 23346172 DOI: 10.4048/jbc.2012.15.4.427] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 0.9] [Reference Citation Analysis]
9 Lehmann BD, Pietenpol JA. Identification and use of biomarkers in treatment strategies for triple-negative breast cancer subtypes. J Pathol. 2014;232:142-150. [PMID: 24114677 DOI: 10.1002/path.4280] [Cited by in Crossref: 227] [Cited by in F6Publishing: 212] [Article Influence: 32.4] [Reference Citation Analysis]
10 McFarland DC, Naikan J, Rozenblit M, Mandeli J, Bleiweiss I, Tiersten A. Changes in Pathological Complete Response Rates after Neoadjuvant Chemotherapy for Breast Carcinoma over Five Years. J Oncol 2016;2016:4324863. [PMID: 27382369 DOI: 10.1155/2016/4324863] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
11 Eswaran J, Cyanam D, Mudvari P, Reddy SD, Pakala SB, Nair SS, Florea L, Fuqua SA, Godbole S, Kumar R. Transcriptomic landscape of breast cancers through mRNA sequencing. Sci Rep 2012;2:264. [PMID: 22355776 DOI: 10.1038/srep00264] [Cited by in Crossref: 64] [Cited by in F6Publishing: 51] [Article Influence: 7.1] [Reference Citation Analysis]
12 Sharma P, Stecklein SR, Kimler BF, Sethi G, Petroff BK, Phillips TA, Tawfik OW, Godwin AK, Jensen RA. The prognostic value of BRCA1 promoter methylation in early stage triple negative breast cancer. J Cancer Ther Res 2014;3:1-11. [PMID: 25177489 DOI: 10.7243/2049-7962-3-2] [Cited by in Crossref: 28] [Cited by in F6Publishing: 29] [Article Influence: 4.0] [Reference Citation Analysis]
13 Jian Y, Huang X, Fang L, Wang M, Liu Q, Xu H, Kong L, Chen X, Ouyang Y, Wang X, Wei W, Song L. Actin-like protein 6A/MYC/CDK2 axis confers high proliferative activity in triple-negative breast cancer. J Exp Clin Cancer Res 2021;40:56. [PMID: 33541412 DOI: 10.1186/s13046-021-01856-3] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
14 Wang LC, Wang LS, Li AX, Shi ZZ, Li YQ, Huang W, Chen SM, Han F, Zhu DQ. Combinational Treatment of Doxorubicin With Neoadjuvant Docetaxel for Different Subtypes of Patients With Breast Cancer. Technol Cancer Res Treat 2020;19:1533033820928435. [PMID: 32508292 DOI: 10.1177/1533033820928435] [Reference Citation Analysis]
15 Grosse-Wilde A, Kuestner RE, Skelton SM, MacIntosh E, d'Hérouël AF, Ertaylan G, Del Sol A, Skupin A, Huang S. Loss of inter-cellular cooperation by complete epithelial-mesenchymal transition supports favorable outcomes in basal breast cancer patients. Oncotarget 2018;9:20018-33. [PMID: 29732000 DOI: 10.18632/oncotarget.25034] [Cited by in Crossref: 15] [Cited by in F6Publishing: 10] [Article Influence: 5.0] [Reference Citation Analysis]
16 Solin LJ, Gray R, Goldstein LJ, Recht A, Baehner FL, Shak S, Badve S, Perez EA, Shulman LN, Martino S, Davidson NE, Sledge GW Jr, Sparano JA. Prognostic value of biologic subtype and the 21-gene recurrence score relative to local recurrence after breast conservation treatment with radiation for early stage breast carcinoma: results from the Eastern Cooperative Oncology Group E2197 study. Breast Cancer Res Treat 2012;134:683-92. [PMID: 22547108 DOI: 10.1007/s10549-012-2072-y] [Cited by in Crossref: 49] [Cited by in F6Publishing: 41] [Article Influence: 5.4] [Reference Citation Analysis]
17 Hastak K, Alli E, Ford JM. Synergistic chemosensitivity of triple-negative breast cancer cell lines to poly(ADP-Ribose) polymerase inhibition, gemcitabine, and cisplatin. Cancer Res. 2010;70:7970-7980. [PMID: 20798217 DOI: 10.1158/0008-5472.can-09-4521] [Cited by in Crossref: 114] [Cited by in F6Publishing: 68] [Article Influence: 10.4] [Reference Citation Analysis]
18 Wang J, Sang D, Xu B, Yuan P, Ma F, Luo Y, Li Q, Zhang P, Cai R, Fan Y, Chen S, Li Q. Value of Breast Cancer Molecular Subtypes and Ki67 Expression for the Prediction of Efficacy and Prognosis of Neoadjuvant Chemotherapy in a Chinese Population. Medicine (Baltimore) 2016;95:e3518. [PMID: 27149453 DOI: 10.1097/MD.0000000000003518] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
19 Sharma P, López-Tarruella S, García-Saenz JA, Khan QJ, Gómez HL, Prat A, Moreno F, Jerez-Gilarranz Y, Barnadas A, Picornell AC, Monte-Millán MD, González-Rivera M, Massarrah T, Pelaez-Lorenzo B, Palomero MI, González Del Val R, Cortés J, Fuentes-Rivera H, Morales DB, Márquez-Rodas I, Perou CM, Lehn C, Wang YY, Klemp JR, Mammen JV, Wagner JL, Amin AL, O'Dea AP, Heldstab J, Jensen RA, Kimler BF, Godwin AK, Martín M. Pathological Response and Survival in Triple-Negative Breast Cancer Following Neoadjuvant Carboplatin plus Docetaxel. Clin Cancer Res 2018;24:5820-9. [PMID: 30061361 DOI: 10.1158/1078-0432.CCR-18-0585] [Cited by in Crossref: 28] [Cited by in F6Publishing: 18] [Article Influence: 9.3] [Reference Citation Analysis]
20 Yuan Y, Lee JS, Yost SE, Li SM, Frankel PH, Ruel C, Schmolze D, Robinson K, Tang A, Martinez N, Stewart D, Waisman J, Kruper L, Jones V, Menicucci A, Uygun S, Yoder E, van der Baan B, Yim JH, Yeon C, Somlo G, Mortimer J. Phase II Trial of Neoadjuvant Carboplatin and Nab-Paclitaxel in Patients with Triple-Negative Breast Cancer. Oncologist 2021;26:e382-93. [PMID: 33098195 DOI: 10.1002/onco.13574] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
21 Kurian AW, Fish K, Shema SJ, Clarke CA. Lifetime risks of specific breast cancer subtypes among women in four racial/ethnic groups. Breast Cancer Res 2010;12:R99. [PMID: 21092082 DOI: 10.1186/bcr2780] [Cited by in Crossref: 101] [Cited by in F6Publishing: 88] [Article Influence: 9.2] [Reference Citation Analysis]
22 Tang L, Wei D, Yan F. MicroRNA-145 functions as a tumor suppressor by targeting matrix metalloproteinase 11 and Rab GTPase family 27a in triple-negative breast cancer. Cancer Gene Ther 2016;23:258-65. [PMID: 27364572 DOI: 10.1038/cgt.2016.27] [Cited by in Crossref: 22] [Cited by in F6Publishing: 17] [Article Influence: 4.4] [Reference Citation Analysis]
23 Berger ER, Iyengar NM. Obesity and Energy Balance Considerations in Triple-Negative Breast Cancer. Cancer J 2021;27:17-24. [PMID: 33475289 DOI: 10.1097/PPO.0000000000000502] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
24 Maycotte P, Thorburn A. Targeting autophagy in breast cancer. World J Clin Oncol 2014;5:224-40. [PMID: 25114840 DOI: 10.5306/wjco.v5.i3.224] [Cited by in CrossRef: 38] [Cited by in F6Publishing: 35] [Article Influence: 5.4] [Reference Citation Analysis]
25 Bertucci F, Finetti P, Birnbaum D. Basal breast cancer: a complex and deadly molecular subtype. Curr Mol Med. 2012;12:96-110. [PMID: 22082486 DOI: 10.2174/156652412798376134] [Cited by in Crossref: 120] [Cited by in F6Publishing: 98] [Article Influence: 13.3] [Reference Citation Analysis]
26 Ibrahim E, Al-Gahmi AM, Zeenelin AA, Zekri JM, Elkhodary TR, Gaballa HE, Fawzy EE, El sayed ME, Alzahrani MS. Basal vs. luminal A breast cancer subtypes: a matched case-control study using estrogen receptor, progesterone receptor, and HER-2 as surrogate markers. Med Oncol 2009;26:372-8. [PMID: 19034706 DOI: 10.1007/s12032-008-9131-6] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 1.6] [Reference Citation Analysis]
27 Mohyeldin MM, Akl MR, Ebrahim HY, Dragoi AM, Dykes S, Cardelli JA, El Sayed KA. The oleocanthal-based homovanillyl sinapate as a novel c-Met inhibitor. Oncotarget 2016;7:32247-73. [PMID: 27086914 DOI: 10.18632/oncotarget.8681] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 4.0] [Reference Citation Analysis]
28 Keam B, Im SA, Lee KH, Han SW, Oh DY, Kim JH, Lee SH, Han W, Kim DW, Kim TY, Park IA, Noh DY, Heo DS, Bang YJ. Ki-67 can be used for further classification of triple negative breast cancer into two subtypes with different response and prognosis. Breast Cancer Res 2011;13:R22. [PMID: 21366896 DOI: 10.1186/bcr2834] [Cited by in Crossref: 132] [Cited by in F6Publishing: 120] [Article Influence: 13.2] [Reference Citation Analysis]
29 Wu K, Yang Q, Liu Y, Wu A, Yang Z. Meta-analysis on the association between pathologic complete response and triple-negative breast cancer after neoadjuvant chemotherapy. World J Surg Oncol 2014;12:95. [PMID: 24731479 DOI: 10.1186/1477-7819-12-95] [Cited by in Crossref: 22] [Cited by in F6Publishing: 24] [Article Influence: 3.1] [Reference Citation Analysis]
30 Kim S, Roopra A, Alexander CM. A phenotypic mouse model of basaloid breast tumors. PLoS One 2012;7:e30979. [PMID: 22347416 DOI: 10.1371/journal.pone.0030979] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 1.1] [Reference Citation Analysis]
31 Yang L, Perez AA, Fujie S, Warden C, Li J, Wang Y, Yung B, Chen YR, Liu X, Zhang H, Zheng S, Liu Z, Ann D, Yen Y. Wnt modulates MCL1 to control cell survival in triple negative breast cancer. BMC Cancer 2014;14:124. [PMID: 24564888 DOI: 10.1186/1471-2407-14-124] [Cited by in Crossref: 38] [Cited by in F6Publishing: 35] [Article Influence: 5.4] [Reference Citation Analysis]
32 Kim YW, Eom BW, Kook MC, Kim HS, Kim MK, Hwang HL, Chandra V, Poojan S, Song Y, Koh JS, Bae CD, Ro J, Hong KM. Clinical implications of proliferation activity in T1 or T2 male gastric cancer patients. Exp Mol Med 2015;47:e193. [PMID: 26542785 DOI: 10.1038/emm.2015.79] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
33 Allison KH. Prognostic and predictive parameters in breast pathology: a pathologist's primer. Mod Pathol 2021;34:94-106. [PMID: 33154551 DOI: 10.1038/s41379-020-00704-7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
34 Howlader N, Altekruse SF, Li CI, Chen VW, Clarke CA, Ries LA, Cronin KA. US incidence of breast cancer subtypes defined by joint hormone receptor and HER2 status. J Natl Cancer Inst 2014;106:dju055. [PMID: 24777111 DOI: 10.1093/jnci/dju055] [Cited by in Crossref: 524] [Cited by in F6Publishing: 455] [Article Influence: 74.9] [Reference Citation Analysis]
35 Meijnen P, Peterse JL, Antonini N, Rutgers EJ, van de Vijver MJ. Immunohistochemical categorisation of ductal carcinoma in situ of the breast. Br J Cancer 2008;98:137-42. [PMID: 18043578 DOI: 10.1038/sj.bjc.6604112] [Cited by in Crossref: 80] [Cited by in F6Publishing: 60] [Article Influence: 5.7] [Reference Citation Analysis]
36 Moon YW, Lee S, Park BW, Kim EK, Kim SI, Koo JS, Park S, Kim MJ, Chung HC, Kim JH, Sohn J. S-1 combined with docetaxel following doxorubicin plus cyclophosphamide as neoadjuvant therapy in breast cancer: phase II trial. BMC Cancer 2013;13:583. [PMID: 24314307 DOI: 10.1186/1471-2407-13-583] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
37 Guo W, Li J, Huang H, Fu F, Lin Y, Wang C. LncRNA PCIR Is an Oncogenic Driver via Strengthen the Binding of TAB3 and PABPC4 in Triple Negative Breast Cancer. Front Oncol 2021;11:630300. [PMID: 34012913 DOI: 10.3389/fonc.2021.630300] [Reference Citation Analysis]
38 Savci-Heijink CD, Halfwerk H, Koster J, Van de Vijver MJ. Association between gene expression profile of the primary tumor and chemotherapy response of metastatic breast cancer. BMC Cancer 2017;17:755. [PMID: 29132326 DOI: 10.1186/s12885-017-3691-9] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
39 Conway K, Edmiston SN, May R, Kuan PF, Chu H, Bryant C, Tse CK, Swift-Scanlan T, Geradts J, Troester MA, Millikan RC. DNA methylation profiling in the Carolina Breast Cancer Study defines cancer subclasses differing in clinicopathologic characteristics and survival. Breast Cancer Res 2014;16:450. [PMID: 25287138 DOI: 10.1186/s13058-014-0450-6] [Cited by in Crossref: 58] [Cited by in F6Publishing: 46] [Article Influence: 8.3] [Reference Citation Analysis]
40 Castrellon AB, Pidhorecky I, Valero V, Raez LE. The Role of Carboplatin in the Neoadjuvant Chemotherapy Treatment of Triple Negative Breast Cancer. Oncol Rev 2017;11:324. [PMID: 28382189 DOI: 10.4081/oncol.2017.324] [Cited by in Crossref: 11] [Cited by in F6Publishing: 16] [Article Influence: 2.8] [Reference Citation Analysis]
41 Cheang MC, Voduc KD, Tu D, Jiang S, Leung S, Chia SK, Shepherd LE, Levine MN, Pritchard KI, Davies S, Stijleman IJ, Davis C, Ebbert MT, Parker JS, Ellis MJ, Bernard PS, Perou CM, Nielsen TO. Responsiveness of intrinsic subtypes to adjuvant anthracycline substitution in the NCIC.CTG MA.5 randomized trial. Clin Cancer Res 2012;18:2402-12. [PMID: 22351696 DOI: 10.1158/1078-0432.CCR-11-2956] [Cited by in Crossref: 106] [Cited by in F6Publishing: 45] [Article Influence: 11.8] [Reference Citation Analysis]
42 Cai H, Wang C, Shukla S, Steinmetz NF. Cowpea Mosaic Virus Immunotherapy Combined with Cyclophosphamide Reduces Breast Cancer Tumor Burden and Inhibits Lung Metastasis. Adv Sci (Weinh) 2019;6:1802281. [PMID: 31453050 DOI: 10.1002/advs.201802281] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 8.5] [Reference Citation Analysis]
43 Logsdon DK, Beeghly GF, Munson JM. Chemoprotection Across the Tumor Border: Cancer Cell Response to Doxorubicin Depends on Stromal Fibroblast Ratios and Interstitial Therapeutic Transport. Cell Mol Bioeng 2017;10:463-81. [PMID: 31719872 DOI: 10.1007/s12195-017-0498-3] [Cited by in Crossref: 7] [Cited by in F6Publishing: 2] [Article Influence: 1.8] [Reference Citation Analysis]
44 Mateo AM, Mazor AM, Obeid E, Daly JM, Sigurdson ER, Handorf EA, DeMora L, Aggon AA, Bleicher RJ. Time to Surgery and the Impact of Delay in the Non-Neoadjuvant Setting on Triple-Negative Breast Cancers and Other Phenotypes. Ann Surg Oncol 2020;27:1679-92. [PMID: 31712923 DOI: 10.1245/s10434-019-08050-y] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 5.0] [Reference Citation Analysis]
45 Kim S, Lee Y, Koo JS. Differential expression of lipid metabolism-related proteins in different breast cancer subtypes. PLoS One. 2015;10:e0119473. [PMID: 25751270 DOI: 10.1371/journal.pone.0119473] [Cited by in Crossref: 65] [Cited by in F6Publishing: 59] [Article Influence: 10.8] [Reference Citation Analysis]
46 DeMichele A, Yee D, Berry DA, Albain KS, Benz CC, Boughey J, Buxton M, Chia SK, Chien AJ, Chui SY, Clark A, Edmiston K, Elias AD, Forero-Torres A, Haddad TC, Haley B, Haluska P, Hylton NM, Isaacs C, Kaplan H, Korde L, Leyland-Jones B, Liu MC, Melisko M, Minton SE, Moulder SL, Nanda R, Olopade OI, Paoloni M, Park JW, Parker BA, Perlmutter J, Petricoin EF, Rugo H, Symmans F, Tripathy D, van't Veer LJ, Viscusi RK, Wallace A, Wolf D, Yau C, Esserman LJ. The Neoadjuvant Model Is Still the Future for Drug Development in Breast Cancer. Clin Cancer Res 2015;21:2911-5. [PMID: 25712686 DOI: 10.1158/1078-0432.CCR-14-1760] [Cited by in Crossref: 55] [Cited by in F6Publishing: 31] [Article Influence: 9.2] [Reference Citation Analysis]
47 Sánchez-Muñoz A, Gallego E, de Luque V, Pérez-Rivas LG, Vicioso L, Ribelles N, Lozano J, Alba E. Lack of evidence for KRAS oncogenic mutations in triple-negative breast cancer. BMC Cancer 2010;10:136. [PMID: 20385028 DOI: 10.1186/1471-2407-10-136] [Cited by in Crossref: 43] [Cited by in F6Publishing: 35] [Article Influence: 3.9] [Reference Citation Analysis]
48 Boissière-Michot F, Chabab G, Mollevi C, Guiu S, Lopez-Crapez E, Ramos J, Bonnefoy N, Lafont V, Jacot W. Clinicopathological Correlates of γδ T Cell Infiltration in Triple-Negative Breast Cancer. Cancers (Basel) 2021;13:765. [PMID: 33673133 DOI: 10.3390/cancers13040765] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
49 Recchia F, Candeloro G, Desideri G, Necozione S, Recchia CO, Cirulli V, Rea S. Triple-negative breast cancer: multipronged approach, single-arm pilot phase II study. Cancer Med 2012;1:89-95. [PMID: 23342258 DOI: 10.1002/cam4.3] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
50 Simmons CE, Brezden-Masley C, McCarthy J, McLeod D, Joy AA. Positive progress: current and evolving role of immune checkpoint inhibitors in metastatic triple-negative breast cancer. Ther Adv Med Oncol 2020;12:1758835920909091. [PMID: 33014143 DOI: 10.1177/1758835920909091] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
51 D’Amato NC, Ostrander JH, Bowie ML, Sistrunk C, Borowsky A, Cardiff RD, Bell K, Young LJ, Simin K, Bachelder RE. Evidence for phenotypic plasticity in aggressive triple-negative breast cancer: human biology is recapitulated by a novel model system. PLoS One. 2012;7:e45684. [PMID: 23049838 DOI: 10.1371/journal.pone.0045684] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 1.3] [Reference Citation Analysis]
52 Trošt N, Peña-Llopis S, Koirala S, Stojan J, Potts PR, Fon Tacer K, Martinez ED. γKlotho is a novel marker and cell survival factor in a subset of triple negative breast cancers. Oncotarget 2016;7:2611-28. [PMID: 26556877 DOI: 10.18632/oncotarget.6006] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
53 Yin S, Cheryan VT, Xu L, Rishi AK, Reddy KB. Myc mediates cancer stem-like cells and EMT changes in triple negative breast cancers cells. PLoS One 2017;12:e0183578. [PMID: 28817737 DOI: 10.1371/journal.pone.0183578] [Cited by in Crossref: 30] [Cited by in F6Publishing: 29] [Article Influence: 7.5] [Reference Citation Analysis]
54 Hu Y, Gao J, Wang M, Li M. Potential Prospect of CDK4/6 Inhibitors in Triple-Negative Breast Cancer. Cancer Manag Res 2021;13:5223-37. [PMID: 34234565 DOI: 10.2147/CMAR.S310649] [Reference Citation Analysis]
55 O'Reilly D, Sendi MA, Kelly CM. Overview of recent advances in metastatic triple negative breast cancer. World J Clin Oncol 2021;12:164-82. [PMID: 33767972 DOI: 10.5306/wjco.v12.i3.164] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
56 Kim WH, Lee SW, Kim HJ, Chae YS, Jeong SY, Jung JH, Park HY, Lee WK. Prediction of Advanced Axillary Lymph Node Metastases (ypN2-3) Using Breast MR imaging and PET/CT after Neoadjuvant Chemotherapy in Invasive Ductal Carcinoma Patients. Sci Rep 2018;8:3181. [PMID: 29453385 DOI: 10.1038/s41598-018-21554-z] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
57 Chowdhury P, Ghosh U, Samanta K, Jaggi M, Chauhan SC, Yallapu MM. Bioactive nanotherapeutic trends to combat triple negative breast cancer. Bioact Mater 2021;6:3269-87. [PMID: 33778204 DOI: 10.1016/j.bioactmat.2021.02.037] [Reference Citation Analysis]
58 Li HY, Liang JL, Kuo YL, Lee HH, Calkins MJ, Chang HT, Lin FC, Chen YC, Hsu TI, Hsiao M, Ger LP, Lu PJ. miR-105/93-3p promotes chemoresistance and circulating miR-105/93-3p acts as a diagnostic biomarker for triple negative breast cancer. Breast Cancer Res 2017;19:133. [PMID: 29258605 DOI: 10.1186/s13058-017-0918-2] [Cited by in Crossref: 68] [Cited by in F6Publishing: 63] [Article Influence: 17.0] [Reference Citation Analysis]
59 Gülben K, Berberoğlu U, Aydoğan O, Kınaş V. Subtype is a predictive factor of nonsentinel lymph node involvement in sentinel node-positive breast cancer patients. J Breast Cancer 2014;17:370-5. [PMID: 25548586 DOI: 10.4048/jbc.2014.17.4.370] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.4] [Reference Citation Analysis]
60 Ryu DW, Jung MJ, Choi WS, Lee CH. Clinical significance of morphologic characteristics in triple negative breast cancer. J Korean Surg Soc 2011;80:301-6. [PMID: 22066052 DOI: 10.4174/jkss.2011.80.5.301] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.6] [Reference Citation Analysis]
61 Klinakis A, Szabolcs M, Chen G, Xuan S, Hibshoosh H, Efstratiadis A. Igf1r as a therapeutic target in a mouse model of basal-like breast cancer. Proc Natl Acad Sci USA. 2009;106:2359-2364. [PMID: 19174523 DOI: 10.1073/pnas.0810221106] [Cited by in Crossref: 70] [Cited by in F6Publishing: 64] [Article Influence: 5.8] [Reference Citation Analysis]
62 Price ER, Wong J, Mukhtar R, Hylton N, Esserman LJ. How to use magnetic resonance imaging following neoadjuvant chemotherapy in locally advanced breast cancer. World J Clin Cases 2015;3:607-13. [PMID: 26244152 DOI: 10.12998/wjcc.v3.i7.607] [Cited by in CrossRef: 12] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
63 Carey LA, Rugo HS, Marcom PK, Mayer EL, Esteva FJ, Ma CX, Liu MC, Storniolo AM, Rimawi MF, Forero-Torres A, Wolff AC, Hobday TJ, Ivanova A, Chiu WK, Ferraro M, Burrows E, Bernard PS, Hoadley KA, Perou CM, Winer EP. TBCRC 001: randomized phase II study of cetuximab in combination with carboplatin in stage IV triple-negative breast cancer. J Clin Oncol. 2012;30:2615-2623. [PMID: 22665533 DOI: 10.1200/jco.2010.34.5579] [Cited by in Crossref: 304] [Cited by in F6Publishing: 181] [Article Influence: 33.8] [Reference Citation Analysis]
64 Huang L, Xu AM, Liu S, Liu W, Li TJ. Cancer-associated fibroblasts in digestive tumors. World J Gastroenterol. 2014;20:17804-17818. [PMID: 25548479 DOI: 10.3748/wjg.v20.i47.17804] [Cited by in CrossRef: 29] [Cited by in F6Publishing: 31] [Article Influence: 4.8] [Reference Citation Analysis]
65 Mousavi SA, Kasaeian A, Pourkasmaee M, Ghavamzadeh A, Alimoghaddam K, Vaezi M, Kamranzadeh Fumani H, Babakhani D, Tavakoli S. Assessing the prognostic factors, survival, and recurrence incidence of triple negative breast cancer patients, a single center study in Iran. PLoS One 2019;14:e0208701. [PMID: 30608935 DOI: 10.1371/journal.pone.0208701] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
66 Raninga PV, Lee A, Sinha D, Dong LF, Datta KK, Lu X, Kalita-de Croft P, Dutt M, Hill M, Pouliot N, Gowda H, Kalimutho M, Neuzil J, Khanna KK. Marizomib suppresses triple-negative breast cancer via proteasome and oxidative phosphorylation inhibition. Theranostics 2020;10:5259-75. [PMID: 32373211 DOI: 10.7150/thno.42705] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 11.0] [Reference Citation Analysis]
67 Kutanzi KR, Yurchenko OV, Beland FA, Checkhun VF, Pogribny IP. MicroRNA-mediated drug resistance in breast cancer. Clin Epigenetics 2011;2:171-85. [PMID: 21949547 DOI: 10.1007/s13148-011-0040-8] [Cited by in Crossref: 112] [Cited by in F6Publishing: 93] [Article Influence: 11.2] [Reference Citation Analysis]
68 Golshan M, Loibl S, Wong SM, Houber JB, O'Shaughnessy J, Rugo HS, Wolmark N, McKee MD, Maag D, Sullivan DM, Metzger-Filho O, Von Minckwitz G, Geyer CE Jr, Sikov WM, Untch M. Breast Conservation After Neoadjuvant Chemotherapy for Triple-Negative Breast Cancer: Surgical Results From the BrighTNess Randomized Clinical Trial. JAMA Surg 2020;155:e195410. [PMID: 31913413 DOI: 10.1001/jamasurg.2019.5410] [Cited by in Crossref: 21] [Cited by in F6Publishing: 13] [Article Influence: 21.0] [Reference Citation Analysis]
69 Walsh EM, Shalaby A, O'Loughlin M, Keane N, Webber MJ, Kerin MJ, Keane MM, Glynn SA, Callagy GM. Outcome for triple negative breast cancer in a retrospective cohort with an emphasis on response to platinum-based neoadjuvant therapy. Breast Cancer Res Treat. 2019;174:1-13. [PMID: 30488345 DOI: 10.1007/s10549-018-5066-6] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
70 Prat A, Lluch A, Albanell J, Barry WT, Fan C, Chacón JI, Parker JS, Calvo L, Plazaola A, Arcusa A, Seguí-Palmer MA, Burgues O, Ribelles N, Rodriguez-Lescure A, Guerrero A, Ruiz-Borrego M, Munarriz B, López JA, Adamo B, Cheang MC, Li Y, Hu Z, Gulley ML, Vidal MJ, Pitcher BN, Liu MC, Citron ML, Ellis MJ, Mardis E, Vickery T, Hudis CA, Winer EP, Carey LA, Caballero R, Carrasco E, Martín M, Perou CM, Alba E. Predicting response and survival in chemotherapy-treated triple-negative breast cancer. Br J Cancer 2014;111:1532-41. [PMID: 25101563 DOI: 10.1038/bjc.2014.444] [Cited by in Crossref: 67] [Cited by in F6Publishing: 53] [Article Influence: 9.6] [Reference Citation Analysis]
71 Specht JM, Kurland BF, Montgomery SK, Dunnwald LK, Doot RK, Gralow JR, Ellis GK, Linden HM, Livingston RB, Allison KH, Schubert EK, Mankoff DA. Tumor metabolism and blood flow as assessed by positron emission tomography varies by tumor subtype in locally advanced breast cancer. Clin Cancer Res 2010;16:2803-10. [PMID: 20460489 DOI: 10.1158/1078-0432.CCR-10-0026] [Cited by in Crossref: 56] [Cited by in F6Publishing: 26] [Article Influence: 5.1] [Reference Citation Analysis]
72 Fagan-Solis KD, Reaves DK, Rangel MC, Popoff MR, Stiles BG, Fleming JM. Challenging the roles of CD44 and lipolysis stimulated lipoprotein receptor in conveying Clostridium perfringens iota toxin cytotoxicity in breast cancer. Mol Cancer 2014;13:163. [PMID: 24990559 DOI: 10.1186/1476-4598-13-163] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 1.9] [Reference Citation Analysis]
73 Weis JA, Miga MI, Yankeelov TE. Three-dimensional Image-based Mechanical Modeling for Predicting the Response of Breast Cancer to Neoadjuvant Therapy. Comput Methods Appl Mech Eng 2017;314:494-512. [PMID: 28042181 DOI: 10.1016/j.cma.2016.08.024] [Cited by in Crossref: 35] [Cited by in F6Publishing: 28] [Article Influence: 7.0] [Reference Citation Analysis]
74 Ararat E, Sahin I, Altundag K. Aspirin intake may prevent metastasis in patients with triple-negative breast cancer. Med Oncol 2011;28:1308-10. [PMID: 20668965 DOI: 10.1007/s12032-010-9636-7] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
75 Reaves DK, Fagan-Solis KD, Dunphy K, Oliver SD, Scott DW, Fleming JM. The role of lipolysis stimulated lipoprotein receptor in breast cancer and directing breast cancer cell behavior. PLoS One 2014;9:e91747. [PMID: 24637461 DOI: 10.1371/journal.pone.0091747] [Cited by in Crossref: 28] [Cited by in F6Publishing: 25] [Article Influence: 4.0] [Reference Citation Analysis]
76 Vetter M, Fokas S, Biskup E, Schmid T, Schwab F, Schoetzau A, Güth U, Rochlitz C, Zanetti-Dällenbach R. Efficacy of adjuvant chemotherapy with carboplatin for early triple negative breast cancer: a single center experience. Oncotarget 2017;8:75617-26. [PMID: 29088896 DOI: 10.18632/oncotarget.18118] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
77 Saxena T, Lee E, Henderson KD, Clarke CA, West D, Marshall SF, Deapen D, Bernstein L, Ursin G. Menopausal hormone therapy and subsequent risk of specific invasive breast cancer subtypes in the California Teachers Study. Cancer Epidemiol Biomarkers Prev 2010;19:2366-78. [PMID: 20699377 DOI: 10.1158/1055-9965.EPI-10-0162] [Cited by in Crossref: 43] [Cited by in F6Publishing: 18] [Article Influence: 3.9] [Reference Citation Analysis]
78 Kanapathy Pillai SK, Tay A, Nair S, Leong CO. Triple-negative breast cancer is associated with EGFR, CK5/6 and c-KIT expression in Malaysian women. BMC Clin Pathol 2012;12:18. [PMID: 23009686 DOI: 10.1186/1472-6890-12-18] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 2.1] [Reference Citation Analysis]
79 Ko ES, Han H, Han BK, Kim SM, Kim RB, Lee GW, Park YH, Nam SJ. Prognostic Significance of a Complete Response on Breast MRI in Patients Who Received Neoadjuvant Chemotherapy According to the Molecular Subtype. Korean J Radiol 2015;16:986-95. [PMID: 26357493 DOI: 10.3348/kjr.2015.16.5.986] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 2.2] [Reference Citation Analysis]
80 Chuang HC, Kapuriya N, Kulp SK, Chen CS, Shapiro CL. Differential anti-proliferative activities of poly(ADP-ribose) polymerase (PARP) inhibitors in triple-negative breast cancer cells. Breast Cancer Res Treat 2012;134:649-59. [PMID: 22678161 DOI: 10.1007/s10549-012-2106-5] [Cited by in Crossref: 71] [Cited by in F6Publishing: 60] [Article Influence: 7.9] [Reference Citation Analysis]
81 Li Y, Yang D, Chen P, Yin X, Sun J, Li H, Ren G. Efficacy and safety of neoadjuvant chemotherapy regimens for triple-negative breast cancer: a network meta-analysis. Aging (Albany NY) 2019;11:6286-311. [PMID: 31446432 DOI: 10.18632/aging.102188] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
82 Yadav BS, Sharma SC, Chanana P, Jhamb S. Systemic treatment strategies for triple-negative breast cancer. World J Clin Oncol 2014;5:125-33. [PMID: 24829859 DOI: 10.5306/wjco.v5.i2.125] [Cited by in CrossRef: 72] [Cited by in F6Publishing: 65] [Article Influence: 10.3] [Reference Citation Analysis]
83 Huang J, Luo Q, Xiao Y, Li H, Kong L, Ren G. The implication from RAS/RAF/ERK signaling pathway increased activation in epirubicin treated triple negative breast cancer. Oncotarget 2017;8:108249-60. [PMID: 29296238 DOI: 10.18632/oncotarget.22604] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
84 Nahleh Z, Sivasubramaniam D, Dhaliwal S, Sundarajan V, Komrokji R. Residual cancer burden in locally advanced breast cancer: a superior tool. Curr Oncol 2008;15:271-8. [PMID: 19079627 DOI: 10.3747/co.v15i6.242] [Cited by in Crossref: 25] [Cited by in F6Publishing: 14] [Article Influence: 2.3] [Reference Citation Analysis]
85 Wang RX, Chen S, Jin X, Shao ZM. Value of Ki-67 expression in triple-negative breast cancer before and after neoadjuvant chemotherapy with weekly paclitaxel plus carboplatin. Sci Rep 2016;6:30091. [PMID: 27426056 DOI: 10.1038/srep30091] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 2.0] [Reference Citation Analysis]
86 Ovcaricek T, Frkovic SG, Matos E, Mozina B, Borstnar S. Triple negative breast cancer - prognostic factors and survival. Radiol Oncol 2011;45:46-52. [PMID: 22933934 DOI: 10.2478/v10019-010-0054-4] [Cited by in Crossref: 95] [Cited by in F6Publishing: 90] [Article Influence: 8.6] [Reference Citation Analysis]
87 Prat A, Ellis MJ, Perou CM. Practical implications of gene-expression-based assays for breast oncologists. Nat Rev Clin Oncol. 2012;9:48-57. [PMID: 22143140 DOI: 10.1038/nrclinonc.2011.178] [Cited by in Crossref: 195] [Cited by in F6Publishing: 164] [Article Influence: 19.5] [Reference Citation Analysis]
88 Lehmann BD, Bauer JA, Chen X, Sanders ME, Chakravarthy AB, Shyr Y, Pietenpol JA. Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J Clin Invest. 2011;121:2750-2767. [PMID: 21633166 DOI: 10.1172/jci45014] [Cited by in Crossref: 2695] [Cited by in F6Publishing: 1687] [Article Influence: 269.5] [Reference Citation Analysis]
89 Anbalagan M, Ali A, Jones RK, Marsden CG, Sheng M, Carrier L, Bu Y, Hangauer D, Rowan BG. Peptidomimetic Src/pretubulin inhibitor KX-01 alone and in combination with paclitaxel suppresses growth, metastasis in human ER/PR/HER2-negative tumor xenografts. Mol Cancer Ther 2012;11:1936-47. [PMID: 22784709 DOI: 10.1158/1535-7163.MCT-12-0146] [Cited by in Crossref: 20] [Cited by in F6Publishing: 11] [Article Influence: 2.2] [Reference Citation Analysis]
90 Oualla K, El-Zawahry HM, Arun B, Reuben JM, Woodward WA, Gamal El-Din H, Lim B, Mellas N, Ueno NT, Fouad TM. Novel therapeutic strategies in the treatment of triple-negative breast cancer. Ther Adv Med Oncol 2017;9:493-511. [PMID: 28717401 DOI: 10.1177/1758834017711380] [Cited by in Crossref: 37] [Cited by in F6Publishing: 33] [Article Influence: 9.3] [Reference Citation Analysis]
91 Nguyen C, Baskaran K, Pupulin A, Ruvinov I, Zaitoon O, Grewal S, Scaria B, Mehaidli A, Vegh C, Pandey S. Hibiscus flower extract selectively induces apoptosis in breast cancer cells and positively interacts with common chemotherapeutics. BMC Complement Altern Med 2019;19:98. [PMID: 31060537 DOI: 10.1186/s12906-019-2505-9] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 7.0] [Reference Citation Analysis]
92 Perou CM, Børresen-Dale AL. Systems biology and genomics of breast cancer. Cold Spring Harb Perspect Biol 2011;3:a003293. [PMID: 21047916 DOI: 10.1101/cshperspect.a003293] [Cited by in Crossref: 105] [Cited by in F6Publishing: 103] [Article Influence: 10.5] [Reference Citation Analysis]
93 Kim YJ, Sung M, Oh E, Vrancken MV, Song JY, Jung K, Choi YL. Engrailed 1 overexpression as a potential prognostic marker in quintuple-negative breast cancer. Cancer Biol Ther 2018;19:335-45. [PMID: 29333926 DOI: 10.1080/15384047.2018.1423913] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.7] [Reference Citation Analysis]
94 Kwan ML, Kushi LH, Weltzien E, Maring B, Kutner SE, Fulton RS, Lee MM, Ambrosone CB, Caan BJ. Epidemiology of breast cancer subtypes in two prospective cohort studies of breast cancer survivors. Breast Cancer Res 2009;11:R31. [PMID: 19463150 DOI: 10.1186/bcr2261] [Cited by in Crossref: 206] [Cited by in F6Publishing: 177] [Article Influence: 17.2] [Reference Citation Analysis]
95 Chang J, Lee A, Lee J, Lim W, Sung SH, Moon BI. Correlation between the molecular subtype of breast cancer and the in vitro adenosine triphosphate-based chemosensitivity assay. J Korean Surg Soc 2013;84:313-20. [PMID: 23741688 DOI: 10.4174/jkss.2013.84.6.313] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
96 Ma H, Ursin G, Xu X, Lee E, Togawa K, Duan L, Lu Y, Malone KE, Marchbanks PA, McDonald JA, Simon MS, Folger SG, Sullivan-Halley J, Deapen DM, Press MF, Bernstein L. Reproductive factors and the risk of triple-negative breast cancer in white women and African-American women: a pooled analysis. Breast Cancer Res 2017;19:6. [PMID: 28086982 DOI: 10.1186/s13058-016-0799-9] [Cited by in Crossref: 34] [Cited by in F6Publishing: 22] [Article Influence: 8.5] [Reference Citation Analysis]
97 Gencoglu MF, Barney LE, Hall CL, Brooks EA, Schwartz AD, Corbett DC, Stevens KR, Peyton SR. Comparative Study of Multicellular Tumor Spheroid Formation Methods and Implications for Drug Screening. ACS Biomater Sci Eng 2018;4:410-20. [PMID: 29527571 DOI: 10.1021/acsbiomaterials.7b00069] [Cited by in Crossref: 41] [Cited by in F6Publishing: 34] [Article Influence: 10.3] [Reference Citation Analysis]
98 Arun B, Bayraktar S, Liu DD, Gutierrez Barrera AM, Atchley D, Pusztai L, Litton JK, Valero V, Meric-Bernstam F, Hortobagyi GN, Albarracin C. Response to neoadjuvant systemic therapy for breast cancer in BRCA mutation carriers and noncarriers: a single-institution experience. J Clin Oncol 2011;29:3739-46. [PMID: 21900106 DOI: 10.1200/JCO.2011.35.2682] [Cited by in Crossref: 113] [Cited by in F6Publishing: 48] [Article Influence: 11.3] [Reference Citation Analysis]
99 Deng X, Apple S, Zhao H, Song J, Lee M, Luo W, Wu X, Chung D, Pietras RJ, Chang HR. CD24 Expression and differential resistance to chemotherapy in triple-negative breast cancer. Oncotarget 2017;8:38294-308. [PMID: 28418843 DOI: 10.18632/oncotarget.16203] [Cited by in Crossref: 20] [Cited by in F6Publishing: 17] [Article Influence: 6.7] [Reference Citation Analysis]
100 Crozier JA, Advani PP, LaPlant B, Hobday T, Jaslowski AJ, Moreno-Aspitia A, Perez EA. N0436 (Alliance): A Phase II Trial of Irinotecan With Cetuximab in Patients With Metastatic Breast Cancer Previously Exposed to Anthracycline and/or Taxane-Containing Therapy. Clin Breast Cancer 2016;16:23-30. [PMID: 26381420 DOI: 10.1016/j.clbc.2015.08.002] [Cited by in Crossref: 25] [Cited by in F6Publishing: 21] [Article Influence: 4.2] [Reference Citation Analysis]
101 Daniels SL, Burghel GJ, Chambers P, Al-Baba S, Connley DD, Brock IW, Cramp HE, Dotsenko O, Wilks O, Wyld L, Cross SS, Cox A. Levels of DNA Methylation Vary at CpG Sites across the BRCA1 Promoter, and Differ According to Triple Negative and "BRCA-Like" Status, in Both Blood and Tumour DNA. PLoS One 2016;11:e0160174. [PMID: 27463681 DOI: 10.1371/journal.pone.0160174] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 2.0] [Reference Citation Analysis]
102 Ring BZ, Hout DR, Morris SW, Lawrence K, Schweitzer BL, Bailey DB, Lehmann BD, Pietenpol JA, Seitz RS. Generation of an algorithm based on minimal gene sets to clinically subtype triple negative breast cancer patients. BMC Cancer 2016;16:143. [PMID: 26908167 DOI: 10.1186/s12885-016-2198-0] [Cited by in Crossref: 34] [Cited by in F6Publishing: 32] [Article Influence: 6.8] [Reference Citation Analysis]
103 Mosalpuria K, Hall C, Krishnamurthy S, Lodhi A, Hallman DM, Baraniuk MS, Bhattacharyya A, Lucci A. Cyclooxygenase-2 expression in non-metastatic triple-negative breast cancer patients. Mol Clin Oncol 2014;2:845-50. [PMID: 25054056 DOI: 10.3892/mco.2014.327] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 2.3] [Reference Citation Analysis]
104 Verma S, Provencher L, Dent R. Emerging trends in the treatment of triple-negative breast cancer in Canada: a survey. Curr Oncol 2011;18:180-90. [PMID: 21874117 DOI: 10.3747/co.v18i4.913] [Cited by in Crossref: 10] [Cited by in F6Publishing: 13] [Article Influence: 1.0] [Reference Citation Analysis]
105 Darb-Esfahani S, Kronenwett R, von Minckwitz G, Denkert C, Gehrmann M, Rody A, Budczies J, Brase JC, Mehta MK, Bojar H, Ataseven B, Karn T, Weiss E, Zahm DM, Khandan F, Dietel M, Loibl S. Thymosin beta 15A (TMSB15A) is a predictor of chemotherapy response in triple-negative breast cancer. Br J Cancer 2012;107:1892-900. [PMID: 23079573 DOI: 10.1038/bjc.2012.475] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 1.1] [Reference Citation Analysis]
106 Orlando FA, Brown KD. Unraveling breast cancer heterogeneity through transcriptomic and epigenomic analysis. Ann Surg Oncol 2009;16:2270-9. [PMID: 19452229 DOI: 10.1245/s10434-009-0500-y] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 1.1] [Reference Citation Analysis]
107 Zeng Y, Wang G, Zhou CF, Zhang HB, Sun H, Zhang W, Zhou HH, Liu R, Zhu YS. LncRNA Profile Study Reveals a Three-LncRNA Signature Associated With the Pathological Complete Response Following Neoadjuvant Chemotherapy in Breast Cancer. Front Pharmacol 2019;10:574. [PMID: 31191314 DOI: 10.3389/fphar.2019.00574] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 5.0] [Reference Citation Analysis]
108 Kao KJ, Chang KM, Hsu HC, Huang AT. Correlation of microarray-based breast cancer molecular subtypes and clinical outcomes: implications for treatment optimization. BMC Cancer 2011;11:143. [PMID: 21501481 DOI: 10.1186/1471-2407-11-143] [Cited by in Crossref: 174] [Cited by in F6Publishing: 156] [Article Influence: 17.4] [Reference Citation Analysis]
109 Chacón RD, Costanzo MV. Triple-negative breast cancer. Breast Cancer Res 2010;12 Suppl 2:S3. [PMID: 21050424 DOI: 10.1186/bcr2574] [Cited by in Crossref: 136] [Cited by in F6Publishing: 133] [Article Influence: 12.4] [Reference Citation Analysis]
110 Onesti CE, Josse C, Poncin A, Frères P, Poulet C, Bours V, Jerusalem G. Predictive and prognostic role of peripheral blood eosinophil count in triple-negative and hormone receptor-negative/HER2-positive breast cancer patients undergoing neoadjuvant treatment. Oncotarget 2018;9:33719-33. [PMID: 30263098 DOI: 10.18632/oncotarget.26120] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.7] [Reference Citation Analysis]
111 Moon HG, Hwang KT, Kim JA, Kim HS, Lee MJ, Jung EM, Ko E, Han W, Noh DY. NFIB is a potential target for estrogen receptor-negative breast cancers. Mol Oncol 2011;5:538-44. [PMID: 21925980 DOI: 10.1016/j.molonc.2011.08.002] [Cited by in Crossref: 36] [Cited by in F6Publishing: 34] [Article Influence: 3.6] [Reference Citation Analysis]
112 Tan AS, Yeong JPS, Lai CPT, Ong CHC, Lee B, Lim JCT, Thike AA, Iqbal J, Dent RA, Lim EH, Tan PH. The role of Ki-67 in Asian triple negative breast cancers: a novel combinatory panel approach. Virchows Arch 2019;475:709-25. [PMID: 31407032 DOI: 10.1007/s00428-019-02635-4] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
113 Chung MJ, Lee JH, Kim SH, Suh YJ, Choi HJ. Simple Prediction Model of Axillary Lymph Node Positivity After Analyzing Molecular and Clinical Factors in Early Breast Cancer. Medicine (Baltimore) 2016;95:e3689. [PMID: 27196477 DOI: 10.1097/MD.0000000000003689] [Cited by in Crossref: 11] [Cited by in F6Publishing: 3] [Article Influence: 2.8] [Reference Citation Analysis]
114 Sambade MJ, Camp JT, Kimple RJ, Sartor CI, Shields JM. Mechanism of lapatinib-mediated radiosensitization of breast cancer cells is primarily by inhibition of the Raf>MEK>ERK mitogen-activated protein kinase cascade and radiosensitization of lapatinib-resistant cells restored by direct inhibition of MEK. Radiother Oncol 2009;93:639-44. [PMID: 19853943 DOI: 10.1016/j.radonc.2009.09.006] [Cited by in Crossref: 37] [Cited by in F6Publishing: 33] [Article Influence: 3.1] [Reference Citation Analysis]
115 Bastos EP, Brentani H, Pasini FS, Silva AR, Torres CH, Puga RD, Ribeiro Olivieri EH, Piovezani AR, Pereira CA, Machado-Lima A, Carraro DM, Brentani MM. MicroRNAs discriminate familial from sporadic non-BRCA1/2 breast carcinoma arising in patients ≤35 years. PLoS One 2014;9:e101656. [PMID: 25006670 DOI: 10.1371/journal.pone.0101656] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.1] [Reference Citation Analysis]
116 Hamilton N, Austin D, Márquez-Garbán D, Sanchez R, Chau B, Foos K, Wu Y, Vadgama J, Pietras R. Receptors for Insulin-Like Growth Factor-2 and Androgens as Therapeutic Targets in Triple-Negative Breast Cancer. Int J Mol Sci 2017;18:E2305. [PMID: 29099049 DOI: 10.3390/ijms18112305] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
117 Bischoff J, Ignatov A. The Role of Targeted Agents in the Treatment of Metastatic Breast Cancer. Breast Care (Basel) 2010;5:134-41. [PMID: 20847826 DOI: 10.1159/000314996] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
118 Martey O, Nimick M, Taurin S, Sundararajan V, Greish K, Rosengren RJ. Styrene maleic acid-encapsulated RL71 micelles suppress tumor growth in a murine xenograft model of triple negative breast cancer. Int J Nanomedicine 2017;12:7225-37. [PMID: 29042771 DOI: 10.2147/IJN.S148908] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.8] [Reference Citation Analysis]
119 Lyes MA, Payne S, Ferrell P, Pizzo SV, Hollenbeck ST, Bachelder RE. Adipose stem cell crosstalk with chemo-residual breast cancer cells: implications for tumor recurrence. Breast Cancer Res Treat 2019;174:413-22. [PMID: 30594967 DOI: 10.1007/s10549-018-05103-w] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.7] [Reference Citation Analysis]
120 Bower JJ, Song L, Bastola P, Hirsch ML. Harnessing the Natural Biology of Adeno-Associated Virus to Enhance the Efficacy of Cancer Gene Therapy. Viruses 2021;13:1205. [PMID: 34201599 DOI: 10.3390/v13071205] [Reference Citation Analysis]
121 Guha R, Yue B, Dong J, Banerjee A, Serrero G. Anti-progranulin/GP88 antibody AG01 inhibits triple negative breast cancer cell proliferation and migration. Breast Cancer Res Treat 2021;186:637-53. [PMID: 33616772 DOI: 10.1007/s10549-021-06120-y] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
122 Vigata M, Meinert C, Pahoff S, Bock N, Hutmacher DW. Gelatin Methacryloyl Hydrogels Control the Localized Delivery of Albumin-Bound Paclitaxel. Polymers (Basel) 2020;12:E501. [PMID: 32102478 DOI: 10.3390/polym12020501] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 7.0] [Reference Citation Analysis]
123 Kakarala M, Rozek L, Cote M, Liyanage S, Brenner DE. Breast cancer histology and receptor status characterization in Asian Indian and Pakistani women in the U.S.--a SEER analysis. BMC Cancer 2010;10:191. [PMID: 20459777 DOI: 10.1186/1471-2407-10-191] [Cited by in Crossref: 57] [Cited by in F6Publishing: 46] [Article Influence: 5.2] [Reference Citation Analysis]
124 Huang L, Lang GT, Liu Q, Shi JX, Shao ZM, Cao AY. A predictor of pathological complete response to neoadjuvant chemotherapy in triple-negative breast cancer patients with the DNA repair genes. Ann Transl Med 2021;9:301. [PMID: 33708928 DOI: 10.21037/atm-20-4852] [Reference Citation Analysis]
125 Chaudhary LN. Early stage triple negative breast cancer: Management and future directions. Semin Oncol 2020;47:201-8. [PMID: 32507668 DOI: 10.1053/j.seminoncol.2020.05.006] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
126 Cocciolone V, Cannita K, Tessitore A, Mastroiaco V, Rinaldi L, Paradisi S, Irelli A, Baldi PL, Sidoni T, Ricevuto E, Dal Mas A, Calvisi G, Coletti G, Ciccozzi A, Pizzorno L, Resta V, Bafile A, Alesse E, Ficorella C. Neoadjuvant chemotherapy in breast cancer: a dose-dense schedule in real life and putative role of PIK3CA mutations. Oncotarget 2018;9:27380-96. [PMID: 29937992 DOI: 10.18632/oncotarget.25270] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
127 Rowe DL, Ozbay T, O'Regan RM, Nahta R. Modulation of the BRCA1 Protein and Induction of Apoptosis in Triple Negative Breast Cancer Cell Lines by the Polyphenolic Compound Curcumin. Breast Cancer (Auckl) 2009;3:61-75. [PMID: 19809577 DOI: 10.4137/bcbcr.s3067] [Cited by in Crossref: 9] [Cited by in F6Publishing: 13] [Article Influence: 0.8] [Reference Citation Analysis]
128 Fournier MV, Goodwin EC, Chen J, Obenauer JC, Tannenbaum SH, Brufsky AM. A Predictor of Pathological Complete Response to Neoadjuvant Chemotherapy Stratifies Triple Negative Breast Cancer Patients with High Risk of Recurrence. Sci Rep 2019;9:14863. [PMID: 31619719 DOI: 10.1038/s41598-019-51335-1] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
129 Lee E, McKean-Cowdin R, Ma H, Spicer DV, Van Den Berg D, Bernstein L, Ursin G. Characteristics of triple-negative breast cancer in patients with a BRCA1 mutation: results from a population-based study of young women. J Clin Oncol 2011;29:4373-80. [PMID: 22010008 DOI: 10.1200/JCO.2010.33.6446] [Cited by in Crossref: 72] [Cited by in F6Publishing: 35] [Article Influence: 7.2] [Reference Citation Analysis]
130 Yang H, Qian W, Yang L, Xie H, Jiang H. In Vivo Evaluation of a Miniaturized Fluorescence Molecular Tomography (FMT) Endoscope for Breast Cancer Detection Using Targeted Nanoprobes. Int J Mol Sci 2020;21:E9389. [PMID: 33317217 DOI: 10.3390/ijms21249389] [Reference Citation Analysis]
131 Dutta P, Sarkissyan M, Paico K, Wu Y, Vadgama JV. MCP-1 is overexpressed in triple-negative breast cancers and drives cancer invasiveness and metastasis. Breast Cancer Res Treat. 2018;170:477-486. [PMID: 29594759 DOI: 10.1007/s10549-018-4760-8] [Cited by in Crossref: 36] [Cited by in F6Publishing: 33] [Article Influence: 12.0] [Reference Citation Analysis]
132 Press DJ, Miller ME, Liederbach E, Yao K, Huo D. De novo metastasis in breast cancer: occurrence and overall survival stratified by molecular subtype. Clin Exp Metastasis 2017;34:457-65. [PMID: 29288366 DOI: 10.1007/s10585-017-9871-9] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 3.8] [Reference Citation Analysis]
133 Khilko N, Wang J, Wei B, Hicks DG, Tang P. Invasive Lobular Carcinomas Do Not Express Basal Cytokeratin Markers CK5/6, CK14 and CK17. Breast Cancer (Auckl) 2010;4:49-55. [PMID: 21151863 DOI: 10.4137/BCBCR.S5037] [Cited by in Crossref: 1] [Cited by in F6Publishing: 4] [Article Influence: 0.1] [Reference Citation Analysis]
134 Ambs S. Prognostic significance of subtype classification for short- and long-term survival in breast cancer: survival time holds the key. PLoS Med 2010;7:e1000281. [PMID: 20520798 DOI: 10.1371/journal.pmed.1000281] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
135 Jacot W, Lopez-Crapez E, Mollevi C, Boissière-Michot F, Simony-Lafontaine J, Ho-Pun-Cheung A, Chartron E, Theillet C, Lemoine A, Saffroy R, Lamy PJ, Guiu S. BRCA1 Promoter Hypermethylation is Associated with Good Prognosis and Chemosensitivity in Triple-Negative Breast Cancer. Cancers (Basel) 2020;12:E828. [PMID: 32235500 DOI: 10.3390/cancers12040828] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 7.0] [Reference Citation Analysis]
136 Julka PK, Chacko RT, Nag S, Parshad R, Nair A, Oh DS, Hu Z, Koppiker CB, Nair S, Dawar R, Dhindsa N, Miller ID, Ma D, Lin B, Awasthy B, Perou CM. A phase II study of sequential neoadjuvant gemcitabine plus doxorubicin followed by gemcitabine plus cisplatin in patients with operable breast cancer: prediction of response using molecular profiling. Br J Cancer 2008;98:1327-35. [PMID: 18382427 DOI: 10.1038/sj.bjc.6604322] [Cited by in Crossref: 34] [Cited by in F6Publishing: 28] [Article Influence: 2.6] [Reference Citation Analysis]
137 Bajaj R, Tripathi R, Sridhar TS, Korlimarla A, Choudhury KD, Suryavanshi M, Mehta A, Doval DC. Prognostic role of microRNA 182 and microRNA 18a in locally advanced triple negative breast cancer. PLoS One 2020;15:e0242190. [PMID: 33175907 DOI: 10.1371/journal.pone.0242190] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
138 Ademuyiwa FO, Ellis MJ, Ma CX. Neoadjuvant therapy in operable breast cancer: application to triple negative breast cancer. J Oncol 2013;2013:219869. [PMID: 23983689 DOI: 10.1155/2013/219869] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.1] [Reference Citation Analysis]
139 McDaniel JM, Varley KE, Gertz J, Savic DS, Roberts BS, Bailey SK, Shevde LA, Ramaker RC, Lasseigne BN, Kirby MK, Newberry KM, Partridge EC, Jones AL, Boone B, Levy SE, Oliver PG, Sexton KC, Grizzle WE, Forero A, Buchsbaum DJ, Cooper SJ, Myers RM. Genomic regulation of invasion by STAT3 in triple negative breast cancer. Oncotarget 2017;8:8226-38. [PMID: 28030809 DOI: 10.18632/oncotarget.14153] [Cited by in Crossref: 42] [Cited by in F6Publishing: 37] [Article Influence: 14.0] [Reference Citation Analysis]
140 Blows FM, Driver KE, Schmidt MK, Broeks A, van Leeuwen FE, Wesseling J, Cheang MC, Gelmon K, Nielsen TO, Blomqvist C. Subtyping of breast cancer by immunohistochemistry to investigate a relationship between subtype and short and long term survival: a collaborative analysis of data for 10,159 cases from 12 studies. PLoS Med. 2010;7:e1000279. [PMID: 20520800 DOI: 10.1371/journal.pmed.1000279] [Cited by in Crossref: 550] [Cited by in F6Publishing: 484] [Article Influence: 50.0] [Reference Citation Analysis]
141 Esserman LJ, Berry DA, DeMichele A, Carey L, Davis SE, Buxton M, Hudis C, Gray JW, Perou C, Yau C. Pathologic complete response predicts recurrence-free survival more effectively by cancer subset: results from the I-SPY 1 TRIAL--CALGB 150007/150012, ACRIN 6657. J Clin Oncol. 2012;30:3242-3249. [PMID: 22649152 DOI: 10.1200/jco.2011.39.2779] [Cited by in Crossref: 284] [Cited by in F6Publishing: 144] [Article Influence: 31.6] [Reference Citation Analysis]
142 Chung A, Choi M, Han BC, Bose S, Zhang X, Medina-Kauwe L, Sims J, Murali R, Taguiam M, Varda M, Schiff R, Giuliano A, Cui X. Basal Protein Expression Is Associated With Worse Outcome and Trastuzamab Resistance in HER2+ Invasive Breast Cancer. Clin Breast Cancer 2015;15:448-457.e2. [PMID: 26248960 DOI: 10.1016/j.clbc.2015.06.001] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
143 Liu R, Chen H, Zhao P, Chen CH, Liang H, Yang C, Zhou Z, Zhi X, Liu S, Chen C. Mifepristone Derivative FZU-00,003 Suppresses Triple-negative Breast Cancer Cell Growth partially via miR-153-KLF5 axis. Int J Biol Sci 2020;16:611-9. [PMID: 32025209 DOI: 10.7150/ijbs.39491] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
144 Dawood S, Broglio K, Esteva FJ, Yang W, Kau SW, Islam R, Albarracin C, Yu TK, Green M, Hortobagyi GN, Gonzalez-Angulo AM. Survival among women with triple receptor-negative breast cancer and brain metastases. Ann Oncol 2009;20:621-7. [PMID: 19150943 DOI: 10.1093/annonc/mdn682] [Cited by in Crossref: 104] [Cited by in F6Publishing: 96] [Article Influence: 8.7] [Reference Citation Analysis]
145 Bauer JA, Chakravarthy AB, Rosenbluth JM, Mi D, Seeley EH, De Matos Granja-Ingram N, Olivares MG, Kelley MC, Mayer IA, Meszoely IM. Identification of markers of taxane sensitivity using proteomic and genomic analyses of breast tumors from patients receiving neoadjuvant paclitaxel and radiation. Clin Cancer Res. 2010;16:681-690. [PMID: 20068102 DOI: 10.1158/1078-0432.ccr-09-1091] [Cited by in Crossref: 123] [Cited by in F6Publishing: 58] [Article Influence: 11.2] [Reference Citation Analysis]
146 Tischkowitz M, Brunet JS, Bégin LR, Huntsman DG, Cheang MC, Akslen LA, Nielsen TO, Foulkes WD. Use of immunohistochemical markers can refine prognosis in triple negative breast cancer. BMC Cancer. 2007;7:134. [PMID: 17650314 DOI: 10.1186/1471-2407-7-134] [Cited by in Crossref: 259] [Cited by in F6Publishing: 233] [Article Influence: 18.5] [Reference Citation Analysis]
147 Abe S, Yamamoto K, Kurata M, Abe-Suzuki S, Horii R, Akiyama F, Kitagawa M. Targeting MCM2 function as a novel strategy for the treatment of highly malignant breast tumors. Oncotarget 2015;6:34892-909. [PMID: 26430873 DOI: 10.18632/oncotarget.5408] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
148 Wang W, Yuan P, Yu D, Du F, Zhu A, Li Q, Zhang P, Lin D, Xu B. A single-nucleotide polymorphism in the 3'-UTR region of the adipocyte fatty acid binding protein 4 gene is associated with prognosis of triple-negative breast cancer. Oncotarget 2016;7:18984-98. [PMID: 26959740 DOI: 10.18632/oncotarget.7920] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 2.3] [Reference Citation Analysis]
149 Chernyy V, Pustylnyak V, Kozlov V, Gulyaeva L. Increased expression of miR-155 and miR-222 is associated with lymph node positive status. J Cancer 2018;9:135-40. [PMID: 29290778 DOI: 10.7150/jca.22181] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 4.3] [Reference Citation Analysis]
150 Yerushalmi R, Raiter A, Nalbandyan K, Hardy B. Cell surface GRP78: A potential marker of good prognosis and response to chemotherapy in breast cancer. Oncol Lett 2015;10:2149-55. [PMID: 26622810 DOI: 10.3892/ol.2015.3579] [Cited by in Crossref: 17] [Cited by in F6Publishing: 12] [Article Influence: 2.8] [Reference Citation Analysis]
151 Chen F, Li Y, Qin N, Wang F, Du J, Wang C, Du F, Jiang T, Jiang Y, Dai J, Hu Z, Lu C, Shen H. RNA-seq analysis identified hormone-related genes associated with prognosis of triple negative breast cancer. J Biomed Res 2020;34:129-38. [PMID: 32305967 DOI: 10.7555/JBR.34.20190111] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
152 Gaudet MM, Press MF, Haile RW, Lynch CF, Glaser SL, Schildkraut J, Gammon MD, Douglas Thompson W, Bernstein JL. Risk factors by molecular subtypes of breast cancer across a population-based study of women 56 years or younger. Breast Cancer Res Treat 2011;130:587-97. [PMID: 21667121 DOI: 10.1007/s10549-011-1616-x] [Cited by in Crossref: 104] [Cited by in F6Publishing: 99] [Article Influence: 10.4] [Reference Citation Analysis]
153 Sakuma K, Kurosumi M, Oba H, Kobayashi Y, Takei H, Inoue K, Tabei T, Oyama T. Pathological tumor response to neoadjuvant chemotherapy using anthracycline and taxanes in patients with triple-negative breast cancer. Exp Ther Med 2011;2:257-64. [PMID: 22977494 DOI: 10.3892/etm.2011.212] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 0.9] [Reference Citation Analysis]
154 Nakashoji A, Matsui A, Nagayama A, Iwata Y, Sasahara M, Murata Y. Clinical predictors of pathological complete response to neoadjuvant chemotherapy in triple-negative breast cancer. Oncol Lett 2017;14:4135-41. [PMID: 28943920 DOI: 10.3892/ol.2017.6692] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 3.0] [Reference Citation Analysis]
155 Bousquet G, El Bouchtaoui M, Sophie T, Leboeuf C, de Bazelaire C, Ratajczak P, Giacchetti S, de Roquancourt A, Bertheau P, Verneuil L, Feugeas JP, Espié M, Janin A. Targeting autophagic cancer stem-cells to reverse chemoresistance in human triple negative breast cancer. Oncotarget 2017;8:35205-21. [PMID: 28445132 DOI: 10.18632/oncotarget.16925] [Cited by in Crossref: 33] [Cited by in F6Publishing: 27] [Article Influence: 11.0] [Reference Citation Analysis]
156 Wang G, Dong Y, Liu H, Ji N, Cao J, Liu A, Tang X, Ren Y. Loss of miR-873 contributes to gemcitabine resistance in triple-negative breast cancer via targeting ZEB1. Oncol Lett 2019;18:3837-44. [PMID: 31579087 DOI: 10.3892/ol.2019.10697] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 3.5] [Reference Citation Analysis]
157 da Silva GB, Silva TG, Duarte RA, Neto NL, Carrara HH, Donadi EA, Gonçalves MA, Soares EG, Soares CP. Expression of the Classical and Nonclassical HLA Molecules in Breast Cancer. Int J Breast Cancer 2013;2013:250435. [PMID: 24363939 DOI: 10.1155/2013/250435] [Cited by in Crossref: 38] [Cited by in F6Publishing: 36] [Article Influence: 4.8] [Reference Citation Analysis]
158 McGuire A, Casey MC, Waldron RM, Heneghan H, Kalinina O, Holian E, McDermott A, Lowery AJ, Newell J, Dwyer RM, Miller N, Keane M, Brown JAL, Kerin MJ. Prospective Assessment of Systemic MicroRNAs as Markers of Response to Neoadjuvant Chemotherapy in Breast Cancer. Cancers (Basel) 2020;12:E1820. [PMID: 32645898 DOI: 10.3390/cancers12071820] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
159 Usary J, Zhao W, Darr D, Roberts PJ, Liu M, Balletta L, Karginova O, Jordan J, Combest A, Bridges A, Prat A, Cheang MC, Herschkowitz JI, Rosen JM, Zamboni W, Sharpless NE, Perou CM. Predicting drug responsiveness in human cancers using genetically engineered mice. Clin Cancer Res 2013;19:4889-99. [PMID: 23780888 DOI: 10.1158/1078-0432.CCR-13-0522] [Cited by in Crossref: 41] [Cited by in F6Publishing: 34] [Article Influence: 5.1] [Reference Citation Analysis]
160 Jusino S, Fernández-Padín FM, Saavedra HI. Centrosome aberrations and chromosome instability contribute to tumorigenesis and intra-tumor heterogeneity. J Cancer Metastasis Treat 2018;4:43. [PMID: 30381801 DOI: 10.20517/2394-4722.2018.24] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
161 Kurbel S. In search of triple-negative DCIS: tumor-type dependent model of breast cancer progression from DCIS to the invasive cancer. Tumour Biol 2013;34:1-7. [PMID: 23208673 DOI: 10.1007/s13277-012-0602-1] [Cited by in Crossref: 22] [Cited by in F6Publishing: 18] [Article Influence: 2.4] [Reference Citation Analysis]
162 Wang S, Shi Y, Yuan Z, Wang X, Liu D, Peng R, Teng X, Qin T, Peng J, Lin G, Jiang X. Classical CMF regimen as adjuvant chemotherapy for triple-negative breast cancer may be more effective compared with anthracycline or taxane-based regimens. Med Oncol 2012;29:547-53. [PMID: 21528408 DOI: 10.1007/s12032-011-9964-2] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.7] [Reference Citation Analysis]
163 Heiser LM, Sadanandam A, Kuo WL, Benz SC, Goldstein TC, Ng S, Gibb WJ, Wang NJ, Ziyad S, Tong F, Bayani N, Hu Z, Billig JI, Dueregger A, Lewis S, Jakkula L, Korkola JE, Durinck S, Pepin F, Guan Y, Purdom E, Neuvial P, Bengtsson H, Wood KW, Smith PG, Vassilev LT, Hennessy BT, Greshock J, Bachman KE, Hardwicke MA, Park JW, Marton LJ, Wolf DM, Collisson EA, Neve RM, Mills GB, Speed TP, Feiler HS, Wooster RF, Haussler D, Stuart JM, Gray JW, Spellman PT. Subtype and pathway specific responses to anticancer compounds in breast cancer. Proc Natl Acad Sci U S A 2012;109:2724-9. [PMID: 22003129 DOI: 10.1073/pnas.1018854108] [Cited by in Crossref: 321] [Cited by in F6Publishing: 269] [Article Influence: 32.1] [Reference Citation Analysis]
164 Keam B, Im SA, Kim HJ, Oh DY, Kim JH, Lee SH, Chie EK, Han W, Kim DW, Moon WK, Kim TY, Park IA, Noh DY, Heo DS, Ha SW, Bang YJ. Prognostic impact of clinicopathologic parameters in stage II/III breast cancer treated with neoadjuvant docetaxel and doxorubicin chemotherapy: paradoxical features of the triple negative breast cancer. BMC Cancer 2007;7:203. [PMID: 17976237 DOI: 10.1186/1471-2407-7-203] [Cited by in Crossref: 105] [Cited by in F6Publishing: 95] [Article Influence: 7.5] [Reference Citation Analysis]
165 Silver DP, Richardson AL, Eklund AC, Wang ZC, Szallasi Z, Li Q, Juul N, Leong CO, Calogrias D, Buraimoh A, Fatima A, Gelman RS, Ryan PD, Tung NM, De Nicolo A, Ganesan S, Miron A, Colin C, Sgroi DC, Ellisen LW, Winer EP, Garber JE. Efficacy of neoadjuvant Cisplatin in triple-negative breast cancer. J Clin Oncol. 2010;28:1145-1153. [PMID: 20100965 DOI: 10.1200/jco.2009.22.4725] [Cited by in Crossref: 642] [Cited by in F6Publishing: 333] [Article Influence: 58.4] [Reference Citation Analysis]
166 Xie Q, Yang Z, Huang X, Zhang Z, Li J, Ju J, Zhang H, Ma J. Ilamycin C induces apoptosis and inhibits migration and invasion in triple-negative breast cancer by suppressing IL-6/STAT3 pathway. J Hematol Oncol. 2019;12:60. [PMID: 31186039 DOI: 10.1186/s13045-019-0744-3] [Cited by in Crossref: 20] [Cited by in F6Publishing: 23] [Article Influence: 10.0] [Reference Citation Analysis]
167 Sharpe R, Pearson A, Herrera-Abreu MT, Johnson D, Mackay A, Welti JC, Natrajan R, Reynolds AR, Reis-Filho JS, Ashworth A, Turner NC. FGFR signaling promotes the growth of triple-negative and basal-like breast cancer cell lines both in vitro and in vivo. Clin Cancer Res 2011;17:5275-86. [PMID: 21712446 DOI: 10.1158/1078-0432.CCR-10-2727] [Cited by in Crossref: 120] [Cited by in F6Publishing: 75] [Article Influence: 12.0] [Reference Citation Analysis]
168 Juliá EP, Amante A, Pampena MB, Mordoh J, Levy EM. Avelumab, an IgG1 anti-PD-L1 Immune Checkpoint Inhibitor, Triggers NK Cell-Mediated Cytotoxicity and Cytokine Production Against Triple Negative Breast Cancer Cells. Front Immunol 2018;9:2140. [PMID: 30294328 DOI: 10.3389/fimmu.2018.02140] [Cited by in Crossref: 41] [Cited by in F6Publishing: 38] [Article Influence: 13.7] [Reference Citation Analysis]
169 He JH, Luo RZ, Cai MY, Li M, Lu JB, Yuan ZY. Decreased expression of light chain 3 (LC3) increased the risk of distant metastasis in triple-negative breast cancer. Med Oncol 2013;30:468. [PMID: 23345115 DOI: 10.1007/s12032-013-0468-0] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
170 Zhao JJ, Silver DP. Estrogen receptor-negative breast cancer: new insights into subclassification and targeting. Clin Cancer Res. 2009;15:6309-6310. [PMID: 19825953 DOI: 10.1158/1078-0432.ccr-09-2010] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
171 Giro-Perafita A, Luo L, Khodadadi-Jamayran A, Thompson M, Akgol Oksuz B, Tsirigos A, Dynlacht BD, Sánchez I, Esteva FJ. LncRNA RP11-19E11 is an E2F1 target required for proliferation and survival of basal breast cancer. NPJ Breast Cancer 2020;6:1. [PMID: 31934613 DOI: 10.1038/s41523-019-0144-4] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 8.0] [Reference Citation Analysis]
172 Gao Y, Wang X, Li S, Zhang Z, Li X, Lin F. Identification of a DNA Methylation-Based Prognostic Signature for Patients with Triple-Negative Breast Cancer. Med Sci Monit 2021;27:e930025. [PMID: 34003815 DOI: 10.12659/MSM.930025] [Reference Citation Analysis]
173 Toyama T, Yamashita H, Kondo N, Okuda K, Takahashi S, Sasaki H, Sugiura H, Iwase H, Fujii Y. Frequently increased epidermal growth factor receptor (EGFR) copy numbers and decreased BRCA1 mRNA expression in Japanese triple-negative breast cancers. BMC Cancer. 2008;8:309. [PMID: 18950515 DOI: 10.1186/1471-2407-8-309] [Cited by in Crossref: 46] [Cited by in F6Publishing: 49] [Article Influence: 3.5] [Reference Citation Analysis]
174 Agarwal G, Nanda G, Lal P, Mishra A, Agarwal A, Agrawal V, Krishnani N. Outcomes of Triple-Negative Breast Cancers (TNBC) Compared with Non-TNBC: Does the Survival Vary for All Stages? World J Surg 2016;40:1362-72. [PMID: 26842691 DOI: 10.1007/s00268-016-3422-4] [Cited by in Crossref: 35] [Cited by in F6Publishing: 26] [Article Influence: 8.8] [Reference Citation Analysis]
175 Kvokačková B, Remšík J, Jolly MK, Souček K. Phenotypic Heterogeneity of Triple-Negative Breast Cancer Mediated by Epithelial-Mesenchymal Plasticity. Cancers (Basel) 2021;13:2188. [PMID: 34063254 DOI: 10.3390/cancers13092188] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
176 Rody A, Karn T, Liedtke C, Pusztai L, Ruckhaeberle E, Hanker L, Gaetje R, Solbach C, Ahr A, Metzler D, Schmidt M, Müller V, Holtrich U, Kaufmann M. A clinically relevant gene signature in triple negative and basal-like breast cancer. Breast Cancer Res 2011;13:R97. [PMID: 21978456 DOI: 10.1186/bcr3035] [Cited by in Crossref: 217] [Cited by in F6Publishing: 180] [Article Influence: 21.7] [Reference Citation Analysis]
177 Sizemore ST, Sizemore GM, Booth CN, Thompson CL, Silverman P, Bebek G, Abdul-Karim FW, Avril S, Keri RA. Hypomethylation of the MMP7 promoter and increased expression of MMP7 distinguishes the basal-like breast cancer subtype from other triple-negative tumors. Breast Cancer Res Treat 2014;146:25-40. [PMID: 24847890 DOI: 10.1007/s10549-014-2989-4] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 2.3] [Reference Citation Analysis]
178 Ebelt ND, Kaoud TS, Edupuganti R, Van Ravenstein S, Dalby KN, Van Den Berg CL. A c-Jun N-terminal kinase inhibitor, JNK-IN-8, sensitizes triple negative breast cancer cells to lapatinib. Oncotarget. 2017;8:104894-104912. [PMID: 29285221 DOI: 10.18632/oncotarget.20581] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 3.8] [Reference Citation Analysis]
179 Nekulova M, Holcakova J, Gu X, Hrabal V, Galtsidis S, Orzol P, Liu Y, Logotheti S, Zoumpourlis V, Nylander K, Coates PJ, Vojtesek B. ΔNp63α expression induces loss of cell adhesion in triple-negative breast cancer cells. BMC Cancer 2016;16:782. [PMID: 27724925 DOI: 10.1186/s12885-016-2808-x] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.6] [Reference Citation Analysis]
180 Podo F, Buydens LM, Degani H, Hilhorst R, Klipp E, Gribbestad IS, Van Huffel S, van Laarhoven HW, Luts J, Monleon D, Postma GJ, Schneiderhan-Marra N, Santoro F, Wouters H, Russnes HG, Sørlie T, Tagliabue E, Børresen-Dale AL; FEMME Consortium. Triple-negative breast cancer: present challenges and new perspectives. Mol Oncol 2010;4:209-29. [PMID: 20537966 DOI: 10.1016/j.molonc.2010.04.006] [Cited by in Crossref: 181] [Cited by in F6Publishing: 174] [Article Influence: 16.5] [Reference Citation Analysis]
181 Gooding AJ, Schiemann WP. Epithelial-Mesenchymal Transition Programs and Cancer Stem Cell Phenotypes: Mediators of Breast Cancer Therapy Resistance. Mol Cancer Res. 2020;18:1257-1270. [PMID: 32503922 DOI: 10.1158/1541-7786.mcr-20-0067] [Cited by in Crossref: 24] [Cited by in F6Publishing: 16] [Article Influence: 24.0] [Reference Citation Analysis]
182 Panayotopoulou EG, Müller AK, Börries M, Busch H, Hu G, Lev S. Targeting of apoptotic pathways by SMAC or BH3 mimetics distinctly sensitizes paclitaxel-resistant triple negative breast cancer cells. Oncotarget 2017;8:45088-104. [PMID: 28187446 DOI: 10.18632/oncotarget.15125] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 4.3] [Reference Citation Analysis]
183 Purwaha P, Gu F, Piyarathna DWB, Rajendiran T, Ravindran A, Omilian AR, Jiralerspong S, Das G, Morrison C, Ambrosone C, Coarfa C, Putluri N, Sreekumar A. Unbiased Lipidomic Profiling of Triple-Negative Breast Cancer Tissues Reveals the Association of Sphingomyelin Levels with Patient Disease-Free Survival. Metabolites 2018;8:E41. [PMID: 30011843 DOI: 10.3390/metabo8030041] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 3.3] [Reference Citation Analysis]
184 Maxwell KN, Domchek SM. Cancer treatment according to BRCA1 and BRCA2 mutations. Nat Rev Clin Oncol 2012;9:520-8. [PMID: 22825375 DOI: 10.1038/nrclinonc.2012.123] [Cited by in Crossref: 52] [Cited by in F6Publishing: 47] [Article Influence: 5.8] [Reference Citation Analysis]
185 Gao M, Wang T, Ji L, Bai S, Tian L, Song H. Therapy With Carboplatin and Anti-PD-1 Antibodies Before Surgery Demonstrates Sustainable Anti-Tumor Effects for Secondary Cancers in Mice With Triple-Negative Breast Cancer. Front Immunol 2020;11:366. [PMID: 32194569 DOI: 10.3389/fimmu.2020.00366] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 8.0] [Reference Citation Analysis]
186 Yam C, Rauch GM, Rahman T, Karuturi M, Ravenberg E, White J, Clayborn A, McCarthy P, Abouharb S, Lim B, Litton JK, Ramirez DL, Saleem S, Stec J, Symmans WF, Huo L, Damodaran S, Sun R, Moulder SL. A phase II study of Mirvetuximab Soravtansine in triple-negative breast cancer. Invest New Drugs 2021;39:509-15. [PMID: 32984932 DOI: 10.1007/s10637-020-00995-2] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
187 Orr K, Buckley NE, Haddock P, James C, Parent JL, McQuaid S, Mullan PB. Thromboxane A2 receptor (TBXA2R) is a potent survival factor for triple negative breast cancers (TNBCs). Oncotarget 2016;7:55458-72. [PMID: 27487152 DOI: 10.18632/oncotarget.10969] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
188 Ye F, Tang H, Liu Q, Xie X, Wu M, Liu X, Chen B, Xie X. miR-200b as a prognostic factor in breast cancer targets multiple members of RAB family. J Transl Med 2014;12:17. [PMID: 24447584 DOI: 10.1186/1479-5876-12-17] [Cited by in Crossref: 50] [Cited by in F6Publishing: 48] [Article Influence: 7.1] [Reference Citation Analysis]
189 Dine JL, O'Sullivan CC, Voeller D, Greer YE, Chavez KJ, Conway CM, Sinclair S, Stone B, Amiri-Kordestani L, Merchant AS, Hewitt SM, Steinberg SM, Swain SM, Lipkowitz S. The TRAIL receptor agonist drozitumab targets basal B triple-negative breast cancer cells that express vimentin and Axl. Breast Cancer Res Treat 2016;155:235-51. [PMID: 26759246 DOI: 10.1007/s10549-015-3673-z] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
190 Kim JY, Jung EJ, Kim JM, Lee HS, Kwag SJ, Park JH, Park T, Jeong SH, Jeong CY, Ju YT. Dynamic changes of neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio predicts breast cancer prognosis. BMC Cancer 2020;20:1206. [PMID: 33287745 DOI: 10.1186/s12885-020-07700-9] [Reference Citation Analysis]
191 Chen F, Zhang Z, Yu Y, Liu Q, Pu F. HSulf‑1 and palbociclib exert synergistic antitumor effects on RB‑positive triple‑negative breast cancer. Int J Oncol 2020;57:223-36. [PMID: 32377705 DOI: 10.3892/ijo.2020.5057] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
192 Savage P, Pacis A, Kuasne H, Liu L, Lai D, Wan A, Dankner M, Martinez C, Muñoz-Ramos V, Pilon V, Monast A, Zhao H, Souleimanova M, Annis MG, Aguilar-Mahecha A, Lafleur J, Bertos NR, Asselah J, Bouganim N, Petrecca K, Siegel PM, Omeroglu A, Shah SP, Aparicio S, Basik M, Meterissian S, Park M. Chemogenomic profiling of breast cancer patient-derived xenografts reveals targetable vulnerabilities for difficult-to-treat tumors. Commun Biol 2020;3:310. [PMID: 32546838 DOI: 10.1038/s42003-020-1042-x] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 6.0] [Reference Citation Analysis]
193 Zhang C, Wang S, Israel HP, Yan SX, Horowitz DP, Crockford S, Gidea-Addeo D, Clifford Chao KS, Kalinsky K, Connolly EP. Higher locoregional recurrence rate for triple-negative breast cancer following neoadjuvant chemotherapy, surgery and radiotherapy. Springerplus 2015;4:386. [PMID: 26240784 DOI: 10.1186/s40064-015-1116-2] [Cited by in Crossref: 16] [Cited by in F6Publishing: 18] [Article Influence: 2.7] [Reference Citation Analysis]
194 Humbert O, Cochet A, Coudert B, Berriolo-Riedinger A, Kanoun S, Brunotte F, Fumoleau P. Role of positron emission tomography for the monitoring of response to therapy in breast cancer. Oncologist 2015;20:94-104. [PMID: 25561512 DOI: 10.1634/theoncologist.2014-0342] [Cited by in Crossref: 39] [Cited by in F6Publishing: 27] [Article Influence: 6.5] [Reference Citation Analysis]
195 Ruiz de Garibay G, Mateo F, Stradella A, Valdés-Mas R, Palomero L, Serra-Musach J, Puente DA, Díaz-Navarro A, Vargas-Parra G, Tornero E, Morilla I, Farré L, Martinez-Iniesta M, Herranz C, McCormack E, Vidal A, Petit A, Soler T, Lázaro C, Puente XS, Villanueva A, Pujana MA. Tumor xenograft modeling identifies an association between TCF4 loss and breast cancer chemoresistance. Dis Model Mech 2018;11:dmm032292. [PMID: 29666142 DOI: 10.1242/dmm.032292] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.7] [Reference Citation Analysis]
196 Masood S. Neoadjuvant chemotherapy in breast cancers. Womens Health (Lond). 2016;12:480-491. [PMID: 27885165 DOI: 10.1177/1745505716677139] [Cited by in Crossref: 25] [Cited by in F6Publishing: 14] [Article Influence: 6.3] [Reference Citation Analysis]
197 Kim HS, Lee Y, Lim YA, Kang HJ, Kim LS. αB-Crystallin is a Novel Oncoprotein Associated with Poor Prognosis in Breast Cancer. J Breast Cancer 2011;14:14-9. [PMID: 21847389 DOI: 10.4048/jbc.2011.14.1.14] [Cited by in Crossref: 24] [Cited by in F6Publishing: 22] [Article Influence: 2.4] [Reference Citation Analysis]
198 Singh A, Settleman J. EMT, cancer stem cells and drug resistance: an emerging axis of evil in the war on cancer. Oncogene. 2010;29:4741-4751. [PMID: 20531305 DOI: 10.1038/onc.2010.215] [Cited by in Crossref: 1663] [Cited by in F6Publishing: 1543] [Article Influence: 151.2] [Reference Citation Analysis]
199 Alves WEFM, Bonatelli M, Dufloth R, Kerr LM, Carrara GFA, da Costa RFA, Scapulatempo-Neto C, Tiezzi D, da Costa Vieira RA, Pinheiro C. CAIX is a predictor of pathological complete response and is associated with higher survival in locally advanced breast cancer submitted to neoadjuvant chemotherapy. BMC Cancer 2019;19:1173. [PMID: 31795962 DOI: 10.1186/s12885-019-6353-2] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
200 Luo RZ, Yuan ZY, Li M, Xi SY, Fu J, He J. Accumulation of p62 is associated with poor prognosis in patients with triple-negative breast cancer. Onco Targets Ther 2013;6:883-8. [PMID: 23888115 DOI: 10.2147/OTT.S46222] [Cited by in Crossref: 8] [Cited by in F6Publishing: 34] [Article Influence: 1.0] [Reference Citation Analysis]
201 Heiser LM, Wang NJ, Talcott CL, Laderoute KR, Knapp M, Guan Y, Hu Z, Ziyad S, Weber BL, Laquerre S, Jackson JR, Wooster RF, Kuo WL, Gray JW, Spellman PT. Integrated analysis of breast cancer cell lines reveals unique signaling pathways. Genome Biol 2009;10:R31. [PMID: 19317917 DOI: 10.1186/gb-2009-10-3-r31] [Cited by in Crossref: 49] [Cited by in F6Publishing: 41] [Article Influence: 4.1] [Reference Citation Analysis]
202 Zhu X, Zhang Q, Wang D, Liu C, Han B, Yang JM. Expression of PD-L1 Attenuates the Positive Impacts of High-level Tumor-infiltrating Lymphocytes on Prognosis of Triple-negative Breast Cancer. Cancer Biol Ther 2019;20:1105-12. [PMID: 30929569 DOI: 10.1080/15384047.2019.1595282] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 5.5] [Reference Citation Analysis]
203 Girgert R, Emons G, Gründker C. Inhibition of growth hormone receptor by Somavert reduces expression of GPER and prevents growth stimulation of triple-negative breast cancer by 17β-estradiol. Oncol Lett 2018;15:9559-66. [PMID: 29805678 DOI: 10.3892/ol.2018.8521] [Cited by in Crossref: 1] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
204 Mojica CAR, Ybañez WS, Olarte KCV, Poblete ABC, Bagamasbad PD. Differential Glucocorticoid-Dependent Regulation and Function of the ERRFI1 Gene in Triple-Negative Breast Cancer. Endocrinology 2020;161:bqaa082. [PMID: 32432675 DOI: 10.1210/endocr/bqaa082] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
205 Gucalp A, Traina TA. Triple-negative breast cancer: adjuvant therapeutic options. Chemother Res Pract 2011;2011:696208. [PMID: 22312556 DOI: 10.1155/2011/696208] [Cited by in Crossref: 18] [Cited by in F6Publishing: 33] [Article Influence: 1.8] [Reference Citation Analysis]
206 Schüler-Toprak S, Häring J, Inwald EC, Moehle C, Ortmann O, Treeck O. Agonists and knockdown of estrogen receptor β differentially affect invasion of triple-negative breast cancer cells in vitro. BMC Cancer 2016;16:951. [PMID: 28003019 DOI: 10.1186/s12885-016-2973-y] [Cited by in Crossref: 32] [Cited by in F6Publishing: 24] [Article Influence: 6.4] [Reference Citation Analysis]
207 Huijsmans CJ, van den Brule AJ, Rigter H, Poodt J, van der Linden JC, Savelkoul PH, Hilbink M, Hermans MH. Allelic imbalance at the HER2/TOP2A locus in breast cancer. Diagn Pathol 2015;10:56. [PMID: 26022247 DOI: 10.1186/s13000-015-0289-x] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
208 Wen J, Ye F, Li S, Huang X, Yang L, Xiao X, Xie X. The Practicability of a Novel Prognostic Index (PI) Model and Comparison with Nottingham Prognostic Index (NPI) in Stage I-III Breast Cancer Patients Undergoing Surgical Treatment. PLoS One 2015;10:e0143537. [PMID: 26600129 DOI: 10.1371/journal.pone.0143537] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
209 Liedtke C, Bernemann C, Kiesel L, Rody A. Genomic profiling in triple-negative breast cancer. Breast Care (Basel) 2013;8:408-13. [PMID: 24550748 DOI: 10.1159/000357534] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 2.1] [Reference Citation Analysis]
210 Horton JK, Siamakpour-Reihani S, Lee CT, Zhou Y, Chen W, Geradts J, Fels DR, Hoang P, Ashcraft KA, Groth J, Kung HN, Dewhirst MW, Chi JT. FAS Death Receptor: A Breast Cancer Subtype-Specific Radiation Response Biomarker and Potential Therapeutic Target. Radiat Res 2015;184:456-69. [PMID: 26488758 DOI: 10.1667/RR14089.1] [Cited by in Crossref: 19] [Cited by in F6Publishing: 9] [Article Influence: 3.2] [Reference Citation Analysis]
211 Dolle JM, Daling JR, White E, Brinton LA, Doody DR, Porter PL, Malone KE. Risk factors for triple-negative breast cancer in women under the age of 45 years. Cancer Epidemiol Biomarkers Prev. 2009;18:1157-1166. [PMID: 19336554 DOI: 10.1158/1055-9965.epi-08-1005] [Cited by in Crossref: 149] [Cited by in F6Publishing: 89] [Article Influence: 12.4] [Reference Citation Analysis]
212 Anders CK, Zagar TM, Carey LA. The management of early-stage and metastatic triple-negative breast cancer: a review. Hematol Oncol Clin North Am 2013;27:737-49, viii. [PMID: 23915742 DOI: 10.1016/j.hoc.2013.05.003] [Cited by in Crossref: 49] [Cited by in F6Publishing: 41] [Article Influence: 6.1] [Reference Citation Analysis]
213 Ribeiro E, Ganzinelli M, Andreis D, Bertoni R, Giardini R, Fox SB, Broggini M, Bottini A, Zanoni V, Bazzola L, Foroni C, Generali D, Damia G. Triple negative breast cancers have a reduced expression of DNA repair genes. PLoS One 2013;8:e66243. [PMID: 23825533 DOI: 10.1371/journal.pone.0066243] [Cited by in Crossref: 24] [Cited by in F6Publishing: 22] [Article Influence: 3.0] [Reference Citation Analysis]
214 Zhou T, Yi F, Wang Z, Guo Q, Liu J, Bai N, Li X, Dong X, Ren L, Cao L, Song X. The Functions of DNA Damage Factor RNF8 in the Pathogenesis and Progression of Cancer. Int J Biol Sci 2019;15:909-18. [PMID: 31182912 DOI: 10.7150/ijbs.31972] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
215 Vaz-Luis I, Winer EP, Lin NU. Human epidermal growth factor receptor-2-positive breast cancer: does estrogen receptor status define two distinct subtypes? Ann Oncol 2013;24:283-91. [PMID: 23022997 DOI: 10.1093/annonc/mds286] [Cited by in Crossref: 37] [Cited by in F6Publishing: 35] [Article Influence: 4.1] [Reference Citation Analysis]
216 Bennis S, Abbass F, Akasbi Y, Znati K, Joutei KA, El Mesbahi O, Amarti A. Prevalence of molecular subtypes and prognosis of invasive breast cancer in north-east of Morocco: retrospective study. BMC Res Notes 2012;5:436. [PMID: 22889054 DOI: 10.1186/1756-0500-5-436] [Cited by in Crossref: 19] [Cited by in F6Publishing: 12] [Article Influence: 2.1] [Reference Citation Analysis]
217 Lv X, He M, Zhao Y, Zhang L, Zhu W, Jiang L, Yan Y, Fan Y, Zhao H, Zhou S, Ma H, Sun Y, Li X, Xu H, Wei M. Identification of potential key genes and pathways predicting pathogenesis and prognosis for triple-negative breast cancer. Cancer Cell Int 2019;19:172. [PMID: 31297036 DOI: 10.1186/s12935-019-0884-0] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 5.0] [Reference Citation Analysis]
218 Chen L, Yang L, Qiao F, Hu X, Li S, Yao L, Yang XL, Shao ZM. High Levels of Nucleolar Spindle-Associated Protein and Reduced Levels of BRCA1 Expression Predict Poor Prognosis in Triple-Negative Breast Cancer. PLoS One 2015;10:e0140572. [PMID: 26485712 DOI: 10.1371/journal.pone.0140572] [Cited by in Crossref: 31] [Cited by in F6Publishing: 36] [Article Influence: 5.2] [Reference Citation Analysis]
219 Vernieri C, Prisciandaro M, Nichetti F, Lobefaro R, Peverelli G, Ligorio F, Zattarin E, Cona MS, Sepe P, Corti F, Manglaviti S, Brambilla M, Re B, Belfiore A, Pruneri G, Celio L, Mariani G, Bianchi GV, Rivoltini L, Capri G, de Braud F. Oral Capecitabine-Vinorelbine is Associated with Longer Overall Survival When Compared to Single-Agent Capecitabine in Patients with Hormone Receptor-Positive Advanced Breast Cancer. Cancers (Basel) 2020;12:E617. [PMID: 32155941 DOI: 10.3390/cancers12030617] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
220 Weber D, Zhang M, Zhuang P, Zhang Y, Wheat J, Currie G, Al-Eisawi Z. The efficacy of betulinic acid in triple-negative breast cancer. SAGE Open Med 2014;2:2050312114551974. [PMID: 26770742 DOI: 10.1177/2050312114551974] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
221 Echavarria I, López-Tarruella S, Picornell A, García-Saenz JÁ, Jerez Y, Hoadley K, Gómez HL, Moreno F, Monte-Millan MD, Márquez-Rodas I, Alvarez E, Ramos-Medina R, Gayarre J, Massarrah T, Ocaña I, Cebollero M, Fuentes H, Barnadas A, Ballesteros AI, Bohn U, Perou CM, Martin M. Pathological Response in a Triple-Negative Breast Cancer Cohort Treated with Neoadjuvant Carboplatin and Docetaxel According to Lehmann's Refined Classification. Clin Cancer Res 2018;24:1845-52. [PMID: 29378733 DOI: 10.1158/1078-0432.CCR-17-1912] [Cited by in Crossref: 27] [Cited by in F6Publishing: 17] [Article Influence: 9.0] [Reference Citation Analysis]
222 Hylton NM, Gatsonis CA, Rosen MA, Lehman CD, Newitt DC, Partridge SC, Bernreuter WK, Pisano ED, Morris EA, Weatherall PT, Polin SM, Newstead GM, Marques HS, Esserman LJ, Schnall MD; ACRIN 6657 Trial Team and I-SPY 1 TRIAL Investigators. Neoadjuvant Chemotherapy for Breast Cancer: Functional Tumor Volume by MR Imaging Predicts Recurrence-free Survival-Results from the ACRIN 6657/CALGB 150007 I-SPY 1 TRIAL. Radiology 2016;279:44-55. [PMID: 26624971 DOI: 10.1148/radiol.2015150013] [Cited by in Crossref: 106] [Cited by in F6Publishing: 96] [Article Influence: 17.7] [Reference Citation Analysis]
223 Egelston CA, Avalos C, Tu TY, Rosario A, Wang R, Solomon S, Srinivasan G, Nelson MS, Huang Y, Lim MH, Simons DL, He TF, Yim JH, Kruper L, Mortimer J, Yost S, Guo W, Ruel C, Frankel PH, Yuan Y, Lee PP. Resident memory CD8+ T cells within cancer islands mediate survival in breast cancer patients. JCI Insight. 2019;4. [PMID: 31465302 DOI: 10.1172/jci.insight.130000] [Cited by in Crossref: 26] [Cited by in F6Publishing: 22] [Article Influence: 13.0] [Reference Citation Analysis]
224 Asakawa H, Koizumi H, Koike A, Takahashi M, Wu W, Iwase H, Fukuda M, Ohta T. Prediction of breast cancer sensitivity to neoadjuvant chemotherapy based on status of DNA damage repair proteins. Breast Cancer Res. 2010;12:R17. [PMID: 20205718 DOI: 10.1186/bcr2486] [Cited by in Crossref: 70] [Cited by in F6Publishing: 58] [Article Influence: 6.4] [Reference Citation Analysis]
225 Teshome M, Hunt KK. Neoadjuvant therapy in the treatment of breast cancer. Surg Oncol Clin N Am 2014;23:505-23. [PMID: 24882348 DOI: 10.1016/j.soc.2014.03.006] [Cited by in Crossref: 62] [Cited by in F6Publishing: 48] [Article Influence: 8.9] [Reference Citation Analysis]
226 Saravia CH, Flores C, Schwarz LJ, Bravo L, Zavaleta J, Araujo J, Neciosup S, Pinto JA. Patterns of Mutation Enrichment in Metastatic Triple-Negative Breast Cancer. Clin Med Insights Oncol 2019;13:1179554919868482. [PMID: 31447598 DOI: 10.1177/1179554919868482] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
227 McGuire A, Brown JA, Malone C, McLaughlin R, Kerin MJ. Effects of age on the detection and management of breast cancer. Cancers (Basel) 2015;7:908-29. [PMID: 26010605 DOI: 10.3390/cancers7020815] [Cited by in Crossref: 140] [Cited by in F6Publishing: 118] [Article Influence: 23.3] [Reference Citation Analysis]
228 Hu J, Xu J, Wu Y, Chen Q, Zheng W, Lu X, Zhou C, Jiao D. Identification of microRNA-93 as a functional dysregulated miRNA in triple-negative breast cancer. Tumour Biol 2015;36:251-8. [PMID: 25238878 DOI: 10.1007/s13277-014-2611-8] [Cited by in Crossref: 35] [Cited by in F6Publishing: 37] [Article Influence: 5.0] [Reference Citation Analysis]
229 Dunn L, Demichele A. Genomic predictors of outcome and treatment response in breast cancer. Mol Diagn Ther 2009;13:73-90. [PMID: 19537843 DOI: 10.1007/BF03256317] [Cited by in Crossref: 29] [Cited by in F6Publishing: 14] [Article Influence: 2.4] [Reference Citation Analysis]
230 Soung YH, Kashyap T, Nguyen T, Yadav G, Chang H, Landesman Y, Chung J. Selective Inhibitors of Nuclear Export (SINE) compounds block proliferation and migration of triple negative breast cancer cells by restoring expression of ARRDC3. Oncotarget 2017;8:52935-47. [PMID: 28881784 DOI: 10.18632/oncotarget.17987] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 3.5] [Reference Citation Analysis]
231 Yang H, Li L, Zhang M, Zhang S, Xu S, Ma X. Application of neoadjuvant chemotherapy in occult breast cancer: Five case reports. Medicine (Baltimore). 2017;96:e8200. [PMID: 28984771 DOI: 10.1097/md.0000000000008200] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.8] [Reference Citation Analysis]
232 Witkiewicz AK, Chung S, Brough R, Vail P, Franco J, Lord CJ, Knudsen ES. Targeting the Vulnerability of RB Tumor Suppressor Loss in Triple-Negative Breast Cancer. Cell Rep. 2018;22:1185-1199. [PMID: 29386107 DOI: 10.1016/j.celrep.2018.01.022] [Cited by in Crossref: 34] [Cited by in F6Publishing: 29] [Article Influence: 17.0] [Reference Citation Analysis]
233 Pinto-Díez C, García-Recio EM, Pérez-Morgado MI, García-Hernández M, Sanz-Criado L, Sacristán S, Toledo-Lobo MV, Pérez-Mies B, Esteban-Rodríguez I, Pascual A, Garcia-Villanueva M, Martínez-Jañez N, González VM, Martín ME. Increased expression of MNK1b, the spliced isoform of MNK1, predicts poor prognosis and is associated with triple-negative breast cancer. Oncotarget 2018;9:13501-16. [PMID: 29568373 DOI: 10.18632/oncotarget.24417] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
234 Tang L, Lv SJ, Wu Z, Qian M, Xu Y, Gao X, Wang T, Guo W, Hou T, Li X, Li Z, Zhao J, Xiao J, Wei H. Role of betulinic acid derivative SH-479 in triple negative breast cancer and bone microenvironment. Oncol Lett 2021;22:605. [PMID: 34188707 DOI: 10.3892/ol.2021.12866] [Reference Citation Analysis]
235 Groheux D, Giacchetti S, Delord M, de Roquancourt A, Merlet P, Hamy AS, Espié M, Hindié E. Prognostic impact of 18F-FDG PET/CT staging and of pathological response to neoadjuvant chemotherapy in triple-negative breast cancer. Eur J Nucl Med Mol Imaging 2015;42:377-85. [PMID: 25432784 DOI: 10.1007/s00259-014-2941-1] [Cited by in Crossref: 28] [Cited by in F6Publishing: 25] [Article Influence: 4.0] [Reference Citation Analysis]
236 Saenz FR, Ory V, Schmidt MO, Kallakury BV, Mueller SC, Furth PA, Wellstein A, Riegel AT. Depletion of the Transcriptional Coactivator Amplified in Breast Cancer 1 (AIB1) Uncovers Functionally Distinct Subpopulations in Triple-Negative Breast Cancer. Neoplasia 2019;21:963-73. [PMID: 31437536 DOI: 10.1016/j.neo.2019.07.001] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
237 Dai X, Yin C, Zhang Y, Guo G, Zhao C, Wang O, Xiang Y, Zhang X, Liang G. Osthole inhibits triple negative breast cancer cells by suppressing STAT3. J Exp Clin Cancer Res 2018;37:322. [PMID: 30577812 DOI: 10.1186/s13046-018-0992-z] [Cited by in Crossref: 24] [Cited by in F6Publishing: 20] [Article Influence: 8.0] [Reference Citation Analysis]
238 Ungerleider NA, Rao SG, Shahbandi A, Yee D, Niu T, Frey WD, Jackson JG. Breast cancer survival predicted by TP53 mutation status differs markedly depending on treatment. Breast Cancer Res 2018;20:115. [PMID: 30285883 DOI: 10.1186/s13058-018-1044-5] [Cited by in Crossref: 27] [Cited by in F6Publishing: 22] [Article Influence: 9.0] [Reference Citation Analysis]
239 Li XR, Liu M, Zhang YJ, Wang JD, Zheng YQ, Li J, Ma B, Song X. CK5/6, EGFR, Ki-67, cyclin D1, and nm23-H1 protein expressions as predictors of pathological complete response to neoadjuvant chemotherapy in triple-negative breast cancer patients. Med Oncol 2011;28 Suppl 1:S129-34. [PMID: 21080107 DOI: 10.1007/s12032-010-9742-6] [Cited by in Crossref: 18] [Cited by in F6Publishing: 14] [Article Influence: 1.6] [Reference Citation Analysis]
240 Kalra M, Tong Y, Jones DR, Walsh T, Danso MA, Ma CX, Silverman P, King MC, Badve SS, Perkins SM, Miller KD. Cisplatin +/- rucaparib after preoperative chemotherapy in patients with triple-negative or BRCA mutated breast cancer. NPJ Breast Cancer 2021;7:29. [PMID: 33753748 DOI: 10.1038/s41523-021-00240-w] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
241 Szkandera J, Absenger G, Dandachi N, Regitnig P, Lax S, Stotz M, Samonigg H, Renner W, Gerger A. Analysis of functional germline polymorphisms for prediction of response to anthracycline-based neoadjuvant chemotherapy in breast cancer. Mol Genet Genomics 2012;287:755-64. [PMID: 22903472 DOI: 10.1007/s00438-012-0715-7] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 0.4] [Reference Citation Analysis]
242 Chung AH, Leisner TM, Dardis GJ, Bivins MM, Keller AL, Parise LV. CIB1 depletion with docetaxel or TRAIL enhances triple-negative breast cancer cell death. Cancer Cell Int 2019;19:26. [PMID: 30740034 DOI: 10.1186/s12935-019-0740-2] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
243 Rivenbark AG, O'Connor SM, Coleman WB. Molecular and cellular heterogeneity in breast cancer: challenges for personalized medicine. Am J Pathol 2013;183:1113-24. [PMID: 23993780 DOI: 10.1016/j.ajpath.2013.08.002] [Cited by in Crossref: 120] [Cited by in F6Publishing: 120] [Article Influence: 15.0] [Reference Citation Analysis]
244 Takahashi S, Thike AA, Koh VCY, Sasano H, Tan PH. Triple-negative and HER2 positive ductal carcinoma in situ of the breast: characteristics, behavior, and biomarker profile. Virchows Arch 2018;473:275-83. [PMID: 30033510 DOI: 10.1007/s00428-018-2416-z] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
245 Alco G, Bozdogan A, Selamoglu D, Pilanci KN, Tuzlali S, Ordu C, Igdem S, Okkan S, Dincer M, Demir G, Ozmen V. Clinical and histopathological factors associated with Ki-67 expression in breast cancer patients. Oncol Lett 2015;9:1046-54. [PMID: 25663855 DOI: 10.3892/ol.2015.2852] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 1.8] [Reference Citation Analysis]
246 Witkiewicz AK, Balaji U, Knudsen ES. Systematically defining single-gene determinants of response to neoadjuvant chemotherapy reveals specific biomarkers. Clin Cancer Res 2014;20:4837-48. [PMID: 25047707 DOI: 10.1158/1078-0432.CCR-14-0885] [Cited by in Crossref: 10] [Cited by in F6Publishing: 5] [Article Influence: 1.4] [Reference Citation Analysis]
247 Gastaldi S, Comoglio PM, Trusolino L. The Met oncogene and basal-like breast cancer: another culprit to watch out for? Breast Cancer Res 2010;12:208. [PMID: 20804567 DOI: 10.1186/bcr2617] [Cited by in Crossref: 49] [Cited by in F6Publishing: 47] [Article Influence: 4.5] [Reference Citation Analysis]
248 Choi YL, Oh E, Park S, Kim Y, Park YH, Song K, Cho EY, Hong YC, Choi JS, Lee JE, Kim JH, Nam SJ, Im YH, Yang JH, Shin YK. Triple-negative, basal-like, and quintuple-negative breast cancers: better prediction model for survival. BMC Cancer 2010;10:507. [PMID: 20860845 DOI: 10.1186/1471-2407-10-507] [Cited by in Crossref: 36] [Cited by in F6Publishing: 34] [Article Influence: 3.3] [Reference Citation Analysis]
249 Pineda B, Diaz-Lagares A, Pérez-Fidalgo JA, Burgués O, González-Barrallo I, Crujeiras AB, Sandoval J, Esteller M, Lluch A, Eroles P. A two-gene epigenetic signature for the prediction of response to neoadjuvant chemotherapy in triple-negative breast cancer patients. Clin Epigenetics 2019;11:33. [PMID: 30786922 DOI: 10.1186/s13148-019-0626-0] [Cited by in Crossref: 17] [Cited by in F6Publishing: 12] [Article Influence: 8.5] [Reference Citation Analysis]
250 Huang L, Liu Q, Chen S, Shao Z. Cisplatin versus carboplatin in combination with paclitaxel as neoadjuvant regimen for triple negative breast cancer. Onco Targets Ther 2017;10:5739-44. [PMID: 29238206 DOI: 10.2147/OTT.S145934] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
251 Arias-Pulido H, Smith HO, Joste NE, Bocklage T, Qualls CR, Chavez A, Prossnitz ER, Verschraegen CF. Estrogen and progesterone receptor status and outcome in epithelial ovarian cancers and low malignant potential tumors. Gynecol Oncol 2009;114:480-5. [PMID: 19560192 DOI: 10.1016/j.ygyno.2009.05.045] [Cited by in Crossref: 32] [Cited by in F6Publishing: 28] [Article Influence: 2.7] [Reference Citation Analysis]
252 Nogi H, Kamio M, Toriumi Y, Nagasaki E, Suzuki M, Takeyama H. Strong impact of pathological node-negative on long-term overall survival of patients with triple-negative breast cancer receiving neoadjuvant chemotherapy. Mol Clin Oncol 2021;14:99. [PMID: 33815791 DOI: 10.3892/mco.2021.2261] [Reference Citation Analysis]
253 Wang M, Hu Y, Hou L, Pan Q, Tang P, Jiang J. A clinical study on the use of Huaier granules in post-surgical treatment of triple-negative breast cancer. Gland Surg 2019;8:758-65. [PMID: 32042684 DOI: 10.21037/gs.2019.12.08] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
254 Nakazawa Y, Taniyama Y, Sanada F, Morishita R, Nakamori S, Morimoto K, Yeung KT, Yang J. Periostin blockade overcomes chemoresistance via restricting the expansion of mesenchymal tumor subpopulations in breast cancer. Sci Rep 2018;8:4013. [PMID: 29507310 DOI: 10.1038/s41598-018-22340-7] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 3.3] [Reference Citation Analysis]
255 Tokunaga E, Fujita A, Takizawa K, Baba K, Akiyoshi S, Nakamura Y, Ijichi H, Masuda T, Koga C, Tajiri W, Ohno S, Taguchi K, Ishida M. CD44v9 as a poor prognostic factor of triple-negative breast cancer treated with neoadjuvant chemotherapy. Breast Cancer 2019;26:47-57. [PMID: 29971631 DOI: 10.1007/s12282-018-0888-y] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
256 Tao Y, Mao J, Zhang Q, Li L. Overexpression of Hedgehog signaling molecules and its involvement in triple-negative breast cancer. Oncol Lett 2011;2:995-1001. [PMID: 22866163 DOI: 10.3892/ol.2011.357] [Cited by in Crossref: 4] [Cited by in F6Publishing: 32] [Article Influence: 0.4] [Reference Citation Analysis]
257 Ruiu R, Barutello G, Arigoni M, Riccardo F, Conti L, Peppino G, Annaratone L, Marchiò C, Mengozzi G, Calogero RA, Cavallo F, Quaglino E. Identification of TENM4 as a Novel Cancer Stem Cell-Associated Molecule and Potential Target in Triple Negative Breast Cancer. Cancers (Basel) 2021;13:894. [PMID: 33672732 DOI: 10.3390/cancers13040894] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
258 Toft DJ, Cryns VL. Minireview: Basal-like breast cancer: from molecular profiles to targeted therapies. Mol Endocrinol 2011;25:199-211. [PMID: 20861225 DOI: 10.1210/me.2010-0164] [Cited by in Crossref: 95] [Cited by in F6Publishing: 83] [Article Influence: 8.6] [Reference Citation Analysis]
259 Phipps AI, Chlebowski RT, Prentice R, McTiernan A, Wactawski-Wende J, Kuller LH, Adams-Campbell LL, Lane D, Stefanick ML, Vitolins M, Kabat GC, Rohan TE, Li CI. Reproductive history and oral contraceptive use in relation to risk of triple-negative breast cancer. J Natl Cancer Inst 2011;103:470-7. [PMID: 21346227 DOI: 10.1093/jnci/djr030] [Cited by in Crossref: 140] [Cited by in F6Publishing: 124] [Article Influence: 14.0] [Reference Citation Analysis]
260 Casey MC, Sweeney KJ, Brown JA, Kerin MJ. Exploring circulating micro-RNA in the neoadjuvant treatment of breast cancer. Int J Cancer 2016;139:12-22. [PMID: 26756433 DOI: 10.1002/ijc.29985] [Cited by in Crossref: 24] [Cited by in F6Publishing: 20] [Article Influence: 4.8] [Reference Citation Analysis]
261 Schmidt G, Gerlinger C, Juhasz-Böss I, Stickeler E, Rody A, Liedtke C, Wimberger P, Link T, Müller E, Fehm T, Abel M, Stein S, Bohle R, Endrikat J, Solomayer EF. Her2-neu score as a prognostic factor for outcome in patients with triple-negative breast cancer. J Cancer Res Clin Oncol 2016;142:1369-76. [PMID: 27008006 DOI: 10.1007/s00432-016-2146-z] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
262 Li X, Rouchka EC, Brock GN, Yan J, O'Toole TE, Tieri DA, Cooper NGF. A combined approach with gene-wise normalization improves the analysis of RNA-seq data in human breast cancer subtypes. PLoS One 2018;13:e0201813. [PMID: 30089167 DOI: 10.1371/journal.pone.0201813] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
263 Tudoran O, Soritau O, Balacescu L, Visan S, Barbos O, Cojocneanu-Petric R, Balacescu O, Berindan-Neagoe I. Regulation of stem cells-related signaling pathways in response to doxorubicin treatment in Hs578T triple-negative breast cancer cells. Mol Cell Biochem 2015;409:163-76. [PMID: 26187676 DOI: 10.1007/s11010-015-2522-z] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
264 Thomas C, Henry W, Cuiffo BG, Collmann AY, Marangoni E, Benhamo V, Bhasin MK, Fan C, Fuhrmann L, Baldwin AS, Perou C, Vincent-Salomon A, Toker A, Karnoub AE. Pentraxin-3 is a PI3K signaling target that promotes stem cell-like traits in basal-like breast cancers. Sci Signal 2017;10:eaah4674. [PMID: 28223411 DOI: 10.1126/scisignal.aah4674] [Cited by in Crossref: 20] [Cited by in F6Publishing: 17] [Article Influence: 5.0] [Reference Citation Analysis]
265 Pogoda K, Niwińska A, Murawska M, Pieńkowski T. Analysis of pattern, time and risk factors influencing recurrence in triple-negative breast cancer patients. Med Oncol 2013;30:388. [PMID: 23292831 DOI: 10.1007/s12032-012-0388-4] [Cited by in Crossref: 80] [Cited by in F6Publishing: 73] [Article Influence: 10.0] [Reference Citation Analysis]
266 Bryant C, Rawlinson R, Massey AJ. Chk1 inhibition as a novel therapeutic strategy for treating triple-negative breast and ovarian cancers. BMC Cancer 2014;14:570. [PMID: 25104095 DOI: 10.1186/1471-2407-14-570] [Cited by in Crossref: 62] [Cited by in F6Publishing: 55] [Article Influence: 8.9] [Reference Citation Analysis]
267 Brown JM, Wasson MD, Marcato P. The Missing Lnc: The Potential of Targeting Triple-Negative Breast Cancer and Cancer Stem Cells by Inhibiting Long Non-Coding RNAs. Cells 2020;9:E763. [PMID: 32244924 DOI: 10.3390/cells9030763] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 14.0] [Reference Citation Analysis]
268 Montero A, Glück S. Long-Term Complete Remission with nab-Paclitaxel, Bevacizumab, and Gemcitabine Combination Therapy in a Patient with Triple-Negative Metastatic Breast Cancer. Case Rep Oncol 2012;5:687-92. [PMID: 23341813 DOI: 10.1159/000346345] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
269 Anbalagan M, Moroz K, Ali A, Carrier L, Glodowski S, Rowan BG. Subcellular localization of total and activated Src kinase in African American and Caucasian breast cancer. PLoS One 2012;7:e33017. [PMID: 22457730 DOI: 10.1371/journal.pone.0033017] [Cited by in Crossref: 26] [Cited by in F6Publishing: 24] [Article Influence: 2.9] [Reference Citation Analysis]
270 Haque R, Ahmed SA, Inzhakova G, Shi J, Avila C, Polikoff J, Bernstein L, Enger SM, Press MF. Impact of breast cancer subtypes and treatment on survival: an analysis spanning two decades. Cancer Epidemiol Biomarkers Prev 2012;21:1848-55. [PMID: 22989461 DOI: 10.1158/1055-9965.EPI-12-0474] [Cited by in Crossref: 114] [Cited by in F6Publishing: 74] [Article Influence: 12.7] [Reference Citation Analysis]
271 Bengala C. Recent advances in managing triple-negative breast cancers. F1000 Med Rep 2009;1:75. [PMID: 20948704 DOI: 10.3410/M1-75] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
272 Bhatia S, Wang P, Toh A, Thompson EW. New Insights Into the Role of Phenotypic Plasticity and EMT in Driving Cancer Progression. Front Mol Biosci 2020;7:71. [PMID: 32391381 DOI: 10.3389/fmolb.2020.00071] [Cited by in Crossref: 25] [Cited by in F6Publishing: 18] [Article Influence: 25.0] [Reference Citation Analysis]
273 Wu X, Baig A, Kasymjanova G, Kafi K, Holcroft C, Mekouar H, Carbonneau A, Bahoric B, Sultanem K, Muanza T. Pattern of Local Recurrence and Distant Metastasis in Breast Cancer By Molecular Subtype. Cureus 2016;8:e924. [PMID: 28090417 DOI: 10.7759/cureus.924] [Cited by in Crossref: 10] [Cited by in F6Publishing: 16] [Article Influence: 2.0] [Reference Citation Analysis]
274 Fisher CS, Ma CX, Gillanders WE, Aft RL, Eberlein TJ, Gao F, Margenthaler JA. Neoadjuvant chemotherapy is associated with improved survival compared with adjuvant chemotherapy in patients with triple-negative breast cancer only after complete pathologic response. Ann Surg Oncol 2012;19:253-8. [PMID: 21725686 DOI: 10.1245/s10434-011-1877-y] [Cited by in Crossref: 35] [Cited by in F6Publishing: 32] [Article Influence: 3.5] [Reference Citation Analysis]
275 Dawood S, Broglio K, Kau SW, Green MC, Giordano SH, Meric-Bernstam F, Buchholz TA, Albarracin C, Yang WT, Hennessy BT, Hortobagyi GN, Gonzalez-Angulo AM. Triple receptor-negative breast cancer: the effect of race on response to primary systemic treatment and survival outcomes. J Clin Oncol 2009;27:220-6. [PMID: 19047281 DOI: 10.1200/JCO.2008.17.9952] [Cited by in Crossref: 75] [Cited by in F6Publishing: 39] [Article Influence: 5.8] [Reference Citation Analysis]
276 Makvandi M, Tilahun ED, Lieberman BP, Anderson RC, Zeng C, Xu K, Hou C, McDonald ES, Pryma DA, Mach RH. The sigma-2 receptor as a therapeutic target for drug delivery in triple negative breast cancer. Biochem Biophys Res Commun 2015;467:1070-5. [PMID: 26453012 DOI: 10.1016/j.bbrc.2015.09.157] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 2.3] [Reference Citation Analysis]
277 Maire V, Baldeyron C, Richardson M, Tesson B, Vincent-Salomon A, Gravier E, Marty-Prouvost B, De Koning L, Rigaill G, Dumont A. TTK/hMPS1 is an attractive therapeutic target for triple-negative breast cancer. PLoS One. 2013;8:e63712. [PMID: 23700430 DOI: 10.1371/journal.pone.0063712] [Cited by in Crossref: 82] [Cited by in F6Publishing: 73] [Article Influence: 10.3] [Reference Citation Analysis]
278 Kumar D, Haldar S, Gorain M, Kumar S, Mulani FA, Yadav AS, Miele L, Thulasiram HV, Kundu GC. Epoxyazadiradione suppresses breast tumor growth through mitochondrial depolarization and caspase-dependent apoptosis by targeting PI3K/Akt pathway. BMC Cancer 2018;18:52. [PMID: 29310608 DOI: 10.1186/s12885-017-3876-2] [Cited by in Crossref: 26] [Cited by in F6Publishing: 21] [Article Influence: 8.7] [Reference Citation Analysis]
279 Clemens MR, Gladkov OA, Gartner E, Vladimirov V, Crown J, Steinberg J, Jie F, Keating A. Phase II, multicenter, open-label, randomized study of YM155 plus docetaxel as first-line treatment in patients with HER2-negative metastatic breast cancer. Breast Cancer Res Treat 2015;149:171-9. [PMID: 25547219 DOI: 10.1007/s10549-014-3238-6] [Cited by in Crossref: 49] [Cited by in F6Publishing: 46] [Article Influence: 7.0] [Reference Citation Analysis]
280 Trudeau ME, Chapman JA, Guo B, Clemons MJ, Dent RA, Jong RA, Kahn HJ, Pritchard KI, Han L, O'Brien P, Shepherd LE, Parissenti AM. A phase I/II trial of epirubicin and docetaxel in locally advanced breast cancer (LABC) on 2-weekly or 3-weekly schedules: NCIC CTG MA.22. Springerplus 2015;4:631. [PMID: 26543765 DOI: 10.1186/s40064-015-1392-x] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
281 Song C, Liu LZ, Pei XQ, Liu X, Yang L, Ye F, Xie X, Chen J, Tang H, Xie X. miR-200c inhibits breast cancer proliferation by targeting KRAS. Oncotarget 2015;6:34968-78. [PMID: 26392416 DOI: 10.18632/oncotarget.5198] [Cited by in Crossref: 48] [Cited by in F6Publishing: 43] [Article Influence: 9.6] [Reference Citation Analysis]
282 Fitzpatrick A, Tutt A. Controversial issues in the neoadjuvant treatment of triple-negative breast cancer. Ther Adv Med Oncol 2019;11:1758835919882581. [PMID: 31700549 DOI: 10.1177/1758835919882581] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 3.5] [Reference Citation Analysis]
283 Leong AS, Zhuang Z. The changing role of pathology in breast cancer diagnosis and treatment. Pathobiology. 2011;78:99-114. [PMID: 21677473 DOI: 10.1159/000292644] [Cited by in Crossref: 61] [Cited by in F6Publishing: 47] [Article Influence: 6.1] [Reference Citation Analysis]
284 Kim RK, Suh Y, Yoo KC, Cui YH, Hwang E, Kim HJ, Kang JS, Kim MJ, Lee YY, Lee SJ. Phloroglucinol suppresses metastatic ability of breast cancer cells by inhibition of epithelial-mesenchymal cell transition. Cancer Sci 2015;106:94-101. [PMID: 25456733 DOI: 10.1111/cas.12562] [Cited by in Crossref: 32] [Cited by in F6Publishing: 24] [Article Influence: 4.6] [Reference Citation Analysis]
285 Girgert R, Emons G, Gründker C. Inhibition of GPR30 by estriol prevents growth stimulation of triple-negative breast cancer cells by 17β-estradiol. BMC Cancer 2014;14:935. [PMID: 25496649 DOI: 10.1186/1471-2407-14-935] [Cited by in Crossref: 26] [Cited by in F6Publishing: 21] [Article Influence: 3.7] [Reference Citation Analysis]
286 Horimoto Y, Arakawa A, Tanabe M, Sonoue H, Igari F, Senuma K, Tokuda E, Shimizu H, Kosaka T, Saito M. Ki67 expression and the effect of neo-adjuvant chemotherapy on luminal HER2-negative breast cancer. BMC Cancer 2014;14:550. [PMID: 25073969 DOI: 10.1186/1471-2407-14-550] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 2.7] [Reference Citation Analysis]
287 Takada M, Zhuang M, Inuzuka H, Zhang J, Zurlo G, Zhang J, Zhang Q. EglN2 contributes to triple negative breast tumorigenesis by functioning as a substrate for the FBW7 tumor suppressor. Oncotarget 2017;8:6787-95. [PMID: 28036276 DOI: 10.18632/oncotarget.14290] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
288 Gasparyan M, Lo MC, Jiang H, Lin CC, Sun D. Combined p53- and PTEN-deficiency activates expression of mesenchyme homeobox 1 (MEOX1) required for growth of triple-negative breast cancer. J Biol Chem 2020;295:12188-202. [PMID: 32467227 DOI: 10.1074/jbc.RA119.010710] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
289 Lee MM, Chan BD, Wong WY, Qu Z, Chan MS, Leung TW, Lin Y, Mok DK, Chen S, Tai WC. Anti-cancer Activity of Centipeda minima Extract in Triple Negative Breast Cancer via Inhibition of AKT, NF-κB, and STAT3 Signaling Pathways. Front Oncol 2020;10:491. [PMID: 32328465 DOI: 10.3389/fonc.2020.00491] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 8.0] [Reference Citation Analysis]
290 Carlisi D, De Blasio A, Drago-Ferrante R, Di Fiore R, Buttitta G, Morreale M, Scerri C, Vento R, Tesoriere G. Parthenolide prevents resistance of MDA-MB231 cells to doxorubicin and mitoxantrone: the role of Nrf2. Cell Death Discov 2017;3:17078. [PMID: 29354292 DOI: 10.1038/cddiscovery.2017.78] [Cited by in Crossref: 25] [Cited by in F6Publishing: 24] [Article Influence: 6.3] [Reference Citation Analysis]
291 Nunes T, Hamdan D, Leboeuf C, El Bouchtaoui M, Gapihan G, Nguyen TT, Meles S, Angeli E, Ratajczak P, Lu H, Di Benedetto M, Bousquet G, Janin A. Targeting Cancer Stem Cells to Overcome Chemoresistance. Int J Mol Sci 2018;19:E4036. [PMID: 30551640 DOI: 10.3390/ijms19124036] [Cited by in Crossref: 53] [Cited by in F6Publishing: 39] [Article Influence: 17.7] [Reference Citation Analysis]
292 Phipps AI, Malone KE, Porter PL, Daling JR, Li CI. Reproductive and hormonal risk factors for postmenopausal luminal, HER-2-overexpressing, and triple-negative breast cancer. Cancer 2008;113:1521-6. [PMID: 18726992 DOI: 10.1002/cncr.23786] [Cited by in Crossref: 87] [Cited by in F6Publishing: 87] [Article Influence: 6.7] [Reference Citation Analysis]
293 van Roozendaal LM, Smit LHM, Duijsens GHNM, de Vries B, Siesling S, Lobbes MBI, de Boer M, de Wilt JHW, Smidt ML. Risk of regional recurrence in triple-negative breast cancer patients: a Dutch cohort study. Breast Cancer Res Treat 2016;156:465-72. [PMID: 27013474 DOI: 10.1007/s10549-016-3757-4] [Cited by in Crossref: 32] [Cited by in F6Publishing: 28] [Article Influence: 6.4] [Reference Citation Analysis]
294 Tran B, Bedard PL. Luminal-B breast cancer and novel therapeutic targets. Breast Cancer Res. 2011;13:221. [PMID: 22217398 DOI: 10.1186/bcr2904] [Cited by in Crossref: 119] [Cited by in F6Publishing: 106] [Article Influence: 11.9] [Reference Citation Analysis]
295 Martínez-Montiel N, Anaya-Ruiz M, Pérez-Santos M, Martínez-Contreras RD. Alternative Splicing in Breast Cancer and the Potential Development of Therapeutic Tools. Genes (Basel) 2017;8:E217. [PMID: 28981467 DOI: 10.3390/genes8100217] [Cited by in Crossref: 16] [Cited by in F6Publishing: 11] [Article Influence: 4.0] [Reference Citation Analysis]
296 Abdal Dayem A, Choi HY, Yang GM, Kim K, Saha SK, Cho SG. The Anti-Cancer Effect of Polyphenols against Breast Cancer and Cancer Stem Cells: Molecular Mechanisms. Nutrients 2016;8:E581. [PMID: 27657126 DOI: 10.3390/nu8090581] [Cited by in Crossref: 65] [Cited by in F6Publishing: 46] [Article Influence: 13.0] [Reference Citation Analysis]
297 Liu D, He J, Yuan Z, Wang S, Peng R, Shi Y, Teng X, Qin T. EGFR expression correlates with decreased disease-free survival in triple-negative breast cancer: a retrospective analysis based on a tissue microarray. Med Oncol. 2012;29:401-405. [PMID: 21264531 DOI: 10.1007/s12032-011-9827-x] [Cited by in Crossref: 43] [Cited by in F6Publishing: 45] [Article Influence: 4.3] [Reference Citation Analysis]
298 Reynolds DS, Tevis KM, Blessing WA, Colson YL, Zaman MH, Grinstaff MW. Breast Cancer Spheroids Reveal a Differential Cancer Stem Cell Response to Chemotherapeutic Treatment. Sci Rep 2017;7:10382. [PMID: 28871147 DOI: 10.1038/s41598-017-10863-4] [Cited by in Crossref: 54] [Cited by in F6Publishing: 46] [Article Influence: 13.5] [Reference Citation Analysis]
299 Brouckaert O, Wildiers H, Floris G, Neven P. Update on triple-negative breast cancer: prognosis and management strategies. Int J Womens Health 2012;4:511-20. [PMID: 23071421 DOI: 10.2147/IJWH.S18541] [Cited by in Crossref: 17] [Cited by in F6Publishing: 47] [Article Influence: 1.9] [Reference Citation Analysis]
300 Vaklavas C, Forero-Torres A. How do I treat "triple-negative" disease. Curr Treat Options Oncol 2011;12:369-88. [PMID: 22048876 DOI: 10.1007/s11864-011-0168-y] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 0.9] [Reference Citation Analysis]
301 Stewart DA, Winnike JH, McRitchie SL, Clark RF, Pathmasiri WW, Sumner SJ. Metabolomics Analysis of Hormone-Responsive and Triple-Negative Breast Cancer Cell Responses to Paclitaxel Identify Key Metabolic Differences. J Proteome Res 2016;15:3225-40. [PMID: 27447733 DOI: 10.1021/acs.jproteome.6b00430] [Cited by in Crossref: 26] [Cited by in F6Publishing: 22] [Article Influence: 5.2] [Reference Citation Analysis]
302 Yehia L, Boulos F, Jabbour M, Mahfoud Z, Fakhruddin N, El-Sabban M. Expression of HIF-1α and Markers of Angiogenesis Are Not Significantly Different in Triple Negative Breast Cancer Compared to Other Breast Cancer Molecular Subtypes: Implications for Future Therapy. PLoS One 2015;10:e0129356. [PMID: 26046764 DOI: 10.1371/journal.pone.0129356] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 2.7] [Reference Citation Analysis]
303 Ribelles N, Perez-Villa L, Jerez JM, Pajares B, Vicioso L, Jimenez B, de Luque V, Franco L, Gallego E, Marquez A, Alvarez M, Sanchez-Muñoz A, Perez-Rivas L, Alba E. Pattern of recurrence of early breast cancer is different according to intrinsic subtype and proliferation index. Breast Cancer Res 2013;15:R98. [PMID: 24148581 DOI: 10.1186/bcr3559] [Cited by in Crossref: 58] [Cited by in F6Publishing: 56] [Article Influence: 8.3] [Reference Citation Analysis]
304 Medina MA, Oza G, Sharma A, Arriaga LG, Hernández Hernández JM, Rotello VM, Ramirez JT. Triple-Negative Breast Cancer: A Review of Conventional and Advanced Therapeutic Strategies. Int J Environ Res Public Health 2020;17:E2078. [PMID: 32245065 DOI: 10.3390/ijerph17062078] [Cited by in Crossref: 24] [Cited by in F6Publishing: 21] [Article Influence: 24.0] [Reference Citation Analysis]
305 Wang Y, Zhai X, Liu C, Wang N, Wang Y. Trends of triple negative breast cancer research (2007-2015): A bibliometric study. Medicine (Baltimore) 2016;95:e5427. [PMID: 27861384 DOI: 10.1097/MD.0000000000005427] [Cited by in Crossref: 15] [Cited by in F6Publishing: 9] [Article Influence: 3.8] [Reference Citation Analysis]
306 Wang Z, Liu L, Li Y, Song Z, Jing Y, Fan Z, Zhang S. Analysis of CK5/6 and EGFR and Its Effect on Prognosis of Triple Negative Breast Cancer. Front Oncol 2020;10:575317. [PMID: 33552956 DOI: 10.3389/fonc.2020.575317] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
307 Sun Z, Prat A, Cheang MCU, Gelber RD, Perou CM. Chemotherapy benefit for 'ER-positive' breast cancer and contamination of nonluminal subtypes—waiting for TAILORx and RxPONDER. Ann Oncol 2015;26:70-4. [PMID: 25355719 DOI: 10.1093/annonc/mdu493] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.9] [Reference Citation Analysis]
308 Kim HS, Koh JS, Choi YB, Ro J, Kim HK, Kim MK, Nam BH, Kim KT, Chandra V, Seol HS, Noh WC, Kim EK, Park J, Bae CD, Hong KM. Chromatin CKAP2, a new proliferation marker, as independent prognostic indicator in breast cancer. PLoS One 2014;9:e98160. [PMID: 24887265 DOI: 10.1371/journal.pone.0098160] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 1.4] [Reference Citation Analysis]
309 Straver ME, Rutgers EJ, Rodenhuis S, Linn SC, Loo CE, Wesseling J, Russell NS, Oldenburg HS, Antonini N, Vrancken Peeters MT. The relevance of breast cancer subtypes in the outcome of neoadjuvant chemotherapy. Ann Surg Oncol 2010;17:2411-8. [PMID: 20373039 DOI: 10.1245/s10434-010-1008-1] [Cited by in Crossref: 99] [Cited by in F6Publishing: 84] [Article Influence: 9.0] [Reference Citation Analysis]
310 Moon HG, Yi JK, Kim HS, Lee HY, Lee KM, Yi M, Ahn S, Shin HC, Ju JH, Shin I, Han W, Noh DY. Phosphorylation of p90RSK is associated with increased response to neoadjuvant chemotherapy in ER-positive breast cancer. BMC Cancer 2012;12:585. [PMID: 23216670 DOI: 10.1186/1471-2407-12-585] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
311 Oshi M, Katsuta E, Yan L, Ebos JML, Rashid OM, Matsuyama R, Endo I, Takabe K. A Novel 4-Gene Score to Predict Survival, Distant Metastasis and Response to Neoadjuvant Therapy in Breast Cancer. Cancers (Basel) 2020;12:E1148. [PMID: 32370309 DOI: 10.3390/cancers12051148] [Cited by in Crossref: 23] [Cited by in F6Publishing: 21] [Article Influence: 23.0] [Reference Citation Analysis]
312 Prat A, Carey LA, Adamo B, Vidal M, Tabernero J, Cortés J, Parker JS, Perou CM, Baselga J. Molecular features and survival outcomes of the intrinsic subtypes within HER2-positive breast cancer. J Natl Cancer Inst 2014;106:dju152. [PMID: 25139534 DOI: 10.1093/jnci/dju152] [Cited by in Crossref: 107] [Cited by in F6Publishing: 94] [Article Influence: 15.3] [Reference Citation Analysis]
313 Zawlik I, Kaznowska E, Cebulski J, Kolodziej M, Depciuch J, Vongsvivut J, Cholewa M. FPA-FTIR Microspectroscopy for Monitoring Chemotherapy Efficacy in Triple-Negative Breast Cancer. Sci Rep 2016;6:37333. [PMID: 27857183 DOI: 10.1038/srep37333] [Cited by in Crossref: 30] [Cited by in F6Publishing: 26] [Article Influence: 6.0] [Reference Citation Analysis]
314 Gross E, van Tinteren H, Li Z, Raab S, Meul C, Avril S, Laddach N, Aubele M, Propping C, Gkazepis A, Schmitt M, Meindl A, Nederlof PM, Kiechle M, Lips EH. Identification of BRCA1-like triple-negative breast cancers by quantitative multiplex-ligation-dependent probe amplification (MLPA) analysis of BRCA1-associated chromosomal regions: a validation study. BMC Cancer 2016;16:811. [PMID: 27756336 DOI: 10.1186/s12885-016-2848-2] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
315 Zhao J, Zhang H, Lei T, Liu J, Zhang S, Wu N, Sun B, Wang M. Drug resistance gene expression and chemotherapy sensitivity detection in Chinese women with different molecular subtypes of breast cancer. Cancer Biol Med 2020;17:1014-25. [PMID: 33299650 DOI: 10.20892/j.issn.2095-3941.2020.0157] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
316 Funt SA, Chapman PB. The Role of Neoadjuvant Trials in Drug Development for Solid Tumors. Clin Cancer Res 2016;22:2323-8. [PMID: 26842238 DOI: 10.1158/1078-0432.CCR-15-1961] [Cited by in Crossref: 12] [Cited by in F6Publishing: 6] [Article Influence: 2.4] [Reference Citation Analysis]
317 Park JH, Ahn JH, Kim SB. How shall we treat early triple-negative breast cancer (TNBC): from the current standard to upcoming immuno-molecular strategies. ESMO Open 2018;3:e000357. [PMID: 29765774 DOI: 10.1136/esmoopen-2018-000357] [Cited by in Crossref: 53] [Cited by in F6Publishing: 48] [Article Influence: 17.7] [Reference Citation Analysis]
318 Carey LA. CCR 20th Anniversary Commentary: Simpson's Paradox and Neoadjuvant Trials. Clin Cancer Res 2015;21:4027-9. [PMID: 26374072 DOI: 10.1158/1078-0432.CCR-14-3124] [Cited by in Crossref: 3] [Article Influence: 0.6] [Reference Citation Analysis]
319 Bhola NE, Balko JM, Dugger TC, Kuba MG, Sánchez V, Sanders M, Stanford J, Cook RS, Arteaga CL. TGF-β inhibition enhances chemotherapy action against triple-negative breast cancer. J Clin Invest. 2013;123:1348-1358. [PMID: 23391723 DOI: 10.1172/jci65416] [Cited by in Crossref: 353] [Cited by in F6Publishing: 220] [Article Influence: 44.1] [Reference Citation Analysis]
320 Eremin J, Cowley G, Walker LG, Murray E, Stovickova M, Eremin O. Women with large (≥3 cm) and locally advanced breast cancers (T3, 4, N1, 2, M0) receiving neoadjuvant chemotherapy (NAC: cyclophosphamide, doxorubicin, docetaxel): addition of capecitabine improves 4-year disease-free survival. Springerplus 2015;4:9. [PMID: 25995984 DOI: 10.1186/2193-1801-4-9] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
321 Fujii T, Kogawa T, Dong W, Sahin AA, Moulder S, Litton JK, Tripathy D, Iwamoto T, Hunt KK, Pusztai L, Lim B, Shen Y, Ueno NT. Revisiting the definition of estrogen receptor positivity in HER2-negative primary breast cancer. Ann Oncol 2017;28:2420-8. [PMID: 28961844 DOI: 10.1093/annonc/mdx397] [Cited by in Crossref: 44] [Cited by in F6Publishing: 38] [Article Influence: 14.7] [Reference Citation Analysis]
322 Elsheikh SE, Green AR, Rakha EA, Samaka RM, Ammar AA, Powe D, Reis-Filho JS, Ellis IO. Caveolin 1 and Caveolin 2 are associated with breast cancer basal-like and triple-negative immunophenotype. Br J Cancer 2008;99:327-34. [PMID: 18612310 DOI: 10.1038/sj.bjc.6604463] [Cited by in Crossref: 108] [Cited by in F6Publishing: 95] [Article Influence: 8.3] [Reference Citation Analysis]
323 Miyashita M, Ishida T, Ishida K, Tamaki K, Amari M, Watanabe M, Ohuchi N, Sasano H. Histopathological subclassification of triple negative breast cancer using prognostic scoring system: five variables as candidates. Virchows Arch 2011;458:65-72. [PMID: 21104095 DOI: 10.1007/s00428-010-1009-2] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 1.9] [Reference Citation Analysis]
324 Kedzierawski P, Macek P, Ciepiela I, Kowalik A, Gozdz S. Evaluation of Complete Pathological Regression after Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer Patients with BRCA1 Founder Mutation Aided Bayesian A/B Testing Approach. Diagnostics (Basel) 2021;11:1144. [PMID: 34201809 DOI: 10.3390/diagnostics11071144] [Reference Citation Analysis]
325 Tozbikian G, Brogi E, Kadota K, Catalano J, Akram M, Patil S, Ho AY, Reis-Filho JS, Weigelt B, Norton L, Adusumilli PS, Wen HY. Mesothelin expression in triple negative breast carcinomas correlates significantly with basal-like phenotype, distant metastases and decreased survival. PLoS One. 2014;9:e114900. [PMID: 25506917 DOI: 10.1371/journal.pone.0114900] [Cited by in Crossref: 42] [Cited by in F6Publishing: 39] [Article Influence: 6.0] [Reference Citation Analysis]
326 Lee A, Lim W, Moon BI, Paik NS, Koh SH, Song JY. Chemotherapy response assay test and prognosis for breast cancer patients who have undergone anthracycline- and taxane-based chemotherapy. J Breast Cancer 2011;14:283-8. [PMID: 22323914 DOI: 10.4048/jbc.2011.14.4.283] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
327 Aysola K, Desai A, Welch C, Xu J, Qin Y, Reddy V, Matthews R, Owens C, Okoli J, Beech DJ. Triple Negative Breast Cancer - An Overview. Hereditary Genet. 2013;2013:pii: 001. [PMID: 25285241 DOI: 10.4172/2161-1041.s2-001] [Cited by in Crossref: 20] [Cited by in F6Publishing: 41] [Article Influence: 2.2] [Reference Citation Analysis]
328 Chakrabarty A, Chakraborty S, Bhattacharya R, Chowdhury G. Senescence-Induced Chemoresistance in Triple Negative Breast Cancer and Evolution-Based Treatment Strategies. Front Oncol 2021;11:674354. [PMID: 34249714 DOI: 10.3389/fonc.2021.674354] [Reference Citation Analysis]
329 Li XX, Wang LJ, Hou J, Liu HY, Wang R, Wang C, Xie WH. Identification of Long Noncoding RNAs as Predictors of Survival in Triple-Negative Breast Cancer Based on Network Analysis. Biomed Res Int 2020;2020:8970340. [PMID: 32190687 DOI: 10.1155/2020/8970340] [Cited by in Crossref: 7] [Cited by in F6Publishing: 11] [Article Influence: 7.0] [Reference Citation Analysis]
330 Yao H, He G, Yan S, Chen C, Song L, Rosol TJ, Deng X. Triple-negative breast cancer: is there a treatment on the horizon? Oncotarget 2017;8:1913-24. [PMID: 27765921 DOI: 10.18632/oncotarget.12284] [Cited by in Crossref: 143] [Cited by in F6Publishing: 127] [Article Influence: 47.7] [Reference Citation Analysis]
331 Colón-Marrero S, Jusino S, Rivera-Rivera Y, Saavedra HI. Mitotic kinases as drivers of the epithelial-to-mesenchymal transition and as therapeutic targets against breast cancers. Exp Biol Med (Maywood) 2021;246:1036-44. [PMID: 33601912 DOI: 10.1177/1535370221991094] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
332 Cosentino G, Plantamura I, Cataldo A, Iorio MV. MicroRNA and Oxidative Stress Interplay in the Context of Breast Cancer Pathogenesis. Int J Mol Sci 2019;20:E5143. [PMID: 31627322 DOI: 10.3390/ijms20205143] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 6.5] [Reference Citation Analysis]
333 Biswas T, Efird JT, Prasad S, Jindal C, Walker PR. The survival benefit of neoadjuvant chemotherapy and pCR among patients with advanced stage triple negative breast cancer. Oncotarget 2017;8:112712-9. [PMID: 29348858 DOI: 10.18632/oncotarget.22521] [Cited by in Crossref: 22] [Cited by in F6Publishing: 19] [Article Influence: 5.5] [Reference Citation Analysis]
334 Mukherjee A, Shehata M, Moseley P, Rakha E, Ellis I, Chan S. Topo2α protein expression predicts response to anthracycline combination neo-adjuvant chemotherapy in locally advanced primary breast cancer. Br J Cancer 2010;103:1794-800. [PMID: 21063406 DOI: 10.1038/sj.bjc.6605960] [Cited by in Crossref: 17] [Cited by in F6Publishing: 13] [Article Influence: 1.5] [Reference Citation Analysis]
335 Goel AK, Nandy M, Sharma G. Cisplatin as neoadjuvant chemotherapy in triple negative breast cancer: Exciting early results. Indian J Med Paediatr Oncol 2010;31:76-8. [PMID: 21206711 DOI: 10.4103/0971-5851.73588] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
336 Gwark S, Kim J, Kwon NJ, Kim KY, Kim Y, Lee CH, Kim YH, Kim MS, Hong SW, Choi MY, Jeon BH, Chang S, Yu J, Park JY, Lee HJ, Lee SB, Chung IY, Ko BS, Kim HJ, Lee JW, Son BH, Ahn JH, Jung KH, Kim SB, Gong GY, Ahn SH. Analysis of the serial circulating tumor cell count during neoadjuvant chemotherapy in breast cancer patients. Sci Rep 2020;10:17466. [PMID: 33060768 DOI: 10.1038/s41598-020-74577-w] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
337 Powell RT, Redwood A, Liu X, Guo L, Cai S, Zhou X, Tu Y, Zhang X, Qi Y, Jiang Y, Echeverria G, Feng N, Ma X, Giuliani V, Marszalek JR, Heffernan TP, Vellano CP, White JB, Stephan C, Davies PJ, Moulder S, Symmans WF, Chang JT, Piwnica-Worms H. Pharmacologic profiling of patient-derived xenograft models of primary treatment-naïve triple-negative breast cancer. Sci Rep 2020;10:17899. [PMID: 33087803 DOI: 10.1038/s41598-020-74882-4] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
338 King JL, Zhang B, Li Y, Li KP, Ni JJ, Saavedra HI, Dong JT. TTK promotes mesenchymal signaling via multiple mechanisms in triple negative breast cancer. Oncogenesis 2018;7:69. [PMID: 30206215 DOI: 10.1038/s41389-018-0077-z] [Cited by in Crossref: 27] [Cited by in F6Publishing: 25] [Article Influence: 9.0] [Reference Citation Analysis]
339 Yoo C, Ahn JH, Jung KH, Kim SB, Kim HH, Shin HJ, Ahn SH, Son BH, Gong G. Impact of immunohistochemistry-based molecular subtype on chemosensitivity and survival in patients with breast cancer following neoadjuvant chemotherapy. J Breast Cancer 2012;15:203-10. [PMID: 22807938 DOI: 10.4048/jbc.2012.15.2.203] [Cited by in Crossref: 29] [Cited by in F6Publishing: 20] [Article Influence: 3.2] [Reference Citation Analysis]
340 Bergin ART, Loi S. Triple-negative breast cancer: recent treatment advances. F1000Res 2019;8:F1000 Faculty Rev-1342. [PMID: 31448088 DOI: 10.12688/f1000research.18888.1] [Cited by in Crossref: 38] [Cited by in F6Publishing: 25] [Article Influence: 19.0] [Reference Citation Analysis]
341 Ferreira AR, Metzger-Filho O, Sarmento RMB, Bines J. Neoadjuvant Treatment of Stage IIB/III Triple Negative Breast Cancer with Cyclophosphamide, Doxorubicin, and Cisplatin (CAP Regimen): A Single Arm, Single Center Phase II Study (GBECAM 2008/02). Front Oncol 2017;7:329. [PMID: 29416986 DOI: 10.3389/fonc.2017.00329] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
342 Akbaribazm M, Khazaei MR, Khazaei F, Khazaei M. Doxorubicin and Trifolium pratense L. (Red clover) extract synergistically inhibits brain and lung metastases in 4T1 tumor-bearing BALB/c mice. Food Sci Nutr 2020;8:5557-70. [PMID: 33133558 DOI: 10.1002/fsn3.1820] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
343 Reddy KB. Triple-negative breast cancers: an updated review on treatment options. Curr Oncol 2011;18:e173-9. [PMID: 21874107 DOI: 10.3747/co.v18i4.738] [Cited by in Crossref: 45] [Cited by in F6Publishing: 43] [Article Influence: 4.5] [Reference Citation Analysis]
344 Park K, Choi MK, Jung HH, Do IG, Lee KH, Ahn T, Kil WH, Kim SW, Lee JE, Nam SJ, Kim DH, Ahn JS, Im YH, Park YH. Molecular characterization of patients with pathologic complete response or early failure after neoadjuvant chemotherapy for locally advanced breast cancer using next generation sequencing and nCounter assay. Oncotarget 2015;6:24499-510. [PMID: 26009992 DOI: 10.18632/oncotarget.4119] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.2] [Reference Citation Analysis]
345 You S, Kang DK, Jung YS, An YS, Jeon GS, Kim TH. Evaluation of lymph node status after neoadjuvant chemotherapy in breast cancer patients: comparison of diagnostic performance of ultrasound, MRI and 18F-FDG PET/CT. Br J Radiol. 2015;88:20150143. [PMID: 26110204 DOI: 10.1259/bjr.20150143] [Cited by in Crossref: 35] [Cited by in F6Publishing: 28] [Article Influence: 5.8] [Reference Citation Analysis]
346 Heng ZSL, Lee JY, Subhramanyam CS, Wang C, Thanga LZ, Hu Q. The role of 17β‑estradiol‑induced upregulation of Piwi‑like 4 in modulating gene expression and motility in breast cancer cells. Oncol Rep 2018;40:2525-35. [PMID: 30226541 DOI: 10.3892/or.2018.6676] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
347 Richard R, Thomassin I, Chapellier M, Scemama A, de Cremoux P, Varna M, Giacchetti S, Espié M, de Kerviler E, de Bazelaire C. Diffusion-weighted MRI in pretreatment prediction of response to neoadjuvant chemotherapy in patients with breast cancer. Eur Radiol 2013;23:2420-31. [PMID: 23652844 DOI: 10.1007/s00330-013-2850-x] [Cited by in Crossref: 56] [Cited by in F6Publishing: 47] [Article Influence: 7.0] [Reference Citation Analysis]
348 Vahdat LT. Novel combinations for the treatment of metastatic breast cancer. Cancers (Basel) 2010;2:1-19. [PMID: 24281029 DOI: 10.3390/cancers2010001] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
349 Girgert R, Emons G, Gründker C. Inactivation of GPR30 reduces growth of triple-negative breast cancer cells: possible application in targeted therapy. Breast Cancer Res Treat 2012;134:199-205. [PMID: 22290080 DOI: 10.1007/s10549-012-1968-x] [Cited by in Crossref: 59] [Cited by in F6Publishing: 53] [Article Influence: 6.6] [Reference Citation Analysis]
350 Alli E, Sharma VB, Sunderesakumar P, Ford JM. Defective repair of oxidative dna damage in triple-negative breast cancer confers sensitivity to inhibition of poly(ADP-ribose) polymerase. Cancer Res 2009;69:3589-96. [PMID: 19351835 DOI: 10.1158/0008-5472.CAN-08-4016] [Cited by in Crossref: 105] [Cited by in F6Publishing: 64] [Article Influence: 8.8] [Reference Citation Analysis]
351 Haagenson KK, Wu GS. The role of MAP kinases and MAP kinase phosphatase-1 in resistance to breast cancer treatment. Cancer Metastasis Rev 2010;29:143-9. [PMID: 20111893 DOI: 10.1007/s10555-010-9208-5] [Cited by in Crossref: 62] [Cited by in F6Publishing: 54] [Article Influence: 5.6] [Reference Citation Analysis]
352 Li Y, Humphries B, Yang C, Wang Z. Nanoparticle-Mediated Therapeutic Agent Delivery for Treating Metastatic Breast Cancer-Challenges and Opportunities. Nanomaterials (Basel) 2018;8:E361. [PMID: 29794968 DOI: 10.3390/nano8060361] [Cited by in Crossref: 19] [Cited by in F6Publishing: 13] [Article Influence: 6.3] [Reference Citation Analysis]
353 Tzeng HE, Yang L, Chen K, Wang Y, Liu YR, Pan SL, Gaur S, Hu S, Yen Y. The pan-PI3K inhibitor GDC-0941 activates canonical WNT signaling to confer resistance in TNBC cells: resistance reversal with WNT inhibitor. Oncotarget 2015;6:11061-73. [PMID: 25857298 DOI: 10.18632/oncotarget.3568] [Cited by in Crossref: 20] [Cited by in F6Publishing: 16] [Article Influence: 4.0] [Reference Citation Analysis]
354 Tanabe Y, Tsuda H, Yoshida M, Yunokawa M, Yonemori K, Shimizu C, Yamamoto S, Kinoshita T, Fujiwara Y, Tamura K. Pathological features of triple-negative breast cancers that showed progressive disease during neoadjuvant chemotherapy. Cancer Sci 2017;108:1520-9. [PMID: 28474753 DOI: 10.1111/cas.13274] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
355 Humphries B, Wang Z, Oom AL, Fisher T, Tan D, Cui Y, Jiang Y, Yang C. MicroRNA-200b targets protein kinase Cα and suppresses triple-negative breast cancer metastasis. Carcinogenesis 2014;35:2254-63. [PMID: 24925028 DOI: 10.1093/carcin/bgu133] [Cited by in Crossref: 74] [Cited by in F6Publishing: 71] [Article Influence: 10.6] [Reference Citation Analysis]
356 Kairdolf BA, Smith AM, Stokes TH, Wang MD, Young AN, Nie S. Semiconductor quantum dots for bioimaging and biodiagnostic applications. Annu Rev Anal Chem (Palo Alto Calif). 2013;6:143-162. [PMID: 23527547 DOI: 10.1146/annurev-anchem-060908-155136] [Cited by in Crossref: 418] [Cited by in F6Publishing: 275] [Article Influence: 52.3] [Reference Citation Analysis]
357 Anders CK, Carey LA. Biology, metastatic patterns, and treatment of patients with triple-negative breast cancer. Clin Breast Cancer. 2009;9 Suppl 2:S73-S81. [PMID: 19596646 DOI: 10.3816/cbc.2009.s.008] [Cited by in Crossref: 348] [Cited by in F6Publishing: 216] [Article Influence: 29.0] [Reference Citation Analysis]
358 Al-Ejeh F, Simpson PT, Sanus JM, Klein K, Kalimutho M, Shi W, Miranda M, Kutasovic J, Raghavendra A, Madore J, Reid L, Krause L, Chenevix-Trench G, Lakhani SR, Khanna KK. Meta-analysis of the global gene expression profile of triple-negative breast cancer identifies genes for the prognostication and treatment of aggressive breast cancer. Oncogenesis 2014;3:e100. [PMID: 24752235 DOI: 10.1038/oncsis.2014.14] [Cited by in Crossref: 44] [Cited by in F6Publishing: 38] [Article Influence: 6.3] [Reference Citation Analysis]
359 Kong P, Chen L, Yu M, Tao J, Liu J, Wang Y, Pan H, Zhou W, Wang S. miR-3178 inhibits cell proliferation and metastasis by targeting Notch1 in triple-negative breast cancer. Cell Death Dis 2018;9:1059. [PMID: 30333478 DOI: 10.1038/s41419-018-1091-y] [Cited by in Crossref: 19] [Cited by in F6Publishing: 23] [Article Influence: 6.3] [Reference Citation Analysis]
360 Cain EH, Saha A, Harowicz MR, Marks JR, Marcom PK, Mazurowski MA. Multivariate machine learning models for prediction of pathologic response to neoadjuvant therapy in breast cancer using MRI features: a study using an independent validation set. Breast Cancer Res Treat. 2019;173:455-463. [PMID: 30328048 DOI: 10.1007/s10549-018-4990-9] [Cited by in Crossref: 44] [Cited by in F6Publishing: 29] [Article Influence: 14.7] [Reference Citation Analysis]
361 Iglesia MD, Vincent BG, Parker JS, Hoadley KA, Carey LA, Perou CM, Serody JS. Prognostic B-cell signatures using mRNA-seq in patients with subtype-specific breast and ovarian cancer. Clin Cancer Res 2014;20:3818-29. [PMID: 24916698 DOI: 10.1158/1078-0432.CCR-13-3368] [Cited by in Crossref: 142] [Cited by in F6Publishing: 84] [Article Influence: 20.3] [Reference Citation Analysis]
362 Prat A, Cruz C, Hoadley KA, Díez O, Perou CM, Balmaña J. Molecular features of the basal-like breast cancer subtype based on BRCA1 mutation status. Breast Cancer Res Treat 2014;147:185-91. [PMID: 25048467 DOI: 10.1007/s10549-014-3056-x] [Cited by in Crossref: 25] [Cited by in F6Publishing: 21] [Article Influence: 3.6] [Reference Citation Analysis]
363 Collignon J, Lousberg L, Schroeder H, Jerusalem G. Triple-negative breast cancer: treatment challenges and solutions. Breast Cancer (Dove Med Press) 2016;8:93-107. [PMID: 27284266 DOI: 10.2147/BCTT.S69488] [Cited by in Crossref: 37] [Cited by in F6Publishing: 91] [Article Influence: 7.4] [Reference Citation Analysis]
364 Tian J, Hachim MY, Hachim IY, Dai M, Lo C, Raffa FA, Ali S, Lebrun JJ. Cyclooxygenase-2 regulates TGFβ-induced cancer stemness in triple-negative breast cancer. Sci Rep 2017;7:40258. [PMID: 28054666 DOI: 10.1038/srep40258] [Cited by in Crossref: 28] [Cited by in F6Publishing: 28] [Article Influence: 7.0] [Reference Citation Analysis]
365 Wang Z, Li Y, Ahmad A, Azmi AS, Kong D, Banerjee S, Sarkar FH. Targeting miRNAs involved in cancer stem cell and EMT regulation: An emerging concept in overcoming drug resistance. Drug Resist Updat 2010;13:109-18. [PMID: 20692200 DOI: 10.1016/j.drup.2010.07.001] [Cited by in Crossref: 237] [Cited by in F6Publishing: 224] [Article Influence: 21.5] [Reference Citation Analysis]
366 Di Cosimo S, La Verde N, Moretti A, Cazzaniga ME, Generali D, Bianchi GV, Mariani L, Torri V, Crippa F, Paolini B, Scaperrotta G, De Santis MC, Di Nicola M, Apolone G, Gulino A, Tripodo C, Colombo MP, Folli S, de Braud F. Neoadjuvant eribulin mesylate following anthracycline and taxane in triple negative breast cancer: Results from the HOPE study. PLoS One 2019;14:e0220644. [PMID: 31390375 DOI: 10.1371/journal.pone.0220644] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
367 Sánchez-Muñoz A, Plata-Fernández Y, Fernández M, Jaén-Morago A, Fernández-Navarro M, de la Torre-Cabrera C, Ramirez-Tortosa C, Pascual J, Alba E, Sánchez-Rovira P. Tumor histological subtyping determined by hormone receptors and HER2 status defines different pathological complete response and outcome to dose-dense neoadjuvant chemotherapy in breast cancer patients. Clin Transl Oncol 2014;16:548-54. [PMID: 24085576 DOI: 10.1007/s12094-013-1116-z] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
368 Li S, Payne S, Wang F, Claus P, Su Z, Groth J, Geradts J, de Ridder G, Alvarez R, Marcom PK. Nuclear basic fibroblast growth factor regulates triple-negative breast cancer chemo-resistance. Breast Cancer Res. 2015;17:91. [PMID: 26141457 DOI: 10.1186/s13058-015-0590-3] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 2.7] [Reference Citation Analysis]
369 Al-Zahrani KN, Cook DP, Vanderhyden BC, Sabourin LA. Assessing the efficacy of androgen receptor and Sox10 as independent markers of the triple-negative breast cancer subtype by transcriptome profiling. Oncotarget 2018;9:33348-59. [PMID: 30279965 DOI: 10.18632/oncotarget.26072] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
370 Ghosn M, Hajj C, Kattan J, Farhat F, El Karak F, Nasr F, Abadjian G, Chahine G. Triple-negative breast cancer in Lebanon: a case series. Oncologist 2011;16:1552-6. [PMID: 22020211 DOI: 10.1634/theoncologist.2011-0088] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
371 Pajic M, Kersbergen A, van Diepen F, Pfauth A, Jonkers J, Borst P, Rottenberg S. Tumor-initiating cells are not enriched in cisplatin-surviving BRCA1;p53-deficient mammary tumor cells in vivo. Cell Cycle 2010;9:3780-91. [PMID: 20855963 DOI: 10.4161/cc.9.18.13002] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 2.0] [Reference Citation Analysis]
372 Xu X, Zhang Y, Jasper J, Lykken E, Alexander PB, Markowitz GJ, McDonnell DP, Li QJ, Wang XF. MiR-148a functions to suppress metastasis and serves as a prognostic indicator in triple-negative breast cancer. Oncotarget 2016;7:20381-94. [PMID: 26967387 DOI: 10.18632/oncotarget.7953] [Cited by in Crossref: 31] [Cited by in F6Publishing: 37] [Article Influence: 10.3] [Reference Citation Analysis]
373 Hergueta-Redondo M, Palacios J, Cano A, Moreno-Bueno G. "New" molecular taxonomy in breast cancer. Clin Transl Oncol 2008;10:777-85. [PMID: 19068448 DOI: 10.1007/s12094-008-0290-x] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 0.9] [Reference Citation Analysis]
374 Bou Zerdan M, Ibrahim M, Nakib CE, Hajjar R, Assi HI. Genomic Assays in Node Positive Breast Cancer Patients: A Review. Front Oncol 2020;10:609100. [PMID: 33665165 DOI: 10.3389/fonc.2020.609100] [Reference Citation Analysis]
375 Dawood S, Hu R, Homes MD, Collins LC, Schnitt SJ, Connolly J, Colditz GA, Tamimi RM. Defining breast cancer prognosis based on molecular phenotypes: results from a large cohort study. Breast Cancer Res Treat 2011;126:185-92. [PMID: 20711652 DOI: 10.1007/s10549-010-1113-7] [Cited by in Crossref: 81] [Cited by in F6Publishing: 73] [Article Influence: 7.4] [Reference Citation Analysis]
376 Cao MD, Lamichhane S, Lundgren S, Bofin A, Fjøsne H, Giskeødegård GF, Bathen TF. Metabolic characterization of triple negative breast cancer. BMC Cancer 2014;14:941. [PMID: 25495193 DOI: 10.1186/1471-2407-14-941] [Cited by in Crossref: 84] [Cited by in F6Publishing: 70] [Article Influence: 12.0] [Reference Citation Analysis]
377 Shi J, Liu F, Song Y. Progress: Targeted Therapy, Immunotherapy, and New Chemotherapy Strategies in Advanced Triple-Negative Breast Cancer. Cancer Manag Res 2020;12:9375-87. [PMID: 33061626 DOI: 10.2147/CMAR.S272685] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 6.0] [Reference Citation Analysis]
378 Massihnia D, Galvano A, Fanale D, Perez A, Castiglia M, Incorvaia L, Listì A, Rizzo S, Cicero G, Bazan V, Castorina S, Russo A. Triple negative breast cancer: shedding light onto the role of pi3k/akt/mtor pathway. Oncotarget 2016;7:60712-22. [PMID: 27474173 DOI: 10.18632/oncotarget.10858] [Cited by in Crossref: 58] [Cited by in F6Publishing: 54] [Article Influence: 19.3] [Reference Citation Analysis]
379 Shen K, Song N, Kim Y, Tian C, Rice SD, Gabrin MJ, Symmans WF, Pusztai L, Lee JK. A systematic evaluation of multi-gene predictors for the pathological response of breast cancer patients to chemotherapy. PLoS One 2012;7:e49529. [PMID: 23185353 DOI: 10.1371/journal.pone.0049529] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.0] [Reference Citation Analysis]
380 Sun WY, Lee YK, Koo JS. Expression of PD-L1 in triple-negative breast cancer based on different immunohistochemical antibodies. J Transl Med 2016;14:173. [PMID: 27286842 DOI: 10.1186/s12967-016-0925-6] [Cited by in Crossref: 63] [Cited by in F6Publishing: 65] [Article Influence: 12.6] [Reference Citation Analysis]
381 Yokoyama Y, Matsumoto A, Hieda M, Shinchi Y, Ogihara E, Hamada M, Nishioka Y, Kimura H, Yoshidome K, Tsujimoto M, Matsuura N. Loss of histone H4K20 trimethylation predicts poor prognosis in breast cancer and is associated with invasive activity. Breast Cancer Res 2014;16:R66. [PMID: 24953066 DOI: 10.1186/bcr3681] [Cited by in Crossref: 52] [Cited by in F6Publishing: 42] [Article Influence: 7.4] [Reference Citation Analysis]
382 Keam B, Im SA, Koh Y, Han SW, Oh DY, Cho N, Kim JH, Han W, Kang KW, Moon WK, Kim TY, Park IA, Noh DY, Chung JK, Bang YJ. Early metabolic response using FDG PET/CT and molecular phenotypes of breast cancer treated with neoadjuvant chemotherapy. BMC Cancer 2011;11:452. [PMID: 22011459 DOI: 10.1186/1471-2407-11-452] [Cited by in Crossref: 47] [Cited by in F6Publishing: 33] [Article Influence: 4.7] [Reference Citation Analysis]
383 Yamada A, Ishikawa T, Ota I, Kimura M, Shimizu D, Tanabe M, Chishima T, Sasaki T, Ichikawa Y, Morita S, Yoshiura K, Takabe K, Endo I. High expression of ATP-binding cassette transporter ABCC11 in breast tumors is associated with aggressive subtypes and low disease-free survival. Breast Cancer Res Treat 2013;137:773-82. [PMID: 23288347 DOI: 10.1007/s10549-012-2398-5] [Cited by in Crossref: 56] [Cited by in F6Publishing: 52] [Article Influence: 7.0] [Reference Citation Analysis]
384 Ye JH, Wang XH, Shi JJ, Yin X, Chen C, Chen Y, Wu HY, Jiong S, Sun Q, Zhang M, Shi XB, Zhou GR, Hassan S, Feng JF, Xu XY, Zhang WJ. Tumor-associated macrophages are associated with response to neoadjuvant chemotherapy and poor outcomes in patients with triple-negative breast cancer. J Cancer 2021;12:2886-92. [PMID: 33854589 DOI: 10.7150/jca.47566] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
385 Caglevic C, Anabalón J, Soza C, Milla E, Gaete F, Carrasco AM, Panay S, Gallardo C, Mahave M. Triple-negative breast cancer: the reality in Chile and in Latin America. Ecancermedicalscience 2019;13:893. [PMID: 30792810 DOI: 10.3332/ecancer.2019.893] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
386 Zhai G, Kim H, Sarver D, Samuel S, Whitworth L, Umphrey H, Oelschlager DK, Beasley TM, Zinn KR. Early therapy assessment of combined anti-DR5 antibody and carboplatin in triple-negative breast cancer xenografts in mice using diffusion-weighted imaging and (1)H MR spectroscopy. J Magn Reson Imaging 2014;39:1588-94. [PMID: 24151215 DOI: 10.1002/jmri.24319] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 1.4] [Reference Citation Analysis]
387 Moreno-Aspitia A, Perez EA. Treatment options for breast cancer resistant to anthracycline and taxane. Mayo Clin Proc 2009;84:533-45. [PMID: 19483170 DOI: 10.1016/S0025-6196(11)60585-5] [Cited by in F6Publishing: 27] [Reference Citation Analysis]
388 Canonici A, Browne AL, Ibrahim MFK, Fanning KP, Roche S, Conlon NT, O'Neill F, Meiller J, Cremona M, Morgan C, Hennessy BT, Eustace AJ, Solca F, O'Donovan N, Crown J. Combined targeting EGFR and SRC as a potential novel therapeutic approach for the treatment of triple negative breast cancer. Ther Adv Med Oncol 2020;12:1758835919897546. [PMID: 32064003 DOI: 10.1177/1758835919897546] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 7.0] [Reference Citation Analysis]
389 Zhao Y, Dong X, Li R, Ma X, Song J, Li Y, Zhang D. Evaluation of the pathological response and prognosis following neoadjuvant chemotherapy in molecular subtypes of breast cancer. Onco Targets Ther 2015;8:1511-21. [PMID: 26150728 DOI: 10.2147/OTT.S83243] [Cited by in Crossref: 2] [Cited by in F6Publishing: 7] [Article Influence: 0.3] [Reference Citation Analysis]
390 Arnedos M, Bihan C, Delaloge S, Andre F. Triple-negative breast cancer: are we making headway at least? Ther Adv Med Oncol 2012;4:195-210. [PMID: 22754593 DOI: 10.1177/1758834012444711] [Cited by in Crossref: 52] [Cited by in F6Publishing: 47] [Article Influence: 5.8] [Reference Citation Analysis]
391 Caporossi D, Parisi A, Fantini C, Grazioli E, Cerulli C, Dimauro I. AlphaB-crystallin and breast cancer: role and possible therapeutic strategies. Cell Stress Chaperones 2021;26:19-28. [PMID: 33111264 DOI: 10.1007/s12192-020-01175-0] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
392 Marcus DM, Switchenko JM, Prabhu R, O'Regan R, Zelnak A, Fasola C, Mister D, Torres MA. Neoadjuvant Hormonal Therapy is Associated with Comparable Outcomes to Neoadjuvant Chemotherapy in Post-Menopausal Women with Estrogen Receptor-Positive Breast Cancer. Front Oncol 2013;3:317. [PMID: 24409418 DOI: 10.3389/fonc.2013.00317] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
393 Izawa Y, Kashii-Magaribuchi K, Yoshida K, Nosaka M, Tsuji N, Yamamoto A, Kuroyanagi K, Tono K, Tanihata M, Imanishi M, Onishi M, Sakiyama M, Inoue S, Takahashi R. Stem-like Human Breast Cancer Cells Initiate Vasculogenic Mimicry on Matrigel. Acta Histochem Cytochem 2018;51:173-83. [PMID: 30647492 DOI: 10.1267/ahc.18041] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 4.0] [Reference Citation Analysis]
394 Vorobyeva A, Bezverkhniaia E, Konovalova E, Schulga A, Garousi J, Vorontsova O, Abouzayed A, Orlova A, Deyev S, Tolmachev V. Radionuclide Molecular Imaging of EpCAM Expression in Triple-Negative Breast Cancer Using the Scaffold Protein DARPin Ec1. Molecules 2020;25:E4719. [PMID: 33066684 DOI: 10.3390/molecules25204719] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
395 Liu N, Yang Z, Liu X, Niu Y. Lymph node status in different molecular subtype of breast cancer: triple negative tumours are more likely lymph node negative. Oncotarget 2017;8:55534-43. [PMID: 28903439 DOI: 10.18632/oncotarget.15022] [Cited by in Crossref: 17] [Cited by in F6Publishing: 13] [Article Influence: 4.3] [Reference Citation Analysis]
396 Hansen J, Iyengar R. Computation as the mechanistic bridge between precision medicine and systems therapeutics. Clin Pharmacol Ther 2013;93:117-28. [PMID: 23212109 DOI: 10.1038/clpt.2012.199] [Cited by in Crossref: 34] [Cited by in F6Publishing: 23] [Article Influence: 3.8] [Reference Citation Analysis]
397 Babyshkina N, Malinovskaya E, Patalyak S, Bragina O, Tarabanovskaya N, Doroshenko A, Slonimskaya E, Perelmuter V, Cherdyntseva N. Neoadjuvant chemotherapy for different molecular breast cancer subtypes: a retrospective study in Russian population. Med Oncol 2014;31:165. [PMID: 25139196 DOI: 10.1007/s12032-014-0165-7] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
398 Lefort S, Joffre C, Kieffer Y, Givel AM, Bourachot B, Zago G, Bieche I, Dubois T, Meseure D, Vincent-Salomon A, Camonis J, Mechta-Grigoriou F. Inhibition of autophagy as a new means of improving chemotherapy efficiency in high-LC3B triple-negative breast cancers. Autophagy 2014;10:2122-42. [PMID: 25427136 DOI: 10.4161/15548627.2014.981788] [Cited by in Crossref: 90] [Cited by in F6Publishing: 86] [Article Influence: 15.0] [Reference Citation Analysis]
399 de Ruijter TC, Veeck J, de Hoon JP, van Engeland M, Tjan-Heijnen VC. Characteristics of triple-negative breast cancer. J Cancer Res Clin Oncol. 2011;137:183-192. [PMID: 21069385 DOI: 10.1007/s00432-010-0957-x] [Cited by in Crossref: 140] [Cited by in F6Publishing: 124] [Article Influence: 12.7] [Reference Citation Analysis]
400 Lin Y, Yin W, Yan T, Zhou L, Di G, Wu J, Shen Z, Shao Z, Lu J. Site-specific relapse pattern of the triple negative tumors in Chinese breast cancer patients. BMC Cancer 2009;9:342. [PMID: 19778431 DOI: 10.1186/1471-2407-9-342] [Cited by in Crossref: 22] [Cited by in F6Publishing: 23] [Article Influence: 1.8] [Reference Citation Analysis]
401 Jiang X, Wells A, Brufsky A, Neapolitan R. A clinical decision support system learned from data to personalize treatment recommendations towards preventing breast cancer metastasis. PLoS One 2019;14:e0213292. [PMID: 30849111 DOI: 10.1371/journal.pone.0213292] [Cited by in Crossref: 12] [Cited by in F6Publishing: 3] [Article Influence: 6.0] [Reference Citation Analysis]
402 Osako T, Horii R, Matsuura M, Ogiya A, Domoto K, Miyagi Y, Takahashi S, Ito Y, Iwase T, Akiyama F. Common and discriminative clinicopathological features between breast cancers with pathological complete response or progressive disease in response to neoadjuvant chemotherapy. J Cancer Res Clin Oncol. 2010;136:233-241. [PMID: 19685074 DOI: 10.1007/s00432-009-0654-9] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
403 Lim E, Wu D, Pal B, Bouras T, Asselin-Labat ML, Vaillant F, Yagita H, Lindeman GJ, Smyth GK, Visvader JE. Transcriptome analyses of mouse and human mammary cell subpopulations reveal multiple conserved genes and pathways. Breast Cancer Res 2010;12:R21. [PMID: 20346151 DOI: 10.1186/bcr2560] [Cited by in Crossref: 291] [Cited by in F6Publishing: 268] [Article Influence: 26.5] [Reference Citation Analysis]
404 Akbaribazm M, Khazaei MR, Khazaei M. Trifolium pratense L. (red clover) extract and doxorubicin synergistically inhibits proliferation of 4T1 breast cancer in tumor-bearing BALB/c mice through modulation of apoptosis and increase antioxidant and anti-inflammatory related pathways. Food Sci Nutr 2020;8:4276-90. [PMID: 32884708 DOI: 10.1002/fsn3.1724] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
405 Yamashita N, Tokunaga E, Kitao H, Hisamatsu Y, Taketani K, Akiyoshi S, Okada S, Aishima S, Morita M, Maehara Y. Vimentin as a poor prognostic factor for triple-negative breast cancer. J Cancer Res Clin Oncol 2013;139:739-46. [PMID: 23354842 DOI: 10.1007/s00432-013-1376-6] [Cited by in Crossref: 75] [Cited by in F6Publishing: 63] [Article Influence: 9.4] [Reference Citation Analysis]
406 Elsawaf Z, Sinn HP. Triple-Negative Breast Cancer: Clinical and Histological Correlations. Breast Care (Basel) 2011;6:273-8. [PMID: 22135625 DOI: 10.1159/000331643] [Cited by in Crossref: 24] [Cited by in F6Publishing: 22] [Article Influence: 2.4] [Reference Citation Analysis]
407 Prat A, Perou CM. Deconstructing the molecular portraits of breast cancer. Mol Oncol 2011;5:5-23. [PMID: 21147047 DOI: 10.1016/j.molonc.2010.11.003] [Cited by in Crossref: 753] [Cited by in F6Publishing: 639] [Article Influence: 68.5] [Reference Citation Analysis]
408 Kondov B, Milenkovikj Z, Kondov G, Petrushevska G, Basheska N, Bogdanovska-Todorovska M, Tolevska N, Ivkovski L. Presentation of the Molecular Subtypes of Breast Cancer Detected By Immunohistochemistry in Surgically Treated Patients. Open Access Maced J Med Sci 2018;6:961-7. [PMID: 29983785 DOI: 10.3889/oamjms.2018.231] [Cited by in Crossref: 34] [Cited by in F6Publishing: 28] [Article Influence: 11.3] [Reference Citation Analysis]
409 Ha R, Mutasa S, Karcich J, Gupta N, Pascual Van Sant E, Nemer J, Sun M, Chang P, Liu MZ, Jambawalikar S. Predicting Breast Cancer Molecular Subtype with MRI Dataset Utilizing Convolutional Neural Network Algorithm. J Digit Imaging 2019;32:276-82. [PMID: 30706213 DOI: 10.1007/s10278-019-00179-2] [Cited by in Crossref: 30] [Cited by in F6Publishing: 21] [Article Influence: 30.0] [Reference Citation Analysis]
410 Melichar B, Hornychová H, Kalábová H, Bašová H, Mergancová J, Urminská H, Jandík P, Cervinka V, Laco J, Ryška A. Increased efficacy of a dose-dense regimen of neoadjuvant chemotherapy in breast carcinoma: a retrospective analysis. Med Oncol 2012;29:2577-85. [PMID: 22392196 DOI: 10.1007/s12032-012-0195-y] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
411 Wang X, He Y, Fan Z, Wang T, Xie Y, Li J, Ouyang T. Effect of Trastuzumab among HER2-Positive Breast Cancer Patients that Achieved Pathologic Complete Response after Neoadjuvant Chemotherapy. Breast Care (Basel) 2019;14:388-93. [PMID: 31933585 DOI: 10.1159/000495186] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
412 Cai H, Everett RS, Thakker DR. Efficacious dose of metformin for breast cancer therapy is determined by cation transporter expression in tumours. Br J Pharmacol 2019;176:2724-35. [PMID: 31032880 DOI: 10.1111/bph.14694] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 6.5] [Reference Citation Analysis]
413 Laprevotte E, Cochaud S, du Manoir S, Lapierre M, Dejou C, Philippe M, Giustiniani J, Frewer KA, Sanders AJ, Jiang WG, Michaud HA, Colombo PE, Bensussan A, Alberici G, Bastid J, Eliaou JF, Bonnefoy N. The IL-17B-IL-17 receptor B pathway promotes resistance to paclitaxel in breast tumors through activation of the ERK1/2 pathway. Oncotarget 2017;8:113360-72. [PMID: 29371916 DOI: 10.18632/oncotarget.23008] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 4.0] [Reference Citation Analysis]
414 Hagen KR, Zeng X, Lee MY, Tucker Kahn S, Harrison Pitner MK, Zaky SS, Liu Y, O'Regan RM, Deng X, Saavedra HI. Silencing CDK4 radiosensitizes breast cancer cells by promoting apoptosis. Cell Div 2013;8:10. [PMID: 23886499 DOI: 10.1186/1747-1028-8-10] [Cited by in Crossref: 23] [Cited by in F6Publishing: 24] [Article Influence: 2.9] [Reference Citation Analysis]
415 Sharma P, López-Tarruella S, García-Saenz JA, Ward C, Connor CS, Gómez HL, Prat A, Moreno F, Jerez-Gilarranz Y, Barnadas A, Picornell AC, Del Monte-Millán M, Gonzalez-Rivera M, Massarrah T, Pelaez-Lorenzo B, Palomero MI, González Del Val R, Cortes J, Fuentes Rivera H, Bretel Morales D, Márquez-Rodas I, Perou CM, Wagner JL, Mammen JM, McGinness MK, Klemp JR, Amin AL, Fabian CJ, Heldstab J, Godwin AK, Jensen RA, Kimler BF, Khan QJ, Martin M. Efficacy of Neoadjuvant Carboplatin plus Docetaxel in Triple-Negative Breast Cancer: Combined Analysis of Two Cohorts. Clin Cancer Res 2017;23:649-57. [PMID: 27301700 DOI: 10.1158/1078-0432.CCR-16-0162] [Cited by in Crossref: 59] [Cited by in F6Publishing: 27] [Article Influence: 11.8] [Reference Citation Analysis]
416 Banerjee S, Reis-Filho JS, Ashley S, Steele D, Ashworth A, Lakhani SR, Smith IE. Basal-like breast carcinomas: clinical outcome and response to chemotherapy. J Clin Pathol. 2006;59:729-735. [PMID: 16556664 DOI: 10.1136/jcp.2005.033043] [Cited by in Crossref: 197] [Cited by in F6Publishing: 167] [Article Influence: 13.1] [Reference Citation Analysis]
417 He Q, Peng Y, Sun J, Liu J. Platinum-Based Chemotherapy and Immunotherapy in Early Triple-Negative Breast Cancer: A Meta-Analysis and Indirect Treatment Comparison. Front Oncol 2021;11:693542. [PMID: 34277438 DOI: 10.3389/fonc.2021.693542] [Reference Citation Analysis]
418 Azab B, Amundson JR, Cioci A, Stuart H, Yakoub D, Avisar E, Moffat F, Livingstone AS, Franceschi D. The Usefulness of the Pretreatment Neutrophil/Lymphocyte Ratio as a Predictor of the 5-Year Survival in Stage 1-3 Triple Negative Breast Cancer Patients. Breast Care (Basel) 2021;16:43-9. [PMID: 33716631 DOI: 10.1159/000506463] [Reference Citation Analysis]
419 Saura C, Tseng LM, Chan S, Chacko RT, Campone M, Manikhas A, Nag SM, Leichman CG, Dasappa L, Fasching PA, Hurtado de Mendoza F, Symmans WF, Liu D, Mukhopadhyay P, Horak C, Xing G, Pusztai L. Neoadjuvant doxorubicin/cyclophosphamide followed by ixabepilone or paclitaxel in early stage breast cancer and evaluation of βIII-tubulin expression as a predictive marker. Oncologist 2013;18:787-94. [PMID: 23853246 DOI: 10.1634/theoncologist.2013-0075] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 2.6] [Reference Citation Analysis]
420 Xu J, Wu X, Zhou WH, Liu AW, Wu JB, Deng JY, Yue CF, Yang SB, Wang J, Yuan ZY, Liu Q. Aurora-A identifies early recurrence and poor prognosis and promises a potential therapeutic target in triple negative breast cancer. PLoS One 2013;8:e56919. [PMID: 23437271 DOI: 10.1371/journal.pone.0056919] [Cited by in Crossref: 40] [Cited by in F6Publishing: 44] [Article Influence: 5.0] [Reference Citation Analysis]
421 Wang RX, Xu XE, Huang L, Chen S, Shao ZM. eEF2 kinase mediated autophagy as a potential therapeutic target for paclitaxel-resistant triple-negative breast cancer. Ann Transl Med 2019;7:783. [PMID: 32042799 DOI: 10.21037/atm.2019.11.39] [Cited by in Crossref: 5] [Cited by in F6Publishing: 10] [Article Influence: 2.5] [Reference Citation Analysis]
422 Liu XY, Jiang W, Ma D, Ge LP, Yang YS, Gou ZC, Xu XE, Shao ZM, Jiang YZ. SYTL4 downregulates microtubule stability and confers paclitaxel resistance in triple-negative breast cancer. Theranostics 2020;10:10940-56. [PMID: 33042263 DOI: 10.7150/thno.45207] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
423 Tiong KH, Tan BS, Choo HL, Chung FF, Hii LW, Tan SH, Khor NT, Wong SF, See SJ, Tan YF, Rosli R, Cheong SK, Leong CO. Fibroblast growth factor receptor 4 (FGFR4) and fibroblast growth factor 19 (FGF19) autocrine enhance breast cancer cells survival. Oncotarget 2016;7:57633-50. [PMID: 27192118 DOI: 10.18632/oncotarget.9328] [Cited by in Crossref: 41] [Cited by in F6Publishing: 38] [Article Influence: 13.7] [Reference Citation Analysis]
424 Derleth C, Mayer IA. Antiangiogenic therapies in early-stage breast cancer. Clin Breast Cancer 2010;10 Suppl 1:E23-31. [PMID: 20587404 DOI: 10.3816/CBC.2010.s.004] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 1.1] [Reference Citation Analysis]
425 Wu X, Ye C, Wang X, Cai R, Yang J, Yu X, Zhou Y, Shen L, Zhu Y, Liu X. The Efficacy and Toxicity of Neoadjuvant Chemotherapy Regimens of Epirubicin Plus Cyclophosphamide Followed by Docetaxel or Paclitaxel in Female Breast Cancer Patients. Cancer Manag Res 2021;13:1517-27. [PMID: 33623431 DOI: 10.2147/CMAR.S284638] [Reference Citation Analysis]
426 Zhu Q, Huang Y, Marton LJ, Woster PM, Davidson NE, Casero RA Jr. Polyamine analogs modulate gene expression by inhibiting lysine-specific demethylase 1 (LSD1) and altering chromatin structure in human breast cancer cells. Amino Acids 2012;42:887-98. [PMID: 21805138 DOI: 10.1007/s00726-011-1004-1] [Cited by in Crossref: 58] [Cited by in F6Publishing: 55] [Article Influence: 5.8] [Reference Citation Analysis]
427 Adams S, Chakravarthy AB, Donach M, Spicer D, Lymberis S, Singh B, Bauer JA, Hochman T, Goldberg JD, Muggia F, Schneider RJ, Pietenpol JA, Formenti SC. Preoperative concurrent paclitaxel-radiation in locally advanced breast cancer: pathologic response correlates with five-year overall survival. Breast Cancer Res Treat 2010;124:723-32. [PMID: 20878462 DOI: 10.1007/s10549-010-1181-8] [Cited by in Crossref: 39] [Cited by in F6Publishing: 36] [Article Influence: 3.5] [Reference Citation Analysis]
428 Turner TH, Alzubi MA, Harrell JC. Identification of synergistic drug combinations using breast cancer patient-derived xenografts. Sci Rep 2020;10:1493. [PMID: 32001757 DOI: 10.1038/s41598-020-58438-0] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 8.0] [Reference Citation Analysis]
429 Prat A, Perou CM. Mammary development meets cancer genomics. Nat Med 2009;15:842-4. [PMID: 19661985 DOI: 10.1038/nm0809-842] [Cited by in Crossref: 135] [Cited by in F6Publishing: 117] [Article Influence: 11.3] [Reference Citation Analysis]
430 Lin Y, Lin S, Watson M, Trinkaus KM, Kuo S, Naughton MJ, Weilbaecher K, Fleming TP, Aft RL. A gene expression signature that predicts the therapeutic response of the basal-like breast cancer to neoadjuvant chemotherapy. Breast Cancer Res Treat 2010;123:691-9. [PMID: 19967557 DOI: 10.1007/s10549-009-0664-y] [Cited by in Crossref: 22] [Cited by in F6Publishing: 18] [Article Influence: 1.8] [Reference Citation Analysis]
431 Wang RX, Chen S, Huang L, Shao ZM. Predictive and prognostic value of Matrix metalloproteinase (MMP) - 9 in neoadjuvant chemotherapy for triple-negative breast cancer patients. BMC Cancer 2018;18:909. [PMID: 30241470 DOI: 10.1186/s12885-018-4822-7] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
432 Yi SY, Ahn JS, Uhm JE, Lim DH, Ji SH, Jun HJ, Kim KH, Chang MH, Park MJ, Cho EY, Choi YL, Park YH, Im YH. Favorable response to doxorubicin combination chemotherapy does not yield good clinical outcome in patients with metastatic breast cancer with triple-negative phenotype. BMC Cancer 2010;10:527. [PMID: 20920367 DOI: 10.1186/1471-2407-10-527] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.5] [Reference Citation Analysis]
433 Chae S, Kang KM, Kim HJ, Kang E, Park SY, Kim JH, Kim SH, Kim SW, Kim EK. Neutrophil-lymphocyte ratio predicts response to chemotherapy in triple-negative breast cancer. Curr Oncol 2018;25:e113-9. [PMID: 29719435 DOI: 10.3747/co.25.3888] [Cited by in Crossref: 26] [Cited by in F6Publishing: 24] [Article Influence: 8.7] [Reference Citation Analysis]
434 Dent S, Melloni C, Ivars J, Sammons S, Kimmick G. Cardiotoxicities of Modern Treatments in Breast Cancer. Curr Treat Options Cardiovasc Med 2019;21:34. [PMID: 31203459 DOI: 10.1007/s11936-019-0738-z] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
435 Guarneri V, Dieci MV, Conte P. Relapsed triple-negative breast cancer: challenges and treatment strategies. Drugs 2013;73:1257-65. [PMID: 23842749 DOI: 10.1007/s40265-013-0091-6] [Cited by in Crossref: 27] [Cited by in F6Publishing: 26] [Article Influence: 3.9] [Reference Citation Analysis]
436 Choi YJ, Seong MH, Choi SH, Kook SH, Kwag HJ, Park YL, Park CH. Ultrasound and clinicopathological characteristics of triple receptor-negative breast cancers. J Breast Cancer 2011;14:119-23. [PMID: 21847406 DOI: 10.4048/jbc.2011.14.2.119] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 1.6] [Reference Citation Analysis]
437 Weigman VJ, Chao HH, Shabalin AA, He X, Parker JS, Nordgard SH, Grushko T, Huo D, Nwachukwu C, Nobel A, Kristensen VN, Børresen-Dale AL, Olopade OI, Perou CM. Basal-like Breast cancer DNA copy number losses identify genes involved in genomic instability, response to therapy, and patient survival. Breast Cancer Res Treat 2012;133:865-80. [PMID: 22048815 DOI: 10.1007/s10549-011-1846-y] [Cited by in Crossref: 71] [Cited by in F6Publishing: 71] [Article Influence: 7.1] [Reference Citation Analysis]
438 Ursini-Siegel J. Can pharmacological receptor tyrosine kinase inhibitors sensitize poor outcome breast tumors to immune-based therapies? Front Oncol 2013;3:23. [PMID: 23408142 DOI: 10.3389/fonc.2013.00023] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
439 Arumugam A, Subramani R, Nandy SB, Terreros D, Dwivedi AK, Saltzstein E, Lakshmanaswamy R. Silencing growth hormone receptor inhibits estrogen receptor negative breast cancer through ATP-binding cassette sub-family G member 2. Exp Mol Med 2019;51:1-13. [PMID: 30617282 DOI: 10.1038/s12276-018-0197-8] [Cited by in Crossref: 24] [Cited by in F6Publishing: 23] [Article Influence: 12.0] [Reference Citation Analysis]
440 Mariotto AB, Zou Z, Zhang F, Howlader N, Kurian AW, Etzioni R. Can We Use Survival Data from Cancer Registries to Learn about Disease Recurrence? The Case of Breast Cancer. Cancer Epidemiol Biomarkers Prev 2018;27:1332-41. [PMID: 30337342 DOI: 10.1158/1055-9965.EPI-17-1129] [Cited by in Crossref: 11] [Cited by in F6Publishing: 5] [Article Influence: 3.7] [Reference Citation Analysis]
441 Núñez Abad M, Calabuig-Fariñas S, Lobo de Mena M, José Godes Sanz de Bremond M, García González C, Torres Martínez S, García-García JÁ, Iranzo González-Cruz V, Camps Herrero C. Update on systemic treatment in early triple negative breast cancer. Ther Adv Med Oncol 2021;13:1758835920986749. [PMID: 33613695 DOI: 10.1177/1758835920986749] [Reference Citation Analysis]
442 Bower JJ, Vance LD, Psioda M, Smith-Roe SL, Simpson DA, Ibrahim JG, Hoadley KA, Perou CM, Kaufmann WK. Patterns of cell cycle checkpoint deregulation associated with intrinsic molecular subtypes of human breast cancer cells. NPJ Breast Cancer 2017;3:9. [PMID: 28649649 DOI: 10.1038/s41523-017-0009-7] [Cited by in Crossref: 26] [Cited by in F6Publishing: 17] [Article Influence: 6.5] [Reference Citation Analysis]
443 Nogi H, Uchida K, Kamio M, Kato K, Toriumi Y, Akiba T, Morikawa T, Suzuki M, Kobayashi T, Takeyama H. Triple-negative breast cancer exhibits a favorable response to neoadjuvant chemotherapy independent of the expression of topoisomerase IIα. Mol Clin Oncol 2016;4:383-9. [PMID: 26998288 DOI: 10.3892/mco.2015.719] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
444 Clark O, Botrel TE, Paladini L, Ferreira MB. Targeted therapy in triple-negative metastatic breast cancer: a systematic review and meta-analysis. Core Evid 2014;9:1-11. [PMID: 24476748 DOI: 10.2147/CE.S52197] [Cited by in Crossref: 26] [Cited by in F6Publishing: 13] [Article Influence: 3.7] [Reference Citation Analysis]
445 Witkiewicz AK, Knudsen ES. Retinoblastoma tumor suppressor pathway in breast cancer: prognosis, precision medicine, and therapeutic interventions. Breast Cancer Res. 2014;16:207. [PMID: 25223380 DOI: 10.1186/bcr3652] [Cited by in Crossref: 59] [Cited by in F6Publishing: 56] [Article Influence: 8.4] [Reference Citation Analysis]
446 Nasr KE, Osman MA, Elkady MS, Ellithy MA. Metronomic methotrexate and cyclophosphamide after carboplatin included adjuvant chemotherapy in triple negative breast cancer: a phase III study. Ann Transl Med. 2015;3:284. [PMID: 26697444 DOI: 10.3978/j.issn.2305-5839.2015.11.14] [Cited by in F6Publishing: 10] [Reference Citation Analysis]
447 Lee HE, Kim JH, Kim YJ, Choi SY, Kim SW, Kang E, Chung IY, Kim IA, Kim EJ, Choi Y. An increase in cancer stem cell population after primary systemic therapy is a poor prognostic factor in breast cancer. Br J Cancer. 2011;104:1730-1738. [PMID: 21559013 DOI: 10.1038/bjc.2011.159] [Cited by in Crossref: 113] [Cited by in F6Publishing: 101] [Article Influence: 11.3] [Reference Citation Analysis]
448 Li L, Huang H, Zhu M, Wu J. Identification of Hub Genes and Pathways of Triple Negative Breast Cancer by Expression Profiles Analysis. Cancer Manag Res 2021;13:2095-104. [PMID: 33688252 DOI: 10.2147/CMAR.S295951] [Reference Citation Analysis]
449 Brandl MB, Pasquier E, Li F, Beck D, Zhang S, Zhao H, Kavallaris M, Wong ST. Computational analysis of image-based drug profiling predicts synergistic drug combinations: applications in triple-negative breast cancer. Mol Oncol 2014;8:1548-60. [PMID: 24997502 DOI: 10.1016/j.molonc.2014.06.007] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 1.4] [Reference Citation Analysis]
450 Fredholm H, Magnusson K, Lindström LS, Garmo H, Fält SE, Lindman H, Bergh J, Holmberg L, Pontén F, Frisell J, Fredriksson I. Long-term outcome in young women with breast cancer: a population-based study. Breast Cancer Res Treat 2016;160:131-43. [PMID: 27624330 DOI: 10.1007/s10549-016-3983-9] [Cited by in Crossref: 38] [Cited by in F6Publishing: 33] [Article Influence: 7.6] [Reference Citation Analysis]
451 Balanis N, Carlin CR. Stress-induced EGF receptor signaling through STAT3 and tumor progression in triple-negative breast cancer. Mol Cell Endocrinol 2017;451:24-30. [PMID: 28088463 DOI: 10.1016/j.mce.2017.01.013] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 2.8] [Reference Citation Analysis]
452 Lin X, Wu M, Liu P, Wei F, Li L, Tang H, Xie X, Liu X, Yang L, Xie X. Up-regulation and worse prognostic marker of cytoplasmic TARBP2 expression in obstinate breast cancer. Med Oncol 2014;31:868. [PMID: 24563327 DOI: 10.1007/s12032-014-0868-9] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.1] [Reference Citation Analysis]
453 Seshie B, Adu-Aryee NA, Dedey F, Calys-Tagoe B, Clegg-Lamptey JN. A retrospective analysis of breast cancer subtype based on ER/PR and HER2 status in Ghanaian patients at the Korle Bu Teaching Hospital, Ghana. BMC Clin Pathol 2015;15:14. [PMID: 26161039 DOI: 10.1186/s12907-015-0014-4] [Cited by in Crossref: 20] [Cited by in F6Publishing: 15] [Article Influence: 3.3] [Reference Citation Analysis]
454 Prat A, Parker JS, Karginova O, Fan C, Livasy C, Herschkowitz JI, He X, Perou CM. Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer. Breast Cancer Res. 2010;12:R68. [PMID: 20813035 DOI: 10.1186/bcr2635] [Cited by in Crossref: 1298] [Cited by in F6Publishing: 1154] [Article Influence: 118.0] [Reference Citation Analysis]
455 Choi SK, Kim HS, Jin T, Hwang EH, Jung M, Moon WK. Overexpression of the miR-141/200c cluster promotes the migratory and invasive ability of triple-negative breast cancer cells through the activation of the FAK and PI3K/AKT signaling pathways by secreting VEGF-A. BMC Cancer 2016;16:570. [PMID: 27484639 DOI: 10.1186/s12885-016-2620-7] [Cited by in Crossref: 41] [Cited by in F6Publishing: 36] [Article Influence: 8.2] [Reference Citation Analysis]
456 Smith IE. Neoadjuvant/presurgical treatments. Breast Cancer Res 2008;10 Suppl 4:S24. [PMID: 19128438 DOI: 10.1186/bcr2184] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
457 Li H, Han X, Liu Y, Liu G, Dong G. Ki67 as a predictor of poor prognosis in patients with triple-negative breast cancer. Oncol Lett 2015;9:149-52. [PMID: 25435949 DOI: 10.3892/ol.2014.2618] [Cited by in Crossref: 17] [Cited by in F6Publishing: 19] [Article Influence: 2.4] [Reference Citation Analysis]
458 Zhao H, Li D, Zhang B, Qi Y, Diao Y, Zhen Y, Shu X. PP2A as the Main Node of Therapeutic Strategies and Resistance Reversal in Triple-Negative Breast Cancer. Molecules 2017;22:E2277. [PMID: 29261144 DOI: 10.3390/molecules22122277] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.8] [Reference Citation Analysis]
459 Deng C, Zhang B, Zhang Y, Xu X, Xiong D, Chen X, Wu J. A long non-coding RNA OLBC15 promotes triple-negative breast cancer progression via enhancing ZNF326 degradation. J Clin Lab Anal 2020;34:e23304. [PMID: 32329931 DOI: 10.1002/jcla.23304] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 6.0] [Reference Citation Analysis]
460 Medioni J, Huchon C, Le Frere-Belda MA, Hofmann H, Bats AS, Eme D, Andrieu JM, Oudard S, Lecuru F, Levy E. Neoadjuvant dose-dense gemcitabine plus docetaxel and vinorelbine plus epirubicin for operable breast cancer: improved prognosis in triple-negative tumors. Drugs R D 2011;11:147-57. [PMID: 21679005 DOI: 10.2165/11591210-000000000-00000] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
461 Drápela S, Bouchal J, Jolly MK, Culig Z, Souček K. ZEB1: A Critical Regulator of Cell Plasticity, DNA Damage Response, and Therapy Resistance. Front Mol Biosci 2020;7:36. [PMID: 32266287 DOI: 10.3389/fmolb.2020.00036] [Cited by in Crossref: 23] [Cited by in F6Publishing: 18] [Article Influence: 23.0] [Reference Citation Analysis]
462 Gregório AC, Lacerda M, Figueiredo P, Simões S, Dias S, Moreira JN. Therapeutic Implications of the Molecular and Immune Landscape of Triple-Negative Breast Cancer. Pathol Oncol Res 2018;24:701-16. [PMID: 28913723 DOI: 10.1007/s12253-017-0307-2] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
463 Kittaneh M, Montero AJ, Glück S. Molecular profiling for breast cancer: a comprehensive review. Biomark Cancer. 2013;5:61-70. [PMID: 24250234 DOI: 10.4137/bic.s9455] [Cited by in Crossref: 93] [Cited by in F6Publishing: 63] [Article Influence: 11.6] [Reference Citation Analysis]
464 Bayraktar S, Gutierrez-Barrera AM, Liu D, Tasbas T, Akar U, Litton JK, Lin E, Albarracin CT, Meric-Bernstam F, Gonzalez-Angulo AM, Hortobagyi GN, Arun BK. Outcome of triple-negative breast cancer in patients with or without deleterious BRCA mutations. Breast Cancer Res Treat 2011;130:145-53. [PMID: 21830012 DOI: 10.1007/s10549-011-1711-z] [Cited by in Crossref: 71] [Cited by in F6Publishing: 61] [Article Influence: 7.1] [Reference Citation Analysis]
465 Camorani S, Crescenzi E, Gramanzini M, Fedele M, Zannetti A, Cerchia L. Aptamer-mediated impairment of EGFR-integrin αvβ3 complex inhibits vasculogenic mimicry and growth of triple-negative breast cancers. Sci Rep 2017;7:46659. [PMID: 28425453 DOI: 10.1038/srep46659] [Cited by in Crossref: 44] [Cited by in F6Publishing: 40] [Article Influence: 11.0] [Reference Citation Analysis]
466 Dębska-Szmich S, Krakowska M, Czernek U, Habib-Lisik M, Zięba A, Potemski P. The role of preoperative systemic treatment in patients with breast cancer. Contemp Oncol (Pozn) 2016;20:93-101. [PMID: 27358586 DOI: 10.5114/wo.2016.60067] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
467 Rhee J, Han SW, Oh DY, Kim JH, Im SA, Han W, Park IA, Noh DY, Bang YJ, Kim TY. The clinicopathologic characteristics and prognostic significance of triple-negativity in node-negative breast cancer. BMC Cancer 2008;8:307. [PMID: 18947390 DOI: 10.1186/1471-2407-8-307] [Cited by in Crossref: 84] [Cited by in F6Publishing: 75] [Article Influence: 6.5] [Reference Citation Analysis]
468 Yang SX, Polley EC. Systemic treatment and radiotherapy, breast cancer subtypes, and survival after long-term clinical follow-up. Breast Cancer Res Treat 2019;175:287-95. [PMID: 30746635 DOI: 10.1007/s10549-019-05142-x] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
469 Hancock BA, Chen YH, Solzak JP, Ahmad MN, Wedge DC, Brinza D, Scafe C, Veitch J, Gottimukkala R, Short W, Atale RV, Ivan M, Badve SS, Schneider BP, Lu X, Miller KD, Radovich M. Profiling molecular regulators of recurrence in chemorefractory triple-negative breast cancers. Breast Cancer Res 2019;21:87. [PMID: 31383035 DOI: 10.1186/s13058-019-1171-7] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 5.5] [Reference Citation Analysis]
470 Oakman C, Bessi S, Zafarana E, Galardi F, Biganzoli L, Di Leo A. Recent advances in systemic therapy: new diagnostics and biological predictors of outcome in early breast cancer. Breast Cancer Res 2009;11:205. [PMID: 19435470 DOI: 10.1186/bcr2238] [Cited by in Crossref: 54] [Cited by in F6Publishing: 47] [Article Influence: 4.5] [Reference Citation Analysis]
471 Ma H, Lu Y, Malone KE, Marchbanks PA, Deapen DM, Spirtas R, Burkman RT, Strom BL, McDonald JA, Folger SG, Simon MS, Sullivan-Halley J, Press MF, Bernstein L. Mortality risk of black women and white women with invasive breast cancer by hormone receptors, HER2, and p53 status. BMC Cancer 2013;13:225. [PMID: 23642215 DOI: 10.1186/1471-2407-13-225] [Cited by in Crossref: 34] [Cited by in F6Publishing: 24] [Article Influence: 4.3] [Reference Citation Analysis]
472 Nadanaka S, Kinouchi H, Kitagawa H. Chondroitin sulfate-mediated N-cadherin/β-catenin signaling is associated with basal-like breast cancer cell invasion. J Biol Chem 2018;293:444-65. [PMID: 29183998 DOI: 10.1074/jbc.M117.814509] [Cited by in Crossref: 28] [Cited by in F6Publishing: 13] [Article Influence: 7.0] [Reference Citation Analysis]
473 Cascione L, Gasparini P, Lovat F, Carasi S, Pulvirenti A, Ferro A, Alder H, He G, Vecchione A, Croce CM, Shapiro CL, Huebner K. Integrated microRNA and mRNA signatures associated with survival in triple negative breast cancer. PLoS One 2013;8:e55910. [PMID: 23405235 DOI: 10.1371/journal.pone.0055910] [Cited by in Crossref: 118] [Cited by in F6Publishing: 109] [Article Influence: 14.8] [Reference Citation Analysis]
474 Liu Y, Yin X, Zhong J, Guan N, Luo Z, Min L, Yao X, Bo X, Dai L, Bai H. Systematic Identification and Assessment of Therapeutic Targets for Breast Cancer Based on Genome-Wide RNA Interference Transcriptomes. Genes (Basel) 2017;8:E86. [PMID: 28245581 DOI: 10.3390/genes8030086] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
475 Goncalves G, Mullan KA, Duscharla D, Ayala R, Croft NP, Faridi P, Purcell AW. IFNγ Modulates the Immunopeptidome of Triple Negative Breast Cancer Cells by Enhancing and Diversifying Antigen Processing and Presentation. Front Immunol 2021;12:645770. [PMID: 33968037 DOI: 10.3389/fimmu.2021.645770] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
476 Minami CA, Chung DU, Chang HR. Management options in triple-negative breast cancer. Breast Cancer (Auckl) 2011;5:175-99. [PMID: 21863131 DOI: 10.4137/BCBCR.S6562] [Cited by in Crossref: 8] [Cited by in F6Publishing: 16] [Article Influence: 0.8] [Reference Citation Analysis]
477 Masuda H, Brewer TM, Liu DD, Iwamoto T, Shen Y, Hsu L, Willey JS, Gonzalez-Angulo AM, Chavez-MacGregor M, Fouad TM, Woodward WA, Reuben JM, Valero V, Alvarez RH, Hortobagyi GN, Ueno NT. Long-term treatment efficacy in primary inflammatory breast cancer by hormonal receptor- and HER2-defined subtypes. Ann Oncol 2014;25:384-91. [PMID: 24351399 DOI: 10.1093/annonc/mdt525] [Cited by in Crossref: 73] [Cited by in F6Publishing: 67] [Article Influence: 9.1] [Reference Citation Analysis]
478 Derkaoui T, Bakkach J, Mansouri M, Loudiyi A, Fihri M, Alaoui FZ, Barakat A, El Yemlahi B, Bihri H, Nourouti NG, Mechita MB. Triple negative breast cancer in North of Morocco: clinicopathologic and prognostic features. BMC Womens Health 2016;16:68. [PMID: 27770782 DOI: 10.1186/s12905-016-0346-y] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
479 Huang Y, Li W, Yan W, Wu J, Chen L, Yao X, Gu F, Lv L, Zhao J, Zhao M, Xia T, Han Q, Li T, Ying X, Li T, Xia Q, Li A, Zhang X, Chen Y, Zhou T. Loss of PICH promotes chromosome instability and cell death in triple-negative breast cancer. Cell Death Dis 2019;10:428. [PMID: 31160555 DOI: 10.1038/s41419-019-1662-6] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
480 Harbhajanka A, Chahar S, Miskimen K, Silverman P, Harris L, Williams N, Varadan V, Gilmore H. Clinicopathological, immunohistochemical and molecular correlation of neural crest transcription factor SOX10 expression in triple-negative breast carcinoma. Hum Pathol 2018;80:163-9. [PMID: 29894722 DOI: 10.1016/j.humpath.2018.06.007] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 6.7] [Reference Citation Analysis]
481 Shigematsu H, Kawaguchi H, Nakamura Y, Tanaka K, Shiotani S, Koga C, Nishimura S, Taguchi K, Nishiyama K, Ohno S. Significant survival improvement of patients with recurrent breast cancer in the periods 2001-2008 vs. 1992-2000. BMC Cancer 2011;11:118. [PMID: 21453503 DOI: 10.1186/1471-2407-11-118] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 1.9] [Reference Citation Analysis]
482 Fu A, Ma S, Wei N, Tan BX, Tan EY, Luo KQ. High expression of MnSOD promotes survival of circulating breast cancer cells and increases their resistance to doxorubicin. Oncotarget 2016;7:50239-57. [PMID: 27384484 DOI: 10.18632/oncotarget.10360] [Cited by in Crossref: 35] [Cited by in F6Publishing: 30] [Article Influence: 11.7] [Reference Citation Analysis]
483 Hall C, Krishnamurthy S, Lodhi A, Mosalpuria K, Kuerer HM, Meric-Bernstam F, Bedrosian I, Hunt KK, Lucci A. Disseminated tumor cells in biologic subtypes of stage I-III breast cancer patients. Ann Surg Oncol 2010;17:3252-8. [PMID: 20559739 DOI: 10.1245/s10434-010-1160-7] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 1.1] [Reference Citation Analysis]
484 Kuzucan A, Chen JH, Bahri S, Mehta RS, Carpenter PM, Fwu PT, Yu HJ, Hsiang DJ, Lane KT, Butler JA. Diagnostic performance of magnetic resonance imaging for assessing tumor response in patients with HER2-negative breast cancer receiving neoadjuvant chemotherapy is associated with molecular biomarker profile. Clin Breast Cancer. 2012;12:110-118. [PMID: 22444717 DOI: 10.1016/j.clbc.2012.01.009] [Cited by in Crossref: 28] [Cited by in F6Publishing: 21] [Article Influence: 3.1] [Reference Citation Analysis]
485 Doherty JA, Peres LC, Wang C, Way GP, Greene CS, Schildkraut JM. Challenges and Opportunities in Studying the Epidemiology of Ovarian Cancer Subtypes. Curr Epidemiol Rep 2017;4:211-20. [PMID: 29226065 DOI: 10.1007/s40471-017-0115-y] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 5.5] [Reference Citation Analysis]
486 Wang Z, Sau S, Alsaab HO, Iyer AK. CD44 directed nanomicellar payload delivery platform for selective anticancer effect and tumor specific imaging of triple negative breast cancer. Nanomedicine 2018;14:1441-54. [PMID: 29678787 DOI: 10.1016/j.nano.2018.04.004] [Cited by in Crossref: 30] [Cited by in F6Publishing: 26] [Article Influence: 10.0] [Reference Citation Analysis]
487 Sandhu R, Rein J, D'Arcy M, Herschkowitz JI, Hoadley KA, Troester MA. Overexpression of miR-146a in basal-like breast cancer cells confers enhanced tumorigenic potential in association with altered p53 status. Carcinogenesis 2014;35:2567-75. [PMID: 25123132 DOI: 10.1093/carcin/bgu175] [Cited by in Crossref: 30] [Cited by in F6Publishing: 27] [Article Influence: 4.3] [Reference Citation Analysis]
488 Mooney R, Weng Y, Garcia E, Bhojane S, Smith-Powell L, Kim SU, Annala AJ, Aboody KS, Berlin JM. Conjugation of pH-responsive nanoparticles to neural stem cells improves intratumoral therapy. J Control Release 2014;191:82-9. [PMID: 24952368 DOI: 10.1016/j.jconrel.2014.06.015] [Cited by in Crossref: 37] [Cited by in F6Publishing: 37] [Article Influence: 5.3] [Reference Citation Analysis]
489 Jiang M, Zhuang H, Xia R, Gan L, Wu Y, Ma J, Sun Y, Zhuang Z. KIF11 is required for proliferation and self-renewal of docetaxel resistant triple negative breast cancer cells. Oncotarget 2017;8:92106-18. [PMID: 29190901 DOI: 10.18632/oncotarget.20785] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 4.0] [Reference Citation Analysis]
490 Reisenauer KN, Tao Y, Das P, Song S, Svatek H, Patel SD, Mikhail S, Ingros A, Sheesley P, Masi M, Boari A, Evidente A, Kornienko A, Romo D, Taube J. Epithelial-mesenchymal transition sensitizes breast cancer cells to cell death via the fungus-derived sesterterpenoid ophiobolin A. Sci Rep 2021;11:10652. [PMID: 34017048 DOI: 10.1038/s41598-021-89923-9] [Reference Citation Analysis]
491 Yin L, Qi XW, Liu XZ, Yang ZY, Cai RL, Cui HJ, Chen L, Yu SC. Icaritin enhances the efficacy of cetuximab against triple-negative breast cancer cells. Oncol Lett 2020;19:3950-8. [PMID: 32382339 DOI: 10.3892/ol.2020.11496] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
492 Loddo M, Kingsbury SR, Rashid M, Proctor I, Holt C, Young J, El-Sheikh S, Falzon M, Eward KL, Prevost T, Sainsbury R, Stoeber K, Williams GH. Cell-cycle-phase progression analysis identifies unique phenotypes of major prognostic and predictive significance in breast cancer. Br J Cancer 2009;100:959-70. [PMID: 19240714 DOI: 10.1038/sj.bjc.6604924] [Cited by in Crossref: 57] [Cited by in F6Publishing: 53] [Article Influence: 4.8] [Reference Citation Analysis]
493 Bernier C, Soliman A, Gravel M, Dankner M, Savage P, Petrecca K, Park M, Siegel PM, Shore GC, Roulston A. DZ-2384 has a superior preclinical profile to taxanes for the treatment of triple-negative breast cancer and is synergistic with anti-CTLA-4 immunotherapy. Anticancer Drugs 2018;29:774-85. [PMID: 29878901 DOI: 10.1097/CAD.0000000000000653] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 4.0] [Reference Citation Analysis]
494 Li Y, Liang Y, Sang Y, Song X, Zhang H, Liu Y, Jiang L, Yang Q. MiR-770 suppresses the chemo-resistance and metastasis of triple negative breast cancer via direct targeting of STMN1. Cell Death Dis 2018;9:14. [PMID: 29323124 DOI: 10.1038/s41419-017-0030-7] [Cited by in Crossref: 48] [Cited by in F6Publishing: 53] [Article Influence: 16.0] [Reference Citation Analysis]
495 Kim S, Goel S, Alexander CM. Differentiation generates paracrine cell pairs that maintain basaloid mouse mammary tumors: proof of concept. PLoS One 2011;6:e19310. [PMID: 21541292 DOI: 10.1371/journal.pone.0019310] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 1.9] [Reference Citation Analysis]
496 Pietrantonio F, Mazzaferro V, Miceli R, Cotsoglou C, Melotti F, Fanetti G, Perrone F, Biondani P, Muscarà C, Di Bartolomeo M, Coppa J, Maggi C, Milione M, Tamborini E, de Braud F. Pathological response after neoadjuvant bevacizumab- or cetuximab-based chemotherapy in resected colorectal cancer liver metastases. Med Oncol 2015;32:182. [PMID: 26003673 DOI: 10.1007/s12032-015-0638-3] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 2.5] [Reference Citation Analysis]
497 Seitz S, Buchholz S, Schally AV, Weber F, Klinkhammer-Schalke M, Inwald EC, Perez R, Rick FG, Szalontay L, Hohla F, Segerer S, Kwok CW, Ortmann O, Engel JB. Triple negative breast cancers express receptors for LHRH and are potential therapeutic targets for cytotoxic LHRH-analogs, AEZS 108 and AEZS 125. BMC Cancer 2014;14:847. [PMID: 25410881 DOI: 10.1186/1471-2407-14-847] [Cited by in Crossref: 35] [Cited by in F6Publishing: 29] [Article Influence: 5.0] [Reference Citation Analysis]
498 Liedtke C, Broglio K, Moulder S, Hsu L, Kau SW, Symmans WF, Albarracin C, Meric-Bernstam F, Woodward W, Theriault RL. Prognostic impact of discordance between triple-receptor measurements in primary and recurrent breast cancer. Ann Oncol. 2009;20:1953-1958. [PMID: 19596702 DOI: 10.1093/annonc/mdp263] [Cited by in Crossref: 206] [Cited by in F6Publishing: 179] [Article Influence: 17.2] [Reference Citation Analysis]
499 Lee G, Lee M. Classification of Genes Based on Age-Related Differential Expression in Breast Cancer. Genomics Inform 2017;15:156-61. [PMID: 29307142 DOI: 10.5808/GI.2017.15.4.156] [Cited by in Crossref: 9] [Cited by in F6Publishing: 4] [Article Influence: 2.3] [Reference Citation Analysis]
500 Bediaga NG, Acha-Sagredo A, Guerra I, Viguri A, Albaina C, Ruiz Diaz I, Rezola R, Alberdi MJ, Dopazo J, Montaner D. DNA methylation epigenotypes in breast cancer molecular subtypes. Breast Cancer Res. 2010;12:R77. [PMID: 20920229 DOI: 10.1186/bcr2721] [Cited by in Crossref: 130] [Cited by in F6Publishing: 105] [Article Influence: 11.8] [Reference Citation Analysis]
501 Yin Y, Zhang P, Xu BH, Zhang BL, Li Q, Yuan P, Cai RG, Wang JY, Wang X, Xu XZ. Unfavorable pathological complete response rate of neoadjuvant chemotherapy epirubicin plus taxanes for locally advanced triple-negative breast cancer. J Huazhong Univ Sci Technolog Med Sci 2013;33:262-5. [PMID: 23592141 DOI: 10.1007/s11596-013-1108-9] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
502 Zhang B, Sun J, Yao X, Li J, Tu Y, Yao F, Sun S. Knockdown of B7H6 inhibits tumor progression in triple-negative breast cancer. Oncol Lett 2018;16:91-6. [PMID: 29963127 DOI: 10.3892/ol.2018.8689] [Cited by in F6Publishing: 6] [Reference Citation Analysis]
503 Nadal R, Fernandez A, Sanchez-Rovira P, Salido M, Rodríguez M, García-Puche JL, Macià M, Corominas JM, Delgado-Rodriguez M, Gonzalez L, Albanell J, Fernández M, Solé F, Lorente JA, Serrano MJ. Biomarkers characterization of circulating tumour cells in breast cancer patients. Breast Cancer Res 2012;14:R71. [PMID: 22554015 DOI: 10.1186/bcr3180] [Cited by in Crossref: 62] [Cited by in F6Publishing: 57] [Article Influence: 6.9] [Reference Citation Analysis]
504 Tsuchida J, Nagahashi M, Takabe K, Wakai T. Clinical Impact of Sphingosine-1-Phosphate in Breast Cancer. Mediators Inflamm 2017;2017:2076239. [PMID: 28912626 DOI: 10.1155/2017/2076239] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 5.5] [Reference Citation Analysis]
505 Legrier ME, Bièche I, Gaston J, Beurdeley A, Yvonnet V, Déas O, Thuleau A, Château-Joubert S, Servely JL, Vacher S, Lassalle M, Depil S, Tucker GC, Fontaine JJ, Poupon MF, Roman-Roman S, Judde JG, Decaudin D, Cairo S, Marangoni E. Activation of IFN/STAT1 signalling predicts response to chemotherapy in oestrogen receptor-negative breast cancer. Br J Cancer 2016;114:177-87. [PMID: 26695443 DOI: 10.1038/bjc.2015.398] [Cited by in Crossref: 40] [Cited by in F6Publishing: 31] [Article Influence: 6.7] [Reference Citation Analysis]
506 Alnegheimish NA, Alshatwi RA, Alhefdhi RM, Arafah MM, AlRikabi AC, Husain S. Molecular subtypes of breast carcinoma in Saudi Arabia. A retrospective study. Saudi Med J 2016;37:506-12. [PMID: 27146612 DOI: 10.15537/smj.2016.5.15000] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 2.8] [Reference Citation Analysis]
507 Anderson WF, Rosenberg PS, Prat A, Perou CM, Sherman ME. How many etiological subtypes of breast cancer: two, three, four, or more? J Natl Cancer Inst. 2014;106. [PMID: 25118203 DOI: 10.1093/jnci/dju165] [Cited by in Crossref: 119] [Cited by in F6Publishing: 108] [Article Influence: 17.0] [Reference Citation Analysis]
508 Galvez M, Castaneda CA, Sanchez J, Castillo M, Rebaza LP, Calderon G, Cruz M, Cotrina JM, Abugattas J, Dunstan J, Guerra H, Mejia O, Gomez HL. Clinicopathological predictors of long-term benefit in breast cancer treated with neoadjuvant chemotherapy. World J Clin Oncol 2018;9:33-41. [PMID: 29651385 DOI: 10.5306/wjco.v9.i2.33] [Cited by in CrossRef: 11] [Cited by in F6Publishing: 9] [Article Influence: 3.7] [Reference Citation Analysis]
509 Saraiva DP, Guadalupe Cabral M, Jacinto A, Braga S. How many diseases is triple negative breast cancer: the protagonism of the immune microenvironment. ESMO Open 2017;2:e000208. [PMID: 29018573 DOI: 10.1136/esmoopen-2017-000208] [Cited by in Crossref: 28] [Cited by in F6Publishing: 27] [Article Influence: 7.0] [Reference Citation Analysis]
510 Uscanga-Perales GI, Santuario-Facio SK, Sanchez-Dominguez CN, Cardona-Huerta S, Muñoz-Maldonado GE, Ruiz-Flores P, Barcenas-Walls JR, Osuna-Rosales LE, Rojas-Martinez A, Gonzalez-Guerrero JF, Valero-Gomez J, Gomez-Macias GS, Barbosa-Quintana A, Barboza-Quintana O, Garza-Guajardo R, Ortiz-Lopez R. Genetic alterations of triple negative breast cancer (TNBC) in women from Northeastern Mexico. Oncol Lett 2019;17:3581-8. [PMID: 30867801 DOI: 10.3892/ol.2019.9984] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
511 Zong Y, Zhu L, Wu J, Chen X, Huang O, Fei X, He J, Chen W, Li Y, Shen K. Progesterone receptor status and Ki-67 index may predict early relapse in luminal B/HER2 negative breast cancer patients: a retrospective study. PLoS One 2014;9:e95629. [PMID: 25170613 DOI: 10.1371/journal.pone.0095629] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 2.7] [Reference Citation Analysis]
512 Mori H, Kubo M, Nishimura R, Osako T, Arima N, Okumura Y, Okido M, Yamada M, Kai M, Kishimoto J, Miyazaki T, Oda Y, Otsuka T, Nakamura M. BRCAness as a Biomarker for Predicting Prognosis and Response to Anthracycline-Based Adjuvant Chemotherapy for Patients with Triple-Negative Breast Cancer. PLoS One 2016;11:e0167016. [PMID: 27977696 DOI: 10.1371/journal.pone.0167016] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 3.6] [Reference Citation Analysis]
513 Tawara K, Scott H, Emathinger J, Ide A, Fox R, Greiner D, LaJoie D, Hedeen D, Nandakumar M, Oler AJ, Holzer R, Jorcyk C. Co-Expression of VEGF and IL-6 Family Cytokines is Associated with Decreased Survival in HER2 Negative Breast Cancer Patients: Subtype-Specific IL-6 Family Cytokine-Mediated VEGF Secretion. Transl Oncol 2019;12:245-55. [PMID: 30439625 DOI: 10.1016/j.tranon.2018.10.004] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 6.0] [Reference Citation Analysis]
514 Boac BM, Abbasi F, Ismail-Khan R, Xiong Y, Siddique A, Park H, Han M, Saeed-Vafa D, Soliman H, Henry B, Pena MJ, McClung EC, Robertson SE, Todd SL, Lopez A, Sun W, Apuri S, Lancaster JM, Berglund AE, Magliocco AM, Marchion DC. Expression of the BAD pathway is a marker of triple-negative status and poor outcome. Sci Rep 2019;9:17496. [PMID: 31767884 DOI: 10.1038/s41598-019-53695-0] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
515 Xu M, Almasi S, Yang Y, Yan C, Sterea AM, Rizvi Syeda AK, Shen B, Richard Derek C, Huang P, Gujar S, Wang J, Zong WX, Trebak M, El Hiani Y, Dong XP. The lysosomal TRPML1 channel regulates triple negative breast cancer development by promoting mTORC1 and purinergic signaling pathways. Cell Calcium 2019;79:80-8. [PMID: 30889511 DOI: 10.1016/j.ceca.2019.02.010] [Cited by in Crossref: 28] [Cited by in F6Publishing: 24] [Article Influence: 14.0] [Reference Citation Analysis]
516 Caruso JA, Hunt KK, Keyomarsi K. The neutrophil elastase inhibitor elafin triggers rb-mediated growth arrest and caspase-dependent apoptosis in breast cancer. Cancer Res 2010;70:7125-36. [PMID: 20823156 DOI: 10.1158/0008-5472.CAN-10-1547] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 1.6] [Reference Citation Analysis]
517 Tečić Vuger A, Šeparović R, Vazdar L, Pavlović M, Lepetić P, Šitić S, Bajić Ž, Šarčević B, Vrbanec D. CHARACTERISTICS AND PROGNOSIS OF TRIPLE-NEGATIVE BREAST CANCER PATIENTS: A CROATIAN SINGLE INstitution RETROSPECTIVE COHORT STUDY. Acta Clin Croat 2020;59:97-108. [PMID: 32724280 DOI: 10.20471/acc.2020.59.01.12] [Reference Citation Analysis]
518 Lengerke C, Fehm T, Kurth R, Neubauer H, Scheble V, Müller F, Schneider F, Petersen K, Wallwiener D, Kanz L. Expression of the embryonic stem cell marker SOX2 in early-stage breast carcinoma. BMC Cancer. 2011;11:42. [PMID: 21276239 DOI: 10.1186/1471-2407-11-42] [Cited by in Crossref: 122] [Cited by in F6Publishing: 109] [Article Influence: 12.2] [Reference Citation Analysis]
519 Miow QH, Tan TZ, Ye J, Lau JA, Yokomizo T, Thiery JP, Mori S. Epithelial-mesenchymal status renders differential responses to cisplatin in ovarian cancer. Oncogene 2015;34:1899-907. [PMID: 24858042 DOI: 10.1038/onc.2014.136] [Cited by in Crossref: 70] [Cited by in F6Publishing: 64] [Article Influence: 10.0] [Reference Citation Analysis]
520 Nedeljković M, Damjanović A. Mechanisms of Chemotherapy Resistance in Triple-Negative Breast Cancer-How We Can Rise to the Challenge. Cells 2019;8:E957. [PMID: 31443516 DOI: 10.3390/cells8090957] [Cited by in Crossref: 97] [Cited by in F6Publishing: 80] [Article Influence: 48.5] [Reference Citation Analysis]
521 Akasbi Y, Bennis S, Abbass F, Znati K, Joutei KA, Amarti A, Mesbahi OE. Clinicopathological, therapeutic and prognostic features of the triple-negative tumors in moroccan breast cancer patients (experience of Hassan II university hospital in Fez). BMC Res Notes 2011;4:500. [PMID: 22088140 DOI: 10.1186/1756-0500-4-500] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
522 Fouqué A, Lepvrier E, Debure L, Gouriou Y, Malleter M, Delcroix V, Ovize M, Ducret T, Li C, Hammadi M, Vacher P, Legembre P. The apoptotic members CD95, BclxL, and Bcl-2 cooperate to promote cell migration by inducing Ca(2+) flux from the endoplasmic reticulum to mitochondria. Cell Death Differ 2016;23:1702-16. [PMID: 27367565 DOI: 10.1038/cdd.2016.61] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 3.8] [Reference Citation Analysis]
523 Hugh J, Hanson J, Cheang MC, Nielsen TO, Perou CM, Dumontet C, Reed J, Krajewska M, Treilleux I, Rupin M. Breast cancer subtypes and response to docetaxel in node-positive breast cancer: use of an immunohistochemical definition in the BCIRG 001 trial. J Clin Oncol. 2009;27:1168-1176. [PMID: 19204205 DOI: 10.1200/jco.2008.18.1024] [Cited by in Crossref: 375] [Cited by in F6Publishing: 152] [Article Influence: 31.3] [Reference Citation Analysis]
524 Tabchy A, Valero V, Vidaurre T, Lluch A, Gomez H, Martin M, Qi Y, Barajas-Figueroa LJ, Souchon E, Coutant C, Doimi FD, Ibrahim NK, Gong Y, Hortobagyi GN, Hess KR, Symmans WF, Pusztai L. Evaluation of a 30-gene paclitaxel, fluorouracil, doxorubicin, and cyclophosphamide chemotherapy response predictor in a multicenter randomized trial in breast cancer. Clin Cancer Res 2010;16:5351-61. [PMID: 20829329 DOI: 10.1158/1078-0432.CCR-10-1265] [Cited by in Crossref: 149] [Cited by in F6Publishing: 80] [Article Influence: 13.5] [Reference Citation Analysis]
525 Kobayashi K, Ito Y, Matsuura M, Fukada I, Horii R, Takahashi S, Akiyama F, Iwase T, Hozumi Y, Yasuda Y, Hatake K. Impact of immunohistological subtypes on the long-term prognosis of patients with metastatic breast cancer. Surg Today 2016;46:821-6. [PMID: 26467559 DOI: 10.1007/s00595-015-1252-x] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 3.0] [Reference Citation Analysis]
526 Dawood S, Lei X, Litton JK, Buchholz TA, Hortobagyi GN, Gonzalez-Angulo AM. Incidence of brain metastases as a first site of recurrence among women with triple receptor-negative breast cancer. Cancer 2012;118:4652-9. [PMID: 22359359 DOI: 10.1002/cncr.27434] [Cited by in Crossref: 48] [Cited by in F6Publishing: 43] [Article Influence: 5.3] [Reference Citation Analysis]
527 Jing N, Ma MW, Gao XS, Liu JT, Gu XB, Zhang M, Zhao B, Wang Y, Wang XL, Jia HX. Development and validation of a prognostic nomogram for patients with triple-negative breast cancer with histology of infiltrating duct carcinoma. Ann Transl Med 2020;8:1447. [PMID: 33313192 DOI: 10.21037/atm-20-413] [Reference Citation Analysis]
528 Voutsadakis IA. The network of pluripotency, epithelial-mesenchymal transition, and prognosis of breast cancer. Breast Cancer (Dove Med Press) 2015;7:303-19. [PMID: 26379447 DOI: 10.2147/BCTT.S71163] [Cited by in Crossref: 7] [Cited by in F6Publishing: 11] [Article Influence: 1.2] [Reference Citation Analysis]
529 Pogue-Geile KL, Kim C, Jeong JH, Tanaka N, Bandos H, Gavin PG, Fumagalli D, Goldstein LC, Sneige N, Burandt E, Taniyama Y, Bohn OL, Lee A, Kim SI, Reilly ML, Remillard MY, Blackmon NL, Kim SR, Horne ZD, Rastogi P, Fehrenbacher L, Romond EH, Swain SM, Mamounas EP, Wickerham DL, Geyer CE Jr, Costantino JP, Wolmark N, Paik S. Predicting degree of benefit from adjuvant trastuzumab in NSABP trial B-31. J Natl Cancer Inst 2013;105:1782-8. [PMID: 24262440 DOI: 10.1093/jnci/djt321] [Cited by in Crossref: 66] [Cited by in F6Publishing: 61] [Article Influence: 8.3] [Reference Citation Analysis]
530 Oakman C, Santarpia L, Di Leo A. Breast cancer assessment tools and optimizing adjuvant therapy. Nat Rev Clin Oncol 2010;7:725-32. [PMID: 20975745 DOI: 10.1038/nrclinonc.2010.170] [Cited by in Crossref: 66] [Cited by in F6Publishing: 62] [Article Influence: 6.0] [Reference Citation Analysis]
531 Santana-Davila R, Perez EA. Treatment options for patients with triple-negative breast cancer. J Hematol Oncol 2010;3:42. [PMID: 20979652 DOI: 10.1186/1756-8722-3-42] [Cited by in Crossref: 38] [Cited by in F6Publishing: 37] [Article Influence: 3.5] [Reference Citation Analysis]
532 Hiller DJ, Chu QD. Current Status of Poly(ADP-ribose) Polymerase Inhibitors as Novel Therapeutic Agents for Triple-Negative Breast Cancer. Int J Breast Cancer 2012;2012:829315. [PMID: 22295252 DOI: 10.1155/2012/829315] [Cited by in Crossref: 5] [Cited by in F6Publishing: 8] [Article Influence: 0.5] [Reference Citation Analysis]
533 Jones EF, Hathi DK, Freimanis R, Mukhtar RA, Chien AJ, Esserman LJ, Van't Veer LJ, Joe BN, Hylton NM. Current Landscape of Breast Cancer Imaging and Potential Quantitative Imaging Markers of Response in ER-Positive Breast Cancers Treated with Neoadjuvant Therapy. Cancers (Basel) 2020;12:E1511. [PMID: 32527022 DOI: 10.3390/cancers12061511] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
534 Ding Y, Ding K, Yu K, Zou D, Yang H, He X, Mo W, Yu X, Ding X. Prognosis and endocrine therapy selection for patients with low hormone receptor-positive breast cancer following neoadjuvant chemotherapy: A retrospective study of 570 patients in China. Oncol Lett 2019;18:6690-6. [PMID: 31807179 DOI: 10.3892/ol.2019.11033] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
535 Zhu Q, Tannenbaum S, Hegde P, Kane M, Xu C, Kurtzman SH. Noninvasive monitoring of breast cancer during neoadjuvant chemotherapy using optical tomography with ultrasound localization. Neoplasia 2008;10:1028-40. [PMID: 18813360 DOI: 10.1593/neo.08602] [Cited by in Crossref: 72] [Cited by in F6Publishing: 53] [Article Influence: 5.5] [Reference Citation Analysis]
536 Matossian MD, Giardina AA, Wright MK, Elliott S, Loch MM, Nguyen K, Zea AH, Lau FH, Moroz K, Riker AI, Jones SD, Martin EC, Bunnell BA, Miele L, Collins-Burow BM, Burow ME. Patient-Derived Xenografts as an Innovative Surrogate Tumor Model for the Investigation of Health Disparities in Triple Negative Breast Cancer. Womens Health Rep (New Rochelle) 2020;1:383-92. [PMID: 33786503 DOI: 10.1089/whr.2020.0037] [Reference Citation Analysis]
537 Harigopal M, Barlow WE, Tedeschi G, Porter PL, Yeh IT, Haskell C, Livingston R, Hortobagyi GN, Sledge G, Shapiro C, Ingle JN, Rimm DL, Hayes DF. Multiplexed assessment of the Southwest Oncology Group-directed Intergroup Breast Cancer Trial S9313 by AQUA shows that both high and low levels of HER2 are associated with poor outcome. Am J Pathol 2010;176:1639-47. [PMID: 20150438 DOI: 10.2353/ajpath.2010.090711] [Cited by in Crossref: 25] [Cited by in F6Publishing: 21] [Article Influence: 2.3] [Reference Citation Analysis]
538 Pal SK, Childs BH, Pegram M. Triple negative breast cancer: unmet medical needs. Breast Cancer Res Treat. 2011;125:627-636. [PMID: 21161370 DOI: 10.1007/s10549-010-1293-1] [Cited by in Crossref: 194] [Cited by in F6Publishing: 180] [Article Influence: 17.6] [Reference Citation Analysis]
539 Yamamoto Y, Iwase H. Clinicopathological features and treatment strategy for triple-negative breast cancer. Int J Clin Oncol 2010;15:341-51. [PMID: 20632057 DOI: 10.1007/s10147-010-0106-1] [Cited by in Crossref: 29] [Cited by in F6Publishing: 28] [Article Influence: 2.6] [Reference Citation Analysis]
540 Ye J, Xia X, Dong W, Hao H, Meng L, Yang Y, Wang R, Lyu Y, Liu Y. Cellular uptake mechanism and comparative evaluation of antineoplastic effects of paclitaxel-cholesterol lipid emulsion on triple-negative and non-triple-negative breast cancer cell lines. Int J Nanomedicine 2016;11:4125-40. [PMID: 27601899 DOI: 10.2147/IJN.S113638] [Cited by in Crossref: 20] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
541 Grewal J, Kesari S. Breast cancer surface receptors predict risk for developing brain metastasis and subsequent prognosis. Breast Cancer Res 2008;10:104. [PMID: 18373884 DOI: 10.1186/bcr1868] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
542 Butthongkomvong K, Raunroadroong N, Sorrarichingchai S, Sangsaikae I, Srimuninnimit V, Harling H, Larsen S. Efficacy and tolerability of BP-C1 in metastatic breast cancer: a Phase II, randomized, double-blind, and placebo-controlled Thai multi-center study. Breast Cancer (Dove Med Press) 2019;11:43-51. [PMID: 30666153 DOI: 10.2147/BCTT.S174298] [Reference Citation Analysis]
543 Dieci MV, Del Mastro L, Cinquini M, Montemurro F, Biganzoli L, Cortesi L, Zambelli A, Criscitiello C, Levaggi A, Conte B, Calabrese M, Fiorentino A, Marchiò C, Tinterri C, Fittipaldo VA, Pappagallo G, Gori S. Inclusion of Platinum Agents in Neoadjuvant Chemotherapy Regimens for Triple-Negative Breast Cancer Patients: Development of GRADE (Grades of Recommendation, Assessment, Development and Evaluation) Recommendation by the Italian Association of Medical Oncology (AIOM). Cancers (Basel) 2019;11:E1137. [PMID: 31398896 DOI: 10.3390/cancers11081137] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
544 Bianchini G, Balko JM, Mayer IA, Sanders ME, Gianni L. Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease. Nat Rev Clin Oncol 2016;13:674-90. [PMID: 27184417 DOI: 10.1038/nrclinonc.2016.66] [Cited by in Crossref: 903] [Cited by in F6Publishing: 808] [Article Influence: 180.6] [Reference Citation Analysis]
545 Hamilton N, Marquez-Garban D, Mah VH, Elshimali Y, Elashoff D, Garon EB, Vadgama J, Pietras R. Estrogen Receptor-β and the Insulin-Like Growth Factor Axis as Potential Therapeutic Targets for Triple-Negative Breast Cancer. Crit Rev Oncog 2015;20:373-90. [PMID: 27279236 DOI: 10.1615/CritRevOncog.v20.i5-6.100] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
546 Onitilo AA, Engel JM, Greenlee RT, Mukesh BN. Breast cancer subtypes based on ER/PR and Her2 expression: comparison of clinicopathologic features and survival. Clin Med Res 2009;7:4-13. [PMID: 19574486 DOI: 10.3121/cmr.2009.825] [Cited by in Crossref: 91] [Cited by in F6Publishing: 305] [Article Influence: 7.6] [Reference Citation Analysis]
547 Yu KD, Zhu R, Zhan M, Rodriguez AA, Yang W, Wong S, Makris A, Lehmann BD, Chen X, Mayer I, Pietenpol JA, Shao ZM, Symmans WF, Chang JC. Identification of prognosis-relevant subgroups in patients with chemoresistant triple-negative breast cancer. Clin Cancer Res 2013;19:2723-33. [PMID: 23549873 DOI: 10.1158/1078-0432.CCR-12-2986] [Cited by in Crossref: 94] [Cited by in F6Publishing: 63] [Article Influence: 11.8] [Reference Citation Analysis]
548 Bittner AK, Keup C, Hoffmann O, Hauch S, Kimmig R, Kasimir-Bauer S. Molecular characterization of circulating tumour cells identifies predictive markers for outcome in primary, triple-negative breast cancer patients. J Cell Mol Med 2020;24:8405-16. [PMID: 32558176 DOI: 10.1111/jcmm.15349] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
549 Karginova O, Siegel MB, Van Swearingen AE, Deal AM, Adamo B, Sambade MJ, Bazyar S, Nikolaishvili-Feinberg N, Bash R, O'Neal S, Sandison K, Parker JS, Santos C, Darr D, Zamboni W, Lee YZ, Miller CR, Anders CK. Efficacy of Carboplatin Alone and in Combination with ABT888 in Intracranial Murine Models of BRCA-Mutated and BRCA-Wild-Type Triple-Negative Breast Cancer. Mol Cancer Ther 2015;14:920-30. [PMID: 25824335 DOI: 10.1158/1535-7163.MCT-14-0474] [Cited by in Crossref: 45] [Cited by in F6Publishing: 25] [Article Influence: 9.0] [Reference Citation Analysis]
550 Miyoshi Y, Murase K, Oh K. Basal-like subtype and BRCA1 dysfunction in breast cancers. Int J Clin Oncol 2008;13:395-400. [PMID: 18946749 DOI: 10.1007/s10147-008-0831-x] [Cited by in Crossref: 26] [Cited by in F6Publishing: 25] [Article Influence: 2.0] [Reference Citation Analysis]
551 Mayer EL, Carey LA, Burstein HJ. Clinical trial update: implications and management of residual disease after neoadjuvant therapy for breast cancer. Breast Cancer Res 2007;9:110. [PMID: 17888189 DOI: 10.1186/bcr1755] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 1.3] [Reference Citation Analysis]
552 He J, Peng R, Yuan Z, Wang S, Peng J, Lin G, Jiang X, Qin T. Prognostic value of androgen receptor expression in operable triple-negative breast cancer: a retrospective analysis based on a tissue microarray. Med Oncol 2012;29:406-10. [PMID: 21264529 DOI: 10.1007/s12032-011-9832-0] [Cited by in Crossref: 90] [Cited by in F6Publishing: 86] [Article Influence: 9.0] [Reference Citation Analysis]
553 El Chediak A, Alameddine RS, Hakim A, Hilal L, Abdel Massih S, Hamieh L, Mukherji D, Temraz S, Charafeddine M, Shamseddine A. Younger age is an independent predictor of worse prognosis among Lebanese nonmetastatic breast cancer patients: analysis of a prospective cohort. Breast Cancer (Dove Med Press) 2017;9:407-14. [PMID: 28670139 DOI: 10.2147/BCTT.S130273] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
554 Conzen SD. Minireview: nuclear receptors and breast cancer. Mol Endocrinol. 2008;22:2215-2228. [PMID: 18417735 DOI: 10.1210/me.2007-0421] [Cited by in Crossref: 92] [Cited by in F6Publishing: 85] [Article Influence: 7.1] [Reference Citation Analysis]
555 Luo Y, Zhang W, Xu L, Chen Y, Xu Y, Yuan L. Long Non-Coding RNA PVT1 Regulates the Resistance of the Breast Cancer Cell Line MDA-MB-231 to Doxorubicin via Nrf2. Technol Cancer Res Treat 2020;19:1533033820980763. [PMID: 33327894 DOI: 10.1177/1533033820980763] [Reference Citation Analysis]
556 Sang MM, Liu FL, Wang Y, Luo RJ, Huan XX, Han LF, Zhang ZT, Feng F, Qu W, Liu W, Zheng F. A novel redox/pH dual-responsive and hyaluronic acid-decorated multifunctional magnetic complex micelle for targeted gambogic acid delivery for the treatment of triple negative breast cancer. Drug Deliv 2018;25:1846-57. [PMID: 30334478 DOI: 10.1080/10717544.2018.1486472] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 5.5] [Reference Citation Analysis]
557 Quinn Z, Mao W, Xia Y, John R, Wan Y. Conferring receptors on recipient cells with extracellular vesicles for targeted drug delivery. Bioact Mater 2021;6:749-56. [PMID: 33024896 DOI: 10.1016/j.bioactmat.2020.09.016] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 6.0] [Reference Citation Analysis]
558 Fayaz MS, El-Sherify MS, El-Basmy A, Zlouf SA, Nazmy N, George T, Samir S, Attia G, Eissa H. Clinicopathological features and prognosis of triple negative breast cancer in Kuwait: A comparative/perspective analysis. Rep Pract Oncol Radiother 2014;19:173-81. [PMID: 24936335 DOI: 10.1016/j.rpor.2013.08.007] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
559 Landry BD, Leete T, Richards R, Cruz-Gordillo P, Schwartz HR, Honeywell ME, Ren G, Schwartz AD, Peyton SR, Lee MJ. Tumor-stroma interactions differentially alter drug sensitivity based on the origin of stromal cells. Mol Syst Biol 2018;14:e8322. [PMID: 30082272 DOI: 10.15252/msb.20188322] [Cited by in Crossref: 14] [Cited by in F6Publishing: 9] [Article Influence: 4.7] [Reference Citation Analysis]
560 Mounika Inavolu S, Renbarger J, Radovich M, Vasudevaraja V, Kinnebrew GH, Zhang S, Cheng L. IODNE: An integrated optimization method for identifying the deregulated subnetwork for precision medicine in cancer. CPT Pharmacometrics Syst Pharmacol 2017;6:168-76. [PMID: 28266149 DOI: 10.1002/psp4.12167] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
561 Shields S, Conroy E, O'Grady T, McGoldrick A, Connor K, Ward MP, Useckaite Z, Dempsey E, Reilly R, Fan Y, Chubb A, Matallanas DG, Kay EW, O'Connor D, McCann A, Gallagher WM, Coppinger JA. BAG3 promotes tumour cell proliferation by regulating EGFR signal transduction pathways in triple negative breast cancer. Oncotarget 2018;9:15673-90. [PMID: 29644001 DOI: 10.18632/oncotarget.24590] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
562 Park K, Woo M, Kim JE, Ahn JH, Jung KH, Roh J, Gong G, Kim SB. Efficacy of assessing circulating cell-free DNA using a simple fluorescence assay in patients with triple-negative breast cancer receiving neoadjuvant chemotherapy: a prospective observational study. Oncotarget 2018;9:3875-86. [PMID: 29423090 DOI: 10.18632/oncotarget.23520] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
563 Abdulkarim BS, Cuartero J, Hanson J, Deschênes J, Lesniak D, Sabri S. Increased risk of locoregional recurrence for women with T1-2N0 triple-negative breast cancer treated with modified radical mastectomy without adjuvant radiation therapy compared with breast-conserving therapy. J Clin Oncol 2011;29:2852-8. [PMID: 21670451 DOI: 10.1200/JCO.2010.33.4714] [Cited by in Crossref: 230] [Cited by in F6Publishing: 82] [Article Influence: 23.0] [Reference Citation Analysis]
564 Di Cosimo S, Baselga J. Management of breast cancer with targeted agents: importance of heterogeneity. [corrected]. Nat Rev Clin Oncol 2010;7:139-47. [PMID: 20125090 DOI: 10.1038/nrclinonc.2009.234] [Cited by in Crossref: 120] [Cited by in F6Publishing: 97] [Article Influence: 10.9] [Reference Citation Analysis]
565 Yin PT, Pongkulapa T, Cho HY, Han J, Pasquale NJ, Rabie H, Kim JH, Choi JW, Lee KB. Overcoming Chemoresistance in Cancer via Combined MicroRNA Therapeutics with Anticancer Drugs Using Multifunctional Magnetic Core-Shell Nanoparticles. ACS Appl Mater Interfaces 2018;10:26954-63. [PMID: 30028120 DOI: 10.1021/acsami.8b09086] [Cited by in Crossref: 32] [Cited by in F6Publishing: 29] [Article Influence: 10.7] [Reference Citation Analysis]
566 Bertos NR, Park M. Breast cancer - one term, many entities? J Clin Invest. 2011;121:3789-3796. [PMID: 21965335 DOI: 10.1172/jci57100] [Cited by in Crossref: 133] [Cited by in F6Publishing: 73] [Article Influence: 13.3] [Reference Citation Analysis]
567 Rabionet M, Yeste M, Puig T, Ciurana J. Electrospinning PCL Scaffolds Manufacture for Three-Dimensional Breast Cancer Cell Culture. Polymers (Basel) 2017;9:E328. [PMID: 30971005 DOI: 10.3390/polym9080328] [Cited by in Crossref: 31] [Cited by in F6Publishing: 16] [Article Influence: 7.8] [Reference Citation Analysis]
568 Esserman LJ, Berry DA, Cheang MC, Yau C, Perou CM, Carey L, DeMichele A, Gray JW, Conway-Dorsey K, Lenburg ME. Chemotherapy response and recurrence-free survival in neoadjuvant breast cancer depends on biomarker profiles: results from the I-SPY 1 TRIAL (CALGB 150007/150012; ACRIN 6657). Breast Cancer Res Treat. 2012;132:1049-1062. [PMID: 22198468 DOI: 10.1007/s10549-011-1895-2] [Cited by in Crossref: 221] [Cited by in F6Publishing: 192] [Article Influence: 22.1] [Reference Citation Analysis]
569 Dong G, Liang X, Wang D, Gao H, Wang L, Wang L, Liu J, Du Z. High expression of miR-21 in triple-negative breast cancers was correlated with a poor prognosis and promoted tumor cell in vitro proliferation. Med Oncol 2014;31:57. [PMID: 24930006 DOI: 10.1007/s12032-014-0057-x] [Cited by in Crossref: 51] [Cited by in F6Publishing: 47] [Article Influence: 7.3] [Reference Citation Analysis]
570 Hwangbo W, Lee JH, Ahn S, Kim S, Park KH, Kim CH, Kim I. EGFR Gene Amplification and Protein Expression in Invasive Ductal Carcinoma of the Breast. Korean J Pathol 2013;47:107-15. [PMID: 23667369 DOI: 10.4132/KoreanJPathol.2013.47.2.107] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 1.8] [Reference Citation Analysis]
571 Ademuyiwa FO, Chen I, Luo J, Rimawi MF, Hagemann IS, Fisk B, Jeffers G, Skidmore ZL, Basu A, Richters M, Ma CX, Weilbaecher K, Davis J, Suresh R, Peterson LL, Bose R, Bagegni N, Rigden CE, Frith A, Rearden TP, Hernandez-Aya LF, Roshal A, Clifton K, Opyrchal M, Akintola-Ogunremi O, Lee BH, Ferrando-Martinez S, Church SE, Anurag M, Ellis MJ, Gao F, Gillanders W, Griffith OL, Griffith M. Immunogenomic profiling and pathological response results from a clinical trial of docetaxel and carboplatin in triple-negative breast cancer. Breast Cancer Res Treat 2021;189:187-202. [PMID: 34173924 DOI: 10.1007/s10549-021-06307-3] [Reference Citation Analysis]
572 Firouzabadi D, Rezvani A, Dehghanian A, Mahmoudi L. Association of ki67 and tumor marker p53 in locally advanced breast cancer patients and evaluation of response to neoadjuvant chemotherapy: a survey in South Iran. Cancer Manag Res 2019;11:6489-97. [PMID: 31372050 DOI: 10.2147/CMAR.S203831] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
573 John T, Starmans MH, Chen YT, Russell PA, Barnett SA, White SC, Mitchell PL, Walkiewicz M, Azad A, Lambin P, Tsao MS, Deb S, Altorki N, Wright G, Knight S, Boutros PC, Cebon JS. The role of Cancer-Testis antigens as predictive and prognostic markers in non-small cell lung cancer. PLoS One 2013;8:e67876. [PMID: 23935846 DOI: 10.1371/journal.pone.0067876] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 2.6] [Reference Citation Analysis]
574 Shah DR, Tseng WH, Martinez SR. Treatment options for metaplastic breast cancer. ISRN Oncol 2012;2012:706162. [PMID: 22778998 DOI: 10.5402/2012/706162] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 2.1] [Reference Citation Analysis]
575 Zeng R, Mohamed A, Khanna KK, Hill MM. Differential Regulation of Lacto-/Neolacto- Glycosphingolipid Biosynthesis Pathway Reveals Transcription Factors as Potential Candidates in Triple-Negative Breast Cancer. Cancers (Basel) 2021;13:3330. [PMID: 34283051 DOI: 10.3390/cancers13133330] [Reference Citation Analysis]
576 Garrido P, Shalaby A, Walsh EM, Keane N, Webber M, Keane MM, Sullivan FJ, Kerin MJ, Callagy G, Ryan AE, Glynn SA. Impact of inducible nitric oxide synthase (iNOS) expression on triple negative breast cancer outcome and activation of EGFR and ERK signaling pathways. Oncotarget 2017;8:80568-88. [PMID: 29113326 DOI: 10.18632/oncotarget.19631] [Cited by in Crossref: 34] [Cited by in F6Publishing: 34] [Article Influence: 8.5] [Reference Citation Analysis]
577 Liu Y, Xu Z, Zhang Z, Wen G, Sun J, Han F. Efficacy and safety of TE/TEC/intensive paclitaxel neoadjuvant chemotherapy for the treatment of breast cancer. Oncol Lett 2019;17:907-12. [PMID: 30655846 DOI: 10.3892/ol.2018.9658] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
578 Hahne JC, Schmidt H, Meyer SR, Engel JB, Dietl J, Honig A. Anti-tumour activity of phosphoinositide-3-kinase antagonist AEZS 126 in models of triple-negative breast cancer. J Cancer Res Clin Oncol 2013;139:905-14. [PMID: 23440492 DOI: 10.1007/s00432-013-1399-z] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
579 Mishima C, Kagara N, Matsui S, Tanei T, Naoi Y, Shimoda M, Shimomura A, Shimazu K, Kim SJ, Noguchi S. Promoter methylation of TRIM9 as a marker for detection of circulating tumor DNA in breast cancer patients. Springerplus 2015;4:635. [PMID: 26543769 DOI: 10.1186/s40064-015-1423-7] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 2.2] [Reference Citation Analysis]
580 Kim JY, Lee SH, Kim S, Kang T, Bae YT. Tumour 18 F-FDG Uptake on preoperative PET/CT may predict axillary lymph node metastasis in ER-positive/HER2-negative and HER2-positive breast cancer subtypes. Eur Radiol. 2015;25:1172-1181. [PMID: 25298170 DOI: 10.1007/s00330-014-3452-y] [Cited by in Crossref: 22] [Cited by in F6Publishing: 15] [Article Influence: 3.1] [Reference Citation Analysis]
581 Liu JC, Voisin V, Wang S, Wang DY, Jones RA, Datti A, Uehling D, Al-awar R, Egan SE, Bader GD, Tsao M, Mak TW, Zacksenhaus E. Combined deletion of Pten and p53 in mammary epithelium accelerates triple-negative breast cancer with dependency on eEF2K. EMBO Mol Med 2014;6:1542-60. [PMID: 25330770 DOI: 10.15252/emmm.201404402] [Cited by in Crossref: 69] [Cited by in F6Publishing: 67] [Article Influence: 11.5] [Reference Citation Analysis]
582 Lee KH, Hsu EC, Guh JH, Yang HC, Wang D, Kulp SK, Shapiro CL, Chen CS. Targeting energy metabolic and oncogenic signaling pathways in triple-negative breast cancer by a novel adenosine monophosphate-activated protein kinase (AMPK) activator. J Biol Chem 2011;286:39247-58. [PMID: 21917926 DOI: 10.1074/jbc.M111.264598] [Cited by in Crossref: 66] [Cited by in F6Publishing: 48] [Article Influence: 6.6] [Reference Citation Analysis]
583 Poh ZW, Gan CH, Lee EJ, Guo S, Yip GW, Lam Y. Divergent Synthesis of Chondroitin Sulfate Disaccharides and Identification of Sulfate Motifs that Inhibit Triple Negative Breast Cancer. Sci Rep 2015;5:14355. [PMID: 26400608 DOI: 10.1038/srep14355] [Cited by in Crossref: 20] [Cited by in F6Publishing: 13] [Article Influence: 3.3] [Reference Citation Analysis]
584 Neuman HB, Morrogh M, Gonen M, Van Zee KJ, Morrow M, King TA. Stage IV breast cancer in the era of targeted therapy: does surgery of the primary tumor matter? Cancer. 2010;116:1226-1233. [PMID: 20101736 DOI: 10.1002/cncr.24873] [Cited by in Crossref: 122] [Cited by in F6Publishing: 89] [Article Influence: 11.1] [Reference Citation Analysis]
585 Purwanto I, Heriyanto DS, Ghozali A, Widodo I, Dwiprahasto I, Aryandono T, Haryana SM. Overexpression of Programmed Death-Ligand 1 Receptor mRNA as an Independent Negative Prognostic Factor for Triple Negative Breast Cancer. World J Oncol 2020;11:216-22. [PMID: 33117465 DOI: 10.14740/wjon1302] [Reference Citation Analysis]
586 Sun W, Li C, Liu M, Liu W, Yang C, Cai LI. Prognostic analysis of triple-negative breast cancer patients treated with adjuvant chemotherapy of fluorouracil, epirubicin and cyclophosphamide. Oncol Lett 2016;11:2320-6. [PMID: 26998170 DOI: 10.3892/ol.2016.4176] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
587 Liu J, Wang S, Wang C, Kong X, Sun P. Prognostic value of using glucosylceramide synthase and cytochrome P450 family 1 subfamily A1 expression levels for patients with triple-negative breast cancer following neoadjuvant chemotherapy. Exp Ther Med 2021;21:247. [PMID: 33603855 DOI: 10.3892/etm.2021.9678] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
588 Bae MS, Park SY, Song SE, Kim WH, Lee SH, Han W, Park IA, Noh DY, Moon WK. Heterogeneity of triple-negative breast cancer: mammographic, US, and MR imaging features according to androgen receptor expression. Eur Radiol 2015;25:419-27. [PMID: 25224727 DOI: 10.1007/s00330-014-3419-z] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 2.4] [Reference Citation Analysis]
589 Sharma P. Biology and Management of Patients With Triple-Negative Breast Cancer. Oncologist 2016;21:1050-62. [PMID: 27401886 DOI: 10.1634/theoncologist.2016-0067] [Cited by in Crossref: 87] [Cited by in F6Publishing: 82] [Article Influence: 17.4] [Reference Citation Analysis]
590 Caramelo O, Silva C, Caramelo F, Frutuoso C, Almeida-Santos T. The effect of neoadjuvant platinum-based chemotherapy in BRCA mutated triple negative breast cancers -systematic review and meta-analysis. Hered Cancer Clin Pract 2019;17:11. [PMID: 30962858 DOI: 10.1186/s13053-019-0111-y] [Cited by in Crossref: 24] [Cited by in F6Publishing: 16] [Article Influence: 12.0] [Reference Citation Analysis]
591 James-Bhasin M, Siegel PM, Nazhat SN. A Three-Dimensional Dense Collagen Hydrogel to Model Cancer Cell/Osteoblast Interactions. J Funct Biomater 2018;9:E72. [PMID: 30545096 DOI: 10.3390/jfb9040072] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 2.3] [Reference Citation Analysis]
592 Maric G, Rose AA, Annis MG, Siegel PM. Glycoprotein non-metastatic b (GPNMB): A metastatic mediator and emerging therapeutic target in cancer. Onco Targets Ther 2013;6:839-52. [PMID: 23874106 DOI: 10.2147/OTT.S44906] [Cited by in Crossref: 16] [Cited by in F6Publishing: 50] [Article Influence: 2.0] [Reference Citation Analysis]
593 Chen Y, Cai H, Chen W, Guan Q, He J, Guo Z, Li J. A Qualitative Transcriptional Signature for Predicting Extreme Resistance of ER-Negative Breast Cancer to Paclitaxel, Doxorubicin, and Cyclophosphamide Neoadjuvant Chemotherapy. Front Mol Biosci 2020;7:34. [PMID: 32269999 DOI: 10.3389/fmolb.2020.00034] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
594 Amos KD, Adamo B, Anders CK. Triple-negative breast cancer: an update on neoadjuvant clinical trials. Int J Breast Cancer 2012;2012:385978. [PMID: 22461984 DOI: 10.1155/2012/385978] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 2.0] [Reference Citation Analysis]
595 Mane A, Khatib KI, Deshmukh SP, Nag SM, Sane SP, Zade BP. A Comparison of Clinical Features, Pathology and Outcomes in Various Subtypes of Breast Cancer in Indian Women. J Clin Diagn Res 2015;9:PC01-4. [PMID: 26500944 DOI: 10.7860/JCDR/2015/15253.6461] [Cited by in Crossref: 1] [Cited by in F6Publishing: 6] [Article Influence: 0.2] [Reference Citation Analysis]
596 Kim H, Samuel SL, Zhai G, Rana S, Taylor M, Umphrey HR, Oelschlager DK, Buchsbaum DJ, Zinn KR. Combination therapy with anti-DR5 antibody and tamoxifen for triple negative breast cancer. Cancer Biol Ther 2014;15:1053-60. [PMID: 25084100 DOI: 10.4161/cbt.29183] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.5] [Reference Citation Analysis]
597 Turkistani S, Sugita BM, Fadda P, Marchi R, Afsari A, Naab T, Apprey V, Copeland RL Jr, Campbell MC, Cavalli LR, Kanaan Y. A panel of miRNAs as prognostic markers for African-American patients with triple negative breast cancer. BMC Cancer 2021;21:861. [PMID: 34315420 DOI: 10.1186/s12885-021-08573-2] [Reference Citation Analysis]
598 Arthur LM, Turnbull AK, Khan LR, Dixon JM. Pre-operative Endocrine Therapy. Curr Breast Cancer Rep 2017;9:202-9. [PMID: 29201277 DOI: 10.1007/s12609-017-0255-6] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 2.5] [Reference Citation Analysis]
599 Dwivedi S, Purohit P, Misra R, Lingeswaran M, Vishnoi JR, Pareek P, Misra S, Sharma P. Single Cell Omics of Breast Cancer: An Update on Characterization and Diagnosis. Indian J Clin Biochem 2019;34:3-18. [PMID: 30728668 DOI: 10.1007/s12291-019-0811-0] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
600 Yam C, Mani SA, Moulder SL. Targeting the Molecular Subtypes of Triple Negative Breast Cancer: Understanding the Diversity to Progress the Field. Oncologist 2017;22:1086-93. [PMID: 28559413 DOI: 10.1634/theoncologist.2017-0095] [Cited by in Crossref: 43] [Cited by in F6Publishing: 36] [Article Influence: 10.8] [Reference Citation Analysis]
601 Colomer R, Saura C, Sánchez-Rovira P, Pascual T, Rubio IT, Burgués O, Marcos L, Rodríguez CA, Martín M, Lluch A. Neoadjuvant Management of Early Breast Cancer: A Clinical and Investigational Position Statement. Oncologist 2019;24:603-11. [PMID: 30710068 DOI: 10.1634/theoncologist.2018-0228] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 7.0] [Reference Citation Analysis]
602 Thorner AR, Hoadley KA, Parker JS, Winkel S, Millikan RC, Perou CM. In vitro and in vivo analysis of B-Myb in basal-like breast cancer. Oncogene 2009;28:742-51. [PMID: 19043454 DOI: 10.1038/onc.2008.430] [Cited by in Crossref: 57] [Cited by in F6Publishing: 58] [Article Influence: 4.4] [Reference Citation Analysis]
603 Shetty PK, Thamake SI, Biswas S, Johansson SL, Vishwanatha JK. Reciprocal regulation of annexin A2 and EGFR with Her-2 in Her-2 negative and herceptin-resistant breast cancer. PLoS One 2012;7:e44299. [PMID: 22957061 DOI: 10.1371/journal.pone.0044299] [Cited by in Crossref: 39] [Cited by in F6Publishing: 39] [Article Influence: 4.3] [Reference Citation Analysis]
604 Mao Y, Qu Q, Zhang Y, Liu J, Chen X, Shen K. The value of tumor infiltrating lymphocytes (TILs) for predicting response to neoadjuvant chemotherapy in breast cancer: a systematic review and meta-analysis. PLoS One 2014;9:e115103. [PMID: 25501357 DOI: 10.1371/journal.pone.0115103] [Cited by in Crossref: 106] [Cited by in F6Publishing: 103] [Article Influence: 15.1] [Reference Citation Analysis]
605 Conway K, Edmiston SN, Tse CK, Bryant C, Kuan PF, Hair BY, Parrish EA, May R, Swift-Scanlan T. Racial variation in breast tumor promoter methylation in the Carolina Breast Cancer Study. Cancer Epidemiol Biomarkers Prev 2015;24:921-30. [PMID: 25809865 DOI: 10.1158/1055-9965.EPI-14-1228] [Cited by in Crossref: 24] [Cited by in F6Publishing: 15] [Article Influence: 4.0] [Reference Citation Analysis]
606 Virostko J, Hainline A, Kang H, Arlinghaus LR, Abramson RG, Barnes SL, Blume JD, Avery S, Patt D, Goodgame B, Yankeelov TE, Sorace AG. Dynamic contrast-enhanced magnetic resonance imaging and diffusion-weighted magnetic resonance imaging for predicting the response of locally advanced breast cancer to neoadjuvant therapy: a meta-analysis. J Med Imaging (Bellingham) 2018;5:011011. [PMID: 29201942 DOI: 10.1117/1.JMI.5.1.011011] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
607 Alkhalifa H, Mohammed F, Taurin S, Greish K, Taha S, Fredericks S. Inhibition of aquaporins as a potential adjunct to breast cancer cryotherapy. Oncol Lett 2021;21:458. [PMID: 33907568 DOI: 10.3892/ol.2021.12719] [Reference Citation Analysis]
608 Mancini P, Angeloni A, Risi E, Orsi E, Mezi S. Standard of care and promising new agents for triple negative metastatic breast cancer. Cancers (Basel) 2014;6:2187-223. [PMID: 25347122 DOI: 10.3390/cancers6042187] [Cited by in Crossref: 31] [Cited by in F6Publishing: 26] [Article Influence: 4.4] [Reference Citation Analysis]
609 Wang DY, Done SJ, McCready DR, Boerner S, Kulkarni S, Leong WL. A new gene expression signature, the ClinicoMolecular Triad Classification, may improve prediction and prognostication of breast cancer at the time of diagnosis. Breast Cancer Res 2011;13:R92. [PMID: 21939527 DOI: 10.1186/bcr3017] [Cited by in Crossref: 16] [Cited by in F6Publishing: 12] [Article Influence: 1.6] [Reference Citation Analysis]
610 Bagegni NA, Tao Y, Ademuyiwa FO. Clinical outcomes with neoadjuvant versus adjuvant chemotherapy for triple negative breast cancer: A report from the National Cancer Database. PLoS One 2019;14:e0222358. [PMID: 31536530 DOI: 10.1371/journal.pone.0222358] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 7.5] [Reference Citation Analysis]
611 Patil VW, Singhai R, Patil AV, Gurav PD. Triple-negative (ER, PgR, HER-2/neu) breast cancer in Indian women. Breast Cancer (Dove Med Press). 2011;3:9-19. [PMID: 24367172 DOI: 10.2147/bctt.s17094] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 0.4] [Reference Citation Analysis]
612 Petrović N, Nakashidze I, Nedeljković M. Breast Cancer Response to Therapy: Can microRNAs Lead the Way? J Mammary Gland Biol Neoplasia 2021;26:157-78. [PMID: 33479880 DOI: 10.1007/s10911-021-09478-3] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
613 Lee CW, Simin K, Liu Q, Plescia J, Guha M, Khan A, Hsieh CC, Altieri DC. A functional Notch-survivin gene signature in basal breast cancer. Breast Cancer Res. 2008;10:R97. [PMID: 19025652 DOI: 10.1186/bcr2200] [Cited by in Crossref: 82] [Cited by in F6Publishing: 77] [Article Influence: 6.3] [Reference Citation Analysis]
614 Masuda H, Qi Y, Liu S, Hayashi N, Kogawa T, Hortobagyi GN, Tripathy D, Ueno NT. Reverse phase protein array identification of triple-negative breast cancer subtypes and comparison with mRNA molecular subtypes. Oncotarget 2017;8:70481-95. [PMID: 29050296 DOI: 10.18632/oncotarget.19719] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]
615 Maksimenko J, Irmejs A, Nakazawa-Miklasevica M, Melbarde-Gorkusa I, Trofimovics G, Gardovskis J, Miklasevics E. Prognostic role of BRCA1 mutation in patients with triple-negative breast cancer. Oncol Lett 2014;7:278-84. [PMID: 24348864 DOI: 10.3892/ol.2013.1684] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 2.1] [Reference Citation Analysis]
616 Isakoff SJ. Triple-negative breast cancer: role of specific chemotherapy agents. Cancer J 2010;16:53-61. [PMID: 20164691 DOI: 10.1097/PPO.0b013e3181d24ff7] [Cited by in Crossref: 184] [Cited by in F6Publishing: 105] [Article Influence: 16.7] [Reference Citation Analysis]
617 Ritter JL, Zhu Z, Thai TC, Mahadevan NR, Mertins P, Knelson EH, Piel BP, Han S, Jaffe JD, Carr SA, Barbie DA, Barbie TU. Phosphorylation of RAB7 by TBK1/IKKε Regulates Innate Immune Signaling in Triple-Negative Breast Cancer. Cancer Res 2020;80:44-56. [PMID: 31662325 DOI: 10.1158/0008-5472.CAN-19-1310] [Cited by in Crossref: 14] [Cited by in F6Publishing: 3] [Article Influence: 7.0] [Reference Citation Analysis]
618 Jordan JJ, Inga A, Conway K, Edmiston S, Carey LA, Wu L, Resnick MA. Altered-function p53 missense mutations identified in breast cancers can have subtle effects on transactivation. Mol Cancer Res 2010;8:701-16. [PMID: 20407015 DOI: 10.1158/1541-7786.MCR-09-0442] [Cited by in Crossref: 41] [Cited by in F6Publishing: 28] [Article Influence: 3.7] [Reference Citation Analysis]
619 Johnstone CN, Pattison AD, Gorringe KL, Harrison PF, Powell DR, Lock P, Baloyan D, Ernst M, Stewart AG, Beilharz TH, Anderson RL. Functional and genomic characterisation of a xenograft model system for the study of metastasis in triple-negative breast cancer. Dis Model Mech 2018;11:dmm032250. [PMID: 29720474 DOI: 10.1242/dmm.032250] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 4.0] [Reference Citation Analysis]
620 Carey L, Winer E, Viale G, Cameron D, Gianni L. Triple-negative breast cancer: disease entity or title of convenience? Nat Rev Clin Oncol. 2010;7:683-692. [PMID: 20877296 DOI: 10.1038/nrclinonc.2010.154] [Cited by in Crossref: 495] [Cited by in F6Publishing: 465] [Article Influence: 45.0] [Reference Citation Analysis]
621 Zheng BH, He ZX, Zhang J, Ma JJ, Zhang HW, Zhu W, Shao ZM, Ni XJ. The Biological Function of TUSC7/miR-1224-3p Axis in Triple-Negative Breast Cancer. Cancer Manag Res 2021;13:5763-74. [PMID: 34305410 DOI: 10.2147/CMAR.S305865] [Reference Citation Analysis]
622 Fernandez-Martinez A, Krop IE, Hillman DW, Polley MY, Parker JS, Huebner L, Hoadley KA, Shepherd J, Tolaney S, Henry NL, Dang C, Harris L, Berry D, Hahn O, Hudis C, Winer E, Partridge A, Perou CM, Carey LA. Survival, Pathologic Response, and Genomics in CALGB 40601 (Alliance), a Neoadjuvant Phase III Trial of Paclitaxel-Trastuzumab With or Without Lapatinib in HER2-Positive Breast Cancer. J Clin Oncol 2020;38:4184-93. [PMID: 33095682 DOI: 10.1200/JCO.20.01276] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 10.0] [Reference Citation Analysis]
623 Kumar P, Mukherjee M, Johnson JP, Patel M, Huey B, Albertson DG, Simin K. Cooperativity of Rb, Brca1, and p53 in malignant breast cancer evolution. PLoS Genet 2012;8:e1003027. [PMID: 23173005 DOI: 10.1371/journal.pgen.1003027] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 1.6] [Reference Citation Analysis]
624 Ting CH, Chen YC, Wu CJ, Chen JY. Targeting FOSB with a cationic antimicrobial peptide, TP4, for treatment of triple-negative breast cancer. Oncotarget 2016;7:40329-47. [PMID: 27248170 DOI: 10.18632/oncotarget.9612] [Cited by in Crossref: 21] [Cited by in F6Publishing: 27] [Article Influence: 7.0] [Reference Citation Analysis]
625 Song X, Liu Z, Yu Z. EGFR Promotes the Development of Triple Negative Breast Cancer Through JAK/STAT3 Signaling. Cancer Manag Res 2020;12:703-17. [PMID: 32099467 DOI: 10.2147/CMAR.S225376] [Cited by in Crossref: 10] [Cited by in F6Publishing: 4] [Article Influence: 10.0] [Reference Citation Analysis]
626 O'Reilly EA, Gubbins L, Sharma S, Tully R, Guang MH, Weiner-Gorzel K, McCaffrey J, Harrison M, Furlong F, Kell M, McCann A. The fate of chemoresistance in triple negative breast cancer (TNBC). BBA Clin 2015;3:257-75. [PMID: 26676166 DOI: 10.1016/j.bbacli.2015.03.003] [Cited by in Crossref: 184] [Cited by in F6Publishing: 173] [Article Influence: 30.7] [Reference Citation Analysis]
627 Chou HH, Kuo WL, Yu CC, Tsai HP, Shen SC, Chu CH, Yu MC, Lo YF, Dabora MA, Chang HK, Lin YC, Ueng SH, Chen SC. Impact of age on pathological complete response and locoregional recurrence in locally advanced breast cancer after neoadjuvant chemotherapy. Biomed J 2019;42:66-74. [PMID: 30987708 DOI: 10.1016/j.bj.2018.10.007] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 4.5] [Reference Citation Analysis]
628 He J, Wang X, Guan H, Chen W, Wang M, Wu H, Wang Z, Zhou R, Qiu S. Clinical efficacy of local targeted chemotherapy for triple-negative breast cancer. Radiol Oncol 2011;45:123-8. [PMID: 22933945 DOI: 10.2478/v10019-011-0014-7] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
629 Darb-Esfahani S, Loibl S, Müller BM, Roller M, Denkert C, Komor M, Schlüns K, Blohmer JU, Budczies J, Gerber B, Noske A, du Bois A, Weichert W, Jackisch C, Dietel M, Richter K, Kaufmann M, von Minckwitz G. Identification of biology-based breast cancer types with distinct predictive and prognostic features: role of steroid hormone and HER2 receptor expression in patients treated with neoadjuvant anthracycline/taxane-based chemotherapy. Breast Cancer Res 2009;11:R69. [PMID: 19758440 DOI: 10.1186/bcr2363] [Cited by in Crossref: 76] [Cited by in F6Publishing: 68] [Article Influence: 6.9] [Reference Citation Analysis]
630 Shao Z, Chaudhri S, Guo M, Zhang L, Rea D. Neoadjuvant Chemotherapy in Triple Negative Breast Cancer: An Observational Study. Oncol Res 2016;23:291-302. [PMID: 27131315 DOI: 10.3727/096504016X14562725373879] [Cited by in Crossref: 16] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
631 Lee HH, Jung J, Moon A, Kang H, Cho H. Antitumor and Anti-Invasive Effect of Apigenin on Human Breast Carcinoma through Suppression of IL-6 Expression. Int J Mol Sci 2019;20:E3143. [PMID: 31252615 DOI: 10.3390/ijms20133143] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 8.0] [Reference Citation Analysis]
632 Kim T, Han W, Kim MK, Lee JW, Kim J, Ahn SK, Lee HB, Moon HG, Lee KH, Kim TY, Han SW, Im SA, Park IA, Kim JY, Noh DY. Predictive Significance of p53, Ki-67, and Bcl-2 Expression for Pathologic Complete Response after Neoadjuvant Chemotherapy for Triple-Negative Breast Cancer. J Breast Cancer 2015;18:16-21. [PMID: 25834606 DOI: 10.4048/jbc.2015.18.1.16] [Cited by in Crossref: 24] [Cited by in F6Publishing: 24] [Article Influence: 4.0] [Reference Citation Analysis]
633 Chaurasiya S, Fong Y. Viroimmunotherapy for breast cancer: promises, problems and future directions. Cancer Gene Ther 2021;28:757-68. [PMID: 33268826 DOI: 10.1038/s41417-020-00265-6] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
634 Liu C, Louhimo R, Laakso M, Lehtonen R, Hautaniemi S. Identification of sample-specific regulations using integrative network level analysis. BMC Cancer 2015;15:319. [PMID: 25928379 DOI: 10.1186/s12885-015-1265-2] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
635 Tan MC, Al Mushawah F, Gao F, Aft RL, Gillanders WE, Eberlein TJ, Margenthaler JA. Predictors of complete pathological response after neoadjuvant systemic therapy for breast cancer. Am J Surg 2009;198:520-5. [PMID: 19800460 DOI: 10.1016/j.amjsurg.2009.06.004] [Cited by in Crossref: 48] [Cited by in F6Publishing: 45] [Article Influence: 4.0] [Reference Citation Analysis]
636 Ye DM, Wang HT, Yu T. The Application of Radiomics in Breast MRI: A Review. Technol Cancer Res Treat 2020;19:1533033820916191. [PMID: 32347167 DOI: 10.1177/1533033820916191] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
637 Brinkman AM, Chen G, Wang Y, Hedman CJ, Sherer NM, Havighurst TC, Gong S, Xu W. Aminoflavone-loaded EGFR-targeted unimolecular micelle nanoparticles exhibit anti-cancer effects in triple negative breast cancer. Biomaterials 2016;101:20-31. [PMID: 27267625 DOI: 10.1016/j.biomaterials.2016.05.041] [Cited by in Crossref: 51] [Cited by in F6Publishing: 45] [Article Influence: 10.2] [Reference Citation Analysis]
638 Hu XQ, Chen WL, Ma HG, Jiang K. Androgen receptor expression identifies patient with favorable outcome in operable triple negative breast cancer. Oncotarget 2017;8:56364-74. [PMID: 28915596 DOI: 10.18632/oncotarget.16913] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 3.3] [Reference Citation Analysis]
639 Mohammed F, Rashid-Doubell F, Taha S, Cassidy S, Fredericks S. Effects of curcumin complexes on MDA‑MB‑231 breast cancer cell proliferation. Int J Oncol 2020;57:445-55. [PMID: 32626932 DOI: 10.3892/ijo.2020.5065] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 6.0] [Reference Citation Analysis]
640 Visvader JE. Keeping abreast of the mammary epithelial hierarchy and breast tumorigenesis. Genes Dev 2009;23:2563-77. [PMID: 19933147 DOI: 10.1101/gad.1849509] [Cited by in Crossref: 385] [Cited by in F6Publishing: 349] [Article Influence: 32.1] [Reference Citation Analysis]
641 Zhang J, Liu C, Shi W, Yang L, Zhang Q, Cui J, Fang Y, Li Y, Ren G, Yang S, Xiang R. The novel VEGF receptor 2 inhibitor YLL545 inhibits angiogenesis and growth in breast cancer. Oncotarget 2016;7:41067-80. [PMID: 27203384 DOI: 10.18632/oncotarget.9392] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 4.0] [Reference Citation Analysis]
642 Horiuchi D, Kusdra L, Huskey NE, Chandriani S, Lenburg ME, Gonzalez-Angulo AM, Creasman KJ, Bazarov AV, Smyth JW, Davis SE, Yaswen P, Mills GB, Esserman LJ, Goga A. MYC pathway activation in triple-negative breast cancer is synthetic lethal with CDK inhibition. J Exp Med 2012;209:679-96. [PMID: 22430491 DOI: 10.1084/jem.20111512] [Cited by in Crossref: 222] [Cited by in F6Publishing: 197] [Article Influence: 24.7] [Reference Citation Analysis]
643 Wang L, Jiang Z, Sui M, Shen J, Xu C, Fan W. The potential biomarkers in predicting pathologic response of breast cancer to three different chemotherapy regimens: a case control study. BMC Cancer 2009;9:226. [PMID: 19591668 DOI: 10.1186/1471-2407-9-226] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 1.6] [Reference Citation Analysis]
644 Nehdi A, Ali R, Alhallaj A, Alzahrani H, Samman N, Mashhour A, Baz O, Barhoumi T, Alghanem B, Khan A, Alriyees L, Boudjelal M. Nuclear Receptors Are Differentially Expressed and Activated in KAIMRC1 Compared to MCF7 and MDA-MB231 Breast Cancer Cells. Molecules 2019;24:E2028. [PMID: 31141879 DOI: 10.3390/molecules24112028] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
645 Jeong YH, Hong SA, Ahn HS, Ahn SK, Kim MK. Clinicopathologic factors affecting discrepancies in HER2 overexpression between core needle biopsy and surgical biopsy in breast cancer patients according to neoadjuvant treatment or not. J Cancer 2021;12:4722-8. [PMID: 34149935 DOI: 10.7150/jca.59419] [Reference Citation Analysis]
646 Zhao J. Cancer stem cells and chemoresistance: The smartest survives the raid. Pharmacol Ther. 2016;160:145-158. [PMID: 26899500 DOI: 10.1016/j.pharmthera.2016.02.008] [Cited by in Crossref: 202] [Cited by in F6Publishing: 189] [Article Influence: 40.4] [Reference Citation Analysis]
647 Arora R, Yates C, Gary BD, McClellan S, Tan M, Xi Y, Reed E, Piazza GA, Owen LB, Dean-Colomb W. Panepoxydone targets NF-kB and FOXM1 to inhibit proliferation, induce apoptosis and reverse epithelial to mesenchymal transition in breast cancer. PLoS One 2014;9:e98370. [PMID: 24896091 DOI: 10.1371/journal.pone.0098370] [Cited by in Crossref: 45] [Cited by in F6Publishing: 38] [Article Influence: 6.4] [Reference Citation Analysis]
648 Lee J, Galloway R, Grandjean G, Jacob J, Humphries J, Bartholomeusz C, Goodstal S, Lim B, Bartholomeusz G, Ueno NT, Rao A. Comprehensive Two- and Three-Dimensional RNAi Screening Identifies PI3K Inhibition as a Complement to MEK Inhibitor AS703026 for Combination Treatment of Triple-Negative Breast Cancer. J Cancer 2015;6:1306-19. [PMID: 26640591 DOI: 10.7150/jca.13266] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 2.0] [Reference Citation Analysis]
649 Siraj AK, Beg S, Jehan Z, Prabhakaran S, Ahmed M, R Hussain A, Al-Dayel F, Tulbah A, Ajarim D, Al-Kuraya KS. ALK alteration is a frequent event in aggressive breast cancers. Breast Cancer Res 2015;17:127. [PMID: 26384210 DOI: 10.1186/s13058-015-0610-3] [Cited by in Crossref: 19] [Cited by in F6Publishing: 14] [Article Influence: 3.2] [Reference Citation Analysis]
650 Oakes SR, Vaillant F, Lim E, Lee L, Breslin K, Feleppa F, Deb S, Ritchie ME, Takano E, Ward T. Sensitization of BCL-2-expressing breast tumors to chemotherapy by the BH3 mimetic ABT-737. Proc Natl Acad Sci USA. 2012;109:2766-2771. [PMID: 21768359 DOI: 10.1073/pnas.1104778108] [Cited by in Crossref: 127] [Cited by in F6Publishing: 122] [Article Influence: 12.7] [Reference Citation Analysis]
651 Seo AN, Lee HJ, Kim EJ, Kim HJ, Jang MH, Lee HE, Kim YJ, Kim JH, Park SY. Tumour-infiltrating CD8+ lymphocytes as an independent predictive factor for pathological complete response to primary systemic therapy in breast cancer. Br J Cancer. 2013;109:2705-2713. [PMID: 24129232 DOI: 10.1038/bjc.2013.634] [Cited by in Crossref: 186] [Cited by in F6Publishing: 169] [Article Influence: 23.3] [Reference Citation Analysis]
652 Chiu HW, Yeh YL, Wang YC, Huang WJ, Chen YA, Chiou YS, Ho SY, Lin P, Wang YJ. Suberoylanilide hydroxamic acid, an inhibitor of histone deacetylase, enhances radiosensitivity and suppresses lung metastasis in breast cancer in vitro and in vivo. PLoS One. 2013;8:e76340. [PMID: 24130769 DOI: 10.1371/journal.pone.0076340] [Cited by in Crossref: 50] [Cited by in F6Publishing: 45] [Article Influence: 6.3] [Reference Citation Analysis]
653 Anand K, Patel T, Niravath P, Rodriguez A, Darcourt J, Belcheva A, Boone T, Ensor J, Chang J. Targeting mTOR and DNA repair pathways in residual triple negative breast cancer post neoadjuvant chemotherapy. Sci Rep 2021;11:82. [PMID: 33420229 DOI: 10.1038/s41598-020-80081-y] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
654 Chen DR, Lu DY, Lin HY, Yeh WL. Mesenchymal stem cell-induced doxorubicin resistance in triple negative breast cancer. Biomed Res Int 2014;2014:532161. [PMID: 25140317 DOI: 10.1155/2014/532161] [Cited by in Crossref: 29] [Cited by in F6Publishing: 39] [Article Influence: 4.1] [Reference Citation Analysis]
655 Masuda H, Baggerly KA, Wang Y, Zhang Y, Gonzalez-Angulo AM, Meric-Bernstam F, Valero V, Lehmann BD, Pietenpol JA, Hortobagyi GN, Symmans WF, Ueno NT. Differential response to neoadjuvant chemotherapy among 7 triple-negative breast cancer molecular subtypes. Clin Cancer Res 2013;19:5533-40. [PMID: 23948975 DOI: 10.1158/1078-0432.CCR-13-0799] [Cited by in Crossref: 378] [Cited by in F6Publishing: 224] [Article Influence: 47.3] [Reference Citation Analysis]
656 Jiang HL, Sun HF, Gao SP, Li LD, Hu X, Wu J, Jin W. Loss of RAB1B promotes triple-negative breast cancer metastasis by activating TGF-β/SMAD signaling. Oncotarget 2015;6:16352-65. [PMID: 25970785 DOI: 10.18632/oncotarget.3877] [Cited by in Crossref: 29] [Cited by in F6Publi